var title_f27_41_28304="Baker cyst MRI";
var content_f27_41_28304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Baker's cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 415px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGfAV8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5cIVct79KVCA/SkIJehiCQQOlADipLN3OKt2z/uFAHzN3qoQSPlPNT2StjDdF5zQBrrb+XZmSRh5w6D2p+mSuoDgZJPIrPVpppQRyBWlZ7gdqr81AGlKB5XmN8pZsfSoJDvk2g9gKCG3sJj8qjI+tPsbbz7iI88tz9KANHWTIkFlbxEhQMn3zVGe0McmCQSQDU2qvJPLhG4j4U1BJJuIyx3gUAMEjwsT1c8YqAxZkUnuMmrEbiVG4zIKYrCOEl+STigBhC8c85p8aBZt5JpQoUBgMlhTkBMoAHA60AVpwDLvj7daRFMpfggnFWCiwSbXOVPNVp2dWZl/DFACi2/eZxkqOajiDLG7E9TxVm0d2dyehU81UMhjXYRnJoAkt8tIQ3T1pJAW3BOAOaljXLhhwMUhUlCE6sTQBs6VAZIYixxuOAa1vE1+mm6QdPtX3PJgyt61Q0d0t7KW6mORCPlHv0rCu3aa3mnlbJc5FAEV+qvaQuM7VHWqEUuBuYe2a1dOYXWkvHt5XqaoJFhWUjOKAJIFjk68d6lY7DkjPvVa2DF2zwO1Sj7oI5welACxOVfjoaeSceSOcc7qEjIDcc4p0JCqNwwxNAEsvyW24dTxVaKJgykfezmtu6syumb0XJ4NZEfmNMAo4AxmgCWW2eTc24BTwRSeQSEUNgDqPWpEZVj2ysRzzUccqyBsnAB4NAFi/tQHSHeCSAeKgkAjITcOOhqJ5TLcYBJ2j71RyKCWYPnFAFa7l8xwr9FqndiJlyDin3bfcYcnvVKRw7lWGNpoAhaQgFR0oQAr70kmMn3p24ZBx060AMx6niplKhAzjPtUWeWx0p784Pc9qAFYrtJAwDTWIGMEY9KCwwVOMCmL05oAeV4PY9Rn0oO4YLDjFIC0jfQUrAjG9hQAm7Kn1zxTQueKcmC7E8kChuDj8aAFxsGcj2q1AjSQkBsBqogBmGKsxhhIVB+VKALkLeQishzjg1rWlyX5C/MBzWKsQxy3B5FbWkuGRgF524zQBahbzVDgZJPIrQSQQWjiNfn7n0qjZqYWLLT3lbyXAOCx5oAgUvKjHOMU0x5XK8k0+IFshjjHeiM+XINvQ0AOKgHanBPWmbFDurc8cUn/Ld+eM06dPuEdupoAjTcrKCflHepkuUwyqOT3qK5VZpYokJAP3jVqCxe4cQwj5ehagCjYpJLczSMC0ajnNRRKR15BJrodbjFgiafZjJZQXcfSsBma3iKsuWFAE0UipbTgc7uhqFGRYl3DLCnXREdiuxcMaSOP/AESMt1frQArSHcMDhhUbTBMr3PGakliVJIlDcYyTSXKIvI5J6UAXri5jNhFbQk5HLVWvgFsFOc47VXlO2dAo69TUl9G50hvU9DQAaLcKY5IwMM3NRyh/tRUd6g0olJEOOOhNamo25EKzRn5hQBnY2s3OCO1TIVYBsYI7U3erlWkHzdfrUobySXK5DcYoAW3LAszfhUMhLXCs35VIx81DsOCvNFuwxvcZNAHY6Ram40efzTwqFh+VcrARDC7twN2B7123gp8aLqFzcrvijXG36iuYvxHPCkqLtgzuAoAzWlEjMhTk0kpRYgFHHSkifdKz4x2pZpY921Rz3oAjAKQbFX5ieTTL50VFCjGetWG+bDLjI7etUb794hc8e1AFC4dEmCKc56VQkz5zg9c1fe2Etj5yH51PNUm65zyODQAGPgZ70xlGcLye9Pbn734VEdoO4ZzQAqbshQBzSqzZbjmnI2IycZ96bnn3oAQtluRzTpMEZ79OKQ8sWNKuC+QMAe9ACKCFBzQS8mM9qWPALhuQRxSRr1znFAAr/P0+Y09ky5I5wOaZgHJHBHSgsVcHPPcUAJ91+BjFWo5BGMnJL1W3ZbJFS23zknrj9KAJmxJKi5wqjmuh0tP9GJQjK8H6Vd0PwdcXfh661u5xFZxMFXdxvJ9Kp2TJbuR/C3agCViFX73BORSXADSx7T8vUmggOxG3inFcAKB16GgBEXzC+eAOlN+5sZ+o4AqVgBgN2oWL7QyNEpbn0oASSHYd0XVucU0by+xu/WluJZYL1kkQpgcZ4pplUqsmfmPWgAFvJPOIYRjsW9q0HmNnAYYHzs5LD1qmLkqCIzhjxkelVGJjLbSTmgC+t7idZLg5yMc1I9oLi3E0DqxZulZx/eKHcfKKLBnS9iRGIUnOKALWuQNGFgKbWA9KqGQC0iUct6VpeIbuRNQkE43MOBWGjFplcDGRxQBM8TeXub75NEwUIg7ilHmM/XjNNvH2lSw49fWgCd2QgjoQBirOpYGhwIp+duuPrVKRQQrFcE9KnlxF5Yl5jHSgCrDHtj3kgKtaMEy3KBPUVjzSNNIyAEJnpViGTyZFRe3cUAE8TRS/MMqDQ7sVyOlWrqGQlZBzG/Wq5Clyu4YxjFAESg7uOpqWQgxIVHHcVGPlQqpy4PBqSMbosr1HagDsvD98LTwffjPzPgEe1cjBPM0JLfczgD0Fa8D+Z4ekUKV+YZNZkbiOER7c5GM0AKIBHtOflbmqk0ShmYZ54qzcTeREAfm44qBWkKD5eTzzQAxA0UgycnFZmoSspbaS3PIrVkRkViw3O3esa7OAxRfmFAD9PuVTzkl4Qjis0/MGbPOelOHzRjJyxNNIC5HVs0AP5MYkJ5HGKbu55A5pQ235XFJjJ4XntQAkY3NjoBSBSOgGKRgQSM80Y4PPNADlAZiucCpDtKbF6jvTIF5bd1oK/MSeATQAjn5sDp0pEcjII68U8qu/5T2zUQGHyTQBIWygAAyDmmOCc5HI5p6n5SfQ5pF+Ytk9RQAjMCg7H1q1YTxwSxllyuefeq4QMB61PbDOVODg8UAdbrfiW4v4LWzgbyrGJceUvAJ9SKr2RBTfIOhrFSLE4zkmtqy+WP8AedO3vQBakOSAowSf0pzNtQlh7UwIdvmN68VJcwPN5OxueuKAILpJI1VlGS3QVp28eo6bFG0VmziTkHbmnaTbm71FEcYZOxHFdXe+ML21litLW1hMMXG5owaAK8fhe7vtKm1HV4vs6Iu4EjBPFcFhGnYKP3SdDXVeIPFOqalKIp5R9mxyijArmZ5tyjy0CgnkYoAhtV3zO5GFzxTnceZ049adtwGZfugdKimckRqF4zk0AWZEH3P4cZpNCBm1uIBN2D0FVJJ2yR+FdB8PrZm1c3e3MKKevTOKAMbxTJ53iC4Ct8obiqJ4CKO3Gan1+Mtr9yx4y1QJg5Gee1AE7xsVA3Y/GllVmtV3gEKaaqlo2XOSOaWO6IiKsuRQBKjF5FHHI4ovGe4h2AcxVV80tdKynFT3kgZSImw38XvQBTDF3DEYGOakRC6gL3PWoowXO1jge1TLujdQhzQBqCU+T5RPbFUZ7cJtC5LE8067mI8pcEEEZNTG7EkPC8igCrbNGJG3dRVmJUXc6kfSooY4mnaT+HHNFrGrXLBTnJ4FAGxNJs0UR4A3sCapHG1QBwop2rSKscMXI2jkVWilIQnOc+vagCOZkaYLjIJ4qC9lkluESPC7Rzipi4RwcZAGRURKjk/fc8e1AD1l8vhyGUdTWVeThmkcL8p6YqW4BjViSStRwqJ7Vs8EHNAGf947SCGqI53ZGTjrVi4cNMSo+tQls9DwRQAj5YD1o3MrYHcUoxnOOlIxO3BHJ/SgABBJY/lS7CCCM0gGQBwDTskMyj9aAEJyvzZBpqkluc4qRfu4cjApm/nkZGetACBeQTkDpQwG7jpTy2STt46CmyNkKQOaAHBSqjkAGlRBu5OFqPnIPXHFSMMnBPOKAGnaCMGpYD5bFmOQardMY61LbLub5jxQBpwv8+4/cxW3aOkscYxnA496xbfy2u9oPyY5Fb1mF2xLCOQcUASpJ8xRxwTUkkgWZTF/D0q3JAks32dAPOPOa6jwl4Zt0mN9rDqLWEZZSetAFXT5owIH8jY78O59KwPEWqtcaq4tQEtlGPrWv4r19bi4eOxjENqPlQD0rk5V3OB6c/WgAEny56+9MRixywx7U+YqFVTwDzUYQRjeTncePagB25QSCeW4ApkjeUrBhyORSiPbOJB83pUkkLSOZOrEYCigCnBA9zMiDgscZrudV1Ky8O+GrbT7AZvXO6V/6VkabFHpsX2rUFxxwprm9V1E3tzLJsOD92gC1fTfbL7ziMBx1qhKmx/kP3an08maxKkcrVf/AFqsM4IPNAE8MhXpgk9aUOrP5aj3zUaxiMjB6ihgdgxxz1oAauPnx26U2ceXAJAfm/ip0wYKNn4ii4Qm2xjJI60AQWzD5zn73Sp4Scbjww4FUoXG1VHbrWoArRKMfeOM0ARzLPNsIHyjvTkyiMOpbitddMZI1dJQU28j3qFrALjcwyTmgCjbgxwEHqTVqJRbN9oGCydhVW4UrIwU5U1d0NRJcyLIcoFJPtxQA24Y3imUrhj+lU5AY4VXHJ5Na6In2cMjjJOKzL1HjYBjlelAFcDMR55PAFPmiZIkKDc3enPtjkRQOtNkmkikMacg0AZd27B2Q8r1NTaaEkSdGOCBkVBcM29/MXGehplvcLHI2B2waAKbFSeD8x60w43YHJo/5aEdyaFUM5VuooAkGCC3JwKB87eoA5pqHD7QeKFwjkHn3oAYRge4pQxEmfzppBbvSso4Gce9ADzwQQtBdT82OfShGKE88GkJ+ZQelAChzsxwAT0phI6Yp+R5hPakbDS56DFAAGKrjGSe9DElg3emsTuz79qV2BAUCgBQoTJIBJ5FLCQWII69Ka2cY7inw4wufvZ4oAuWcR+1IBwSOtdDpcjpKylcEGsk/uXjk68ZrW0q5R2Mz460AaiF0kkkHDAZBog1O+vsWKO5Ep2n2qJ3aa4XZxGeK0fDkIS7vJ1XEUKbt3oc0AZ2tBEkSEHiHr7mq8AQ4MnU9akyLu5IYcuxx70SqiSMikHHWgCGaL7VdJ5YO3IUCrWv2dtbywWtvJukC5kPv6VJFKLWAybR5jfdrKmiaTdLIx80nJoAfGW89Il4VuCfSrw1Cz0qNl4luAcjPasCQynHlN8y1SZGmJI5YdSaANLU9RudQTzZmyhOAtQqwKEYHSqrRsGVEOVqxbIGYgHJoAm0ku1wV6KRg0lzGLedx/ETxVa3la2uwoPzE81pa3GcwyJyWXOaAIc/vFAHIGabG588qT05xSiceUpI+deM1FMVdvMXh6AEkk5csevANTWtwrQtF95hVRNrZiY5J71PFFHFMZIzkAfMKAKe1A5CdWPNX/N2KqKelUJWDMroOSafakq5kkOecYoA0TPJnYsjBCOR70sTSMv72U4zgVXkI3sR1xwKeUUxYyc9aAJJcxIQPmyeKmsz5dxKoJUMvJ/CoVB2B25UdqW3O67R3+6e1ACwbI48K54OTTrl/PClW7dKq3RWOWTb6ipbYKI2Z8jigCFCxceacjOM0lyxW4AU5GOKZG6kOWPy0yQBlxGct1BoApXM7NKFl59DVfksVAxnvVieNZAFBJbuaJYTbhPM+9igClxwe9J1HHBNOx82BSYy5I6CgAT5GAbvT8qDwPqKVNm4ZyR/KmMuCdvrQAKA7ELxSFQc57Uq4GAOGo2knpwe5oAceYlAHINJK3IDDGKQMcZHahjuGW+9mgAB2lh1BGRTvvqu3tRtGwFeucEGhdzPjoBQAiEKQCPejA35HPek2nfjuBSAZ3YP1oAeFySzcCmKQDzwR0pdxbj0pdgbBHA70AaTu7Qw8cetXLU5cIg+X2qik4a2RccKcVo2QO/IGB1oA34YmNodo+YDArR3PZ6ELcZWS4OHPqKo6VcAygyf6pRk1LeX4vJmLrtReENAEFlBiUyv8oi5BpkkChlcNneeasX8qizSNO3LH1qraI5kjkcfuz2oAdrCBeQ3IHArLSRjGWk6Gr+oOrXrsT8oGAKxp5GAf+4KAIZLqJFkEWd/86rLKEjZpDjcP1pXQtHvjiOD3qtkZEb8mgC1FPtjyR7ZpbfdHLkHrREEMgR+lE0ewkhuM0ALdD98HT7/AHrawbnQhMDmSEgEe1Y04CBGB4Hf1rc0IiSyvIT96RSVFAGJJKXbfj5cdKUuJlGz5SBiqjGSJ9mM4ODViH7zMRggcCgCEHypDjlqlhm3MyqfrTScocDk1WhG0FgcHvQBNGuxsFhg1MoP8IzzVbCuR1HvVm2dlLEjI6GgCSL/AFjBvvEVO+9VGB1qpDMHu9nTHSry5Jbc3ToKAHgkxjuq9R6060YM5LDhR+VMG77M+Opp1rC4tJHJ47mgCrOnmMzIc7jV3CLCkbfexiqdqjKpCHdzTrubEyg8EGgCO8jMEBBXhjTbGMvA5zzjg1cu9zqN/MbLwfeqib0iVU6k4/CgCC7QJEEi4YnJNV7yVpYgHOXHGakvPklwWzgVQeQkADp6GgBFyI2AwT7UyMkbsg05DtBwOacAeT60ANPygDPHWjd83A7Clk4Kj0poIVwTmgAcEMM9adlmi44xTWIOGJ4JpVO4ACgBBnAI6DrR1bI+tKFw4UmnN+6JHBoAYuSCOualjkAypFMA2YftSctISlAA2S3y/hSwNsYlhnI6U6NlLqB9KSRfnIVu9ADARnA4JNDfdwDyOvvRvAzkcikxxmgDZ0m1S6DwhgPQ1q2tjNbwv9oPQ4Uiuas3ZSQGKn1FdBpl1K0DxyHeOxoA2rJA6iPjJGQKtrbLIHD4CoOnvWXYOVlLlvmA4q7FJli8jYbOdvrQBE0G4szHA96jt7p5ZNiL8kfGPWnahOSCBwG6VXtZ1tLZ5JcK56UAVryTLs8ny1iXEjmMpz8xyKs6nerNNgnCnpip9MSMwmaRSQvC+5oA04IpLTwp5ssYyWwM+mK5l497+bEPeuo8QTsuhRRyHbu+bb7VzdjMN21fu45oAYSqM2T82KRHzEuTljnipHZDlmXJY4qRHg3rxt20AIz7rVVAya0dEd4buIt0B2ke1ZxWP7SpVsIDlq0bOSFb4y5O0twtAFHWo/I1SbBwGJYVVlkkUjZySvNdT4psLGSa3nWbBaIZ471lRWELoGSYHnH4UAZEZYoi/wATE0TKscuG65xW3ZR2NndSNPl3x8i471D4j0qS0jt7tUJhnyQSKAKcojWAIvPfNIzZhIAxkc1Ukb96EXsMmnxSF02txzigAgy0oOMFe9bNvEGikl6nFY6ExttGDk1tW7OsIjA5agCRCVhKN1bpTpFVdPbbJ8xPIpj7QArt8w/Sqoj8wEbu/wCdAEsERhVcNljTLmJWnVycn0qcgJISeij5aq/8tS7nGRnHpQAsFwN0kcvKA/LVJrtVnLDqDjFOYEuWXk0ySFckuvJ60ASXlnsmjlkP7tuc+tZtxhrhmQYU9K29RYzaTAx4CEisRztyrDj2oAhUYPvT8koQpxjnFAO5Ac49qcqEFhngigCIhsruB55oAJbGKeXYEDtjGaV2J4UcgcmgA2qhGOT6UA7gdowR1pFchw2OlNRyrNgcGgB4Y7WXblj3pMBlweT1zRk7lwOlNjBZmXjpmgBB6HkUsY2nGD60oGHGeOOKUths5yelADAoCAjOc05Bl855FEhK7QcHPPFBB2gEYJoAaSCcnFDOQqgdKcI8NyM8UqgNn26UASQSIuMr061o2l0V3BBgMc1lRK2/bnH1q/DHvmVVPGOaAN6xdS4Xdlm6Vekjd7oY+6o5rFt0ENwr547VrCSV4z5Z+9976UAQCKSaUq7fKDxWX4kuFMqRqTgDHFdJpFxaebOs/ZflPvXH3aMLp3k5UE4oApopZ0Dc7j09K9G8I6fbXN/Z/awE022dXmc9wOtYXgzRv7Wv8FflHUntXY+P3tND8PR6XZOPOkfc7A80AcX8StWtNS8U3p0xdlgrFYgOm3PFc1buY3APQjAqaSMFd2RwMfjSwQhxubtQBJ5wbayrwvrU8VsZEd3wPSqk64QYO3JpzXRC+XvwqigCZ3hjAZs/SmC7VJg+3hhVSKNpmGDlj0qS6gMahXYbvY9KANXUZPtOlI5yWU4H0qhbSIi7UYlsZNT2rj+z3jHzE9Kp2S4LMyn0NAGppM8X9vWpul+XcK95+Jei6Q/gjTWtGT7uQOM185mbdeIRwVNdaPEct5GlpPIdqLhQTwKAOY1S3+zXjkAEE8YqsImkDMv8NaFxie4eLOX6g1VRmgm5GVHBHrQBFajLqzcH3rVXduR1boaRUhuYGlQYZeop0BQREEHPagC9BErszS9cVBdokbjyj70Qys5CninrHtcs44PSgCF5mddxGCOKoXchMR2jnPWtGQAbge/IqhM6iMrwMmgBLc7dp7BcmmzuAoOeWPFOSM+VvPYYqo8bZAHrQBfmH/Em8wnJz0rFbJjDZ+929K2L3ENukP8AeGaxl+X3xQAoG5SvpScrtBPSlU4XIPJ7UFQU3ckg0AK+3ZlDz6UsZQbg3ccYpgXPTil2bUJ6mgAYIQdp6djTeOCDwPalXjrgmkHQqOhoAeOR8o4xyTUaZLDaOakLjI/u9DTW+RvkPtQAjgq3OeaCgzkHintuPzHnHemOR94HHrQAnORnmnO24Et17UgB25PQ8YpB15/CgBw3g+x7mg8BiAc9qfuxkNyBTVXKkk4FACAMfnbsauQSFJQydOnNUQWO4E8ZzVqLEpHOFU0AasUqyOEcjPb2rY0qGRZSztlTxXOxKfMKEYOM5rZi1ERaU0SgmTJwaAIr3S7hp5GglCqOTioTaCaBo+ZJ8jp2qqs8zt5YlO569a+FTaNoum313rVuJrnb8m4Z7H/61AFbwJpzaZos9zeYj3ruBPB4rzbxdqJ1DVJLjdlVbAHrXsVrapr/AIO1y/kuVgVCfJi9BzxXhb27R53NuUfzoAj3glQwIV+tSyEouE59MVbgijliQNj3NWEtUaQIpG0c5oAxpAzACRuant7RbmYBuBWteaakqqEOc8Zp6aa6LvXqgwRQBhsphmCREgqcA0TQMZ/3zc45zWhLZyK5YxnbnINO1SyleOKZAQuMMPWgClbTrFMBGMoBQkwBk3cK3IquqspIVcHNNdJXbLKVQGgCaUxMm5eCeKkVEEQfPzL3qOKBGZHzx3FWVUSxN5anMZ6etAFeKXdcBk4I6mptQjIVZFPLEcUt5CjFXtxtz94ehqa8K/YEYcuODQBXtpzDMUx1HzVoybX8oxDqeRWTZA/acyDqOK2bV445d/UDt70ALEoWUq456g1NcS7+R91e1LI+I2uFGUPGarFw0fy9R1/GgBruGhLjpVF4N0SyFhnOcVcvQEs9qH5jyagMRmtFkUkbRigBA4ki9Av61LaLBI4aQ42cketU5GVLZQp+fOWq5p8UbRs8v38fLQBR1GdZrx+MIBxWc/yv7HpVq6DLK5KZ9qqMzHqOBQAigcetOlYhdo6daGAxuGR60suDyBnPSgBq8dSSPSl5H40kQwcv0HFSEgrzwT0NADCBkkdqFO3mlDbTsboOpofIL9/egBknzZIHGaCRjFSZjMf+0KXahGc8dRQAgZgFXoDzimkKSQeBnpSZPU9R0pOHXI+9npQAqMueaRzu6cEVK0a4DKQcCo8g7vWgB2crkfePFNTJBIFSRgj5hSZKAnIzQA3qAuOas2Skkooy27ioUYSMTJx71JbyGNlZPvBuKAO3svCU1zZm9vpkgiWPKgkZJ9KyJoY422KQVzjNUtQv7u7Mfmzt5YGNoPFEUfmmOEuSSaANXStOG1rvblYjkmti6uHksUB+VW/WrGrYs7G30ywXcZlBkbFUNRj8u9gtkcMEQnj1xQBTu72W2tJbVJmUS87QeK5cNyysTlTg1bnnc35MueDio9QKiRwBjdzmgCB7jygETOan+1lQHLfMRjFZruDGFP3l70xCT05oA1k1SSPAAzjmpYNWnCsp5JrGQ4lPOTil+dOVbrQB0cWutJ+6kVeOnFWp9Wja1VCACOtcxZxF2Db/AJqmuIcyFQ2M80AbaeVcMMgLxkH1qG6Q/ZThQRkgGs6V5IkTbkgccVfs7wtCVOOOcGgCukQgKEj5e/tV/Trb96WAwSRj3rU060g1CxuITxNtBBrTsbWOMWwlQhTwzUAc54hgW3vxGg2rIuazYQEfy5OQRXtXiD4cjWPClrq1jIHmQALGOrAmvJNWspdNuRDcRMsynDBhgigDLBV2OwfPGcfhVm3f5WcrxVaOT/SnKrjPWpEfJaMHhjQBpQzGXTDGBxk8UwqFiZRwOOajtiYJww/1fcVPKysxU/WgClek+UoI56CnQu1rBGko+Vu1R6gSyoO4PFLLm4iEjHBUYAoAbIkTK7L1J6VdiUCz5HzDmspmZgoYYKnIrReb9wIxjcR81AGVfsXkLLwKoOcn8anuiDISpOemKiydoXHSgBWJY8Y20i4JxnA7UzgpxTwFKBR1oAa/BI70IruMdcU87RID6cUiMQ24cEUAJtPfqaUBc8nr2poYszNnFIc5yOtADtmHKmhh5ajPIIpkjsTlupoXIXJ5oAk4wCOmKSJCxODinZ3Q49KSMhF55oAZjAODinoqgHceTSEArnI+lNX5m5IoAV2IAx270cFF9T1pzEZAx0/Wmfx+npQAuc4B4xxinRHDjPamNw3rUlv8z7SfegCy8pI8uFeTzXWfDjQ/7Q1iOfUX2WsR3EtxWDpcKy3qBsBTwPrXZh5PKNrafLFEN0pHpQBr+I7uxLzrpkeMcB8V5+rzw3TGZzu6gmtG61ORSsax4UHgjvWLqUskshmJ+WgCrcM9zenjAzzT7xcR8fNt4qSSL9xHKpw71YsYCwuBIN21SaAMSSPcFKqRnjNAVVQso+bpmp7iSSRUAAVR6VUV2KmPHOaAHQgyS7jwRSSEjbznBpjbkYAUoBzjGaAJ4XRZCQcZq9bxfaXJyRjn8KzYYwykHjFWo7to1JiHXg0AbFnCm/aRuq1BoMmorK8DbJF6D1rFstQxKu77wPFdJY6kU5jbbITQAzRjPazNFLEQy8M1ew6T4A1bVfCKapaqHRVJMQ6kV5R9vmimaWRBIG+93r6h+BWo3sfh5GkImtJSAFznZ2oAyP2eo4by7vLPUJS09mf3du3Yd+PrVD9pDwBFFHJ4htURYjhZABjDHpXWQ6VaaD+0JYDTQEF/p87TIOgwVOa6v426VNq/w31aC25kjVZ8eoQgn9AaAPgaRfKlLd84YUeUrp5i8MDUl5hrlwnJYZpVBjCk+mMUAKz+bIsSnBPWpGco5Lj7vFQRson3Hg0+d2LZxnPagAeMtKO/BxQY91nsJw7HNXbdCIHkYciqM86biIzk4/KgCtEQZhE/OOAaW8DbX+bBFSxYCKQuW3dabf43ZYHGKAMxxlyM4wM5qLdtPrmkZwSR2NNzk9Dj1oAkWPEeSc+1JjYQR+NCEqQWHFK7bm56GgCMnqe9LnHNOcbQM49qFUFM0AKMCEcZJpgPuc0EsQB0ApB2I6nrQA9BvHzHjFBxtxnn0pT8qY4B70iAHkkCgBEO0DPIpd4VflUHJpp+UkY4pQAcDoBQAMAAAtEeEycc0sxAGDjpnikQHZk9+lAEiKAoao3GCOKOMe9I+eMn6UAPVeOT15ojHJIwDTeflA7DBp4XAX69aANPSkKkTM3Q9K6M3UlrYOoPzXHH1FY1lbxXToIX2sF5GetJcpL5paaT5YvuCgCKaaT7R5bHnH5Vm3UpQmNWyvU1Jcs7lX5DE9agdWimBkGc0AdNp9l9rsI5ydqJStKsDyomCWBBNV9GaU2E0CnI+9ioMNkyHp70AZ1wyoxOeN2MVC6qkwx3HFTXarv4/i7VXJZfmfBI6UAI5Ax3Jpibl+btU8gQlQByeaGiUZ3HigCEZKu3vUvHlrt4J60yJC6tg8CpICI+ep6igAVAZRt6jr9au6dMxuCG4K1UjlXzskY7mrUMipceY3fgCgDqLRDI6kNlH65r0j4U+OZPC2oSadevnT7ojkn7hHpXmVonmWW6Jjwc1Y1D5YElbO9RxQB714X1O41/4/2F1bTFoLe3dN+eCpwcV9AeKiq+GNXL42izmz/3wa+c/wBlXybm9uprofvlGUY9cV6P8YPF7Wfw+16SE/KzG1U9/mGKAPia7ZhdAxjHOM1IxLHnrSBQzAFuozULYilHO4Dk0AWViBYZ5XtUSyMJiHGADgVYhbe/HApbhFlYBOlAGrsBgCt90rk1zzxJ5jsrcA4rfnd7XSvnGZMfpXLwtucMTwx6UAXoWMjxqg4B60Xj7HZZVBJHFT6ch2zE8DtUd9Gcb35bGBQBgMAS23pmm5OSopz53sAO9AA2tu+92oAUL5gA3dKbIuAMHikcgnC9uKUHaMHnNAD3XKrTGBAHFPU7UyeQTimByVKHoDmgBzAHaM/WkTb8wOcDvSEkMT0wBTsruJxQAAFjk/dx1o+Vc0ZJbGfwpVA3MWHTtQAz73TmlIwB0puCOnUmlzsbB69cUAITlhxx3qTJOAp4HOKTKhmBHPSnALtAP3jzQBFk5OetA5fBGBQPvNxSqcAnvQAoYA4HUd6niQOwy3BHSoFA8wbuvpUqOFY7hz2oA0Y/l2mE7XXvWtZ2sU+hzyXL/vyx2jPWsG1YvIsYPJOTWvHC8IAdsoTx7UAVLiBXQgdVHSs/kOBKM4q9NP8AZrl9wyD+tVJ/3ky7F+91FAFzTrr7IjSDqxAx7Vbu5kMo24KMvbsay3hIcqPu1IFKBYk+bPU0AVrsgjAHzqc/hVco2AN2c8ipLh2iuW3joMfWpZ7cII5VIyecUAaehpapDLLdjc4GFFZ95l2IVCsYPWpLJGbDEd+la+t3cJtEghiAyPmNAHLuT5zCI9euKlUKrAsedtQphJCWyOeKsOgILnoaAICBu3djVvaoCs3GOlIyxuESPrinyjbGFfgigDo/D9ygG1RnPBFX9WUtCyg5Pr6Vi6QY4YNw++a0DOJIsbuO9AHu/wCy80MUN6x/10UL/liuL+Jvi7+0PBeq2CNnfqYfPsAa6D4GiTTfDfifWjxDHC0an3KGvDNbvWks1gP/AC0k8w+/NAGbKyKoKt84TFFu6RmNj8xbrVBj5tziPPvVt3WGDp8xOKANOVg4IQBc9K1fCFjDf6mscxxHGCzH9awMnyFYHJHauw8EIsSXd3crtj8shfckGgDC8Q3XmXswi4iT5QPasC1Ie4wo+Uc1avfMkuJVXuSaj02LdKCeNxwaANqyZTE4PB6/WszUpC0Wc9DgVvNaoELqRtUY+tYWo/LGWK96AMWMgsxAprN6ck9aUkebx901HnGcjntQADb05zT5WBZQo4HFNQnGSKXG0En1oAUdVz0zzTSBuY44p+f3WQBTWGVyOMUAOdgeFHJ4pjZJAxkCpC5MYIUAL3qNeWANADvTjOabubBHfNOcBX2joaFIQHdye1ACKcBS3rRJ9/cOnamg5GSKmf5gvAHvQAzkkED3px4UHo2c0yZvmwnpToxlckc+9ACoSx46mmsAAM9qVSfMwBzTJc7woOQKAHHLglfzpI5Mg55pFbAIH5U4bd42+nNAGhpYRZVdvvEYA9a37Gxe6uUV5MRA7n9hXN2bqrp3wa30nYTboiQGXB96AIddWG4nK2yjCcA+tV7eARtvPDAcVDbMftkhfgZ4FS3LNyDwDQBArqgkLNyahSRxGMdW5BonRHRSRjFIdwVR2HIoAU25kkV3OcHFHlsjkOSWP3RU+xnXKnqPypjsRJG3Vl4zQBe021uJYJJIRwnJNUr6UovzGrS6lNawS28JwJOpFZQSSZS03QdBQA8BZArAckUSo0cYXr60sSkAFuMUvmE5OMg0AMV0RQ33cVbdBO0RY9aqAKWJmHyjpU9oryuSMhe1AG5p0SrG5AyOlJfRLHbx7Dgk81YsrYgokZJB+8aS/UNNbRDseTQB6nfagNA+D40qCUCfUWWVsHnAzXhd/N51wqsflQYzXTeJ7qWeONGlbZGAq89q5G4VFBAbc3XmgCJHCzAxjnPNWSpkZmccDkCqkS/vEYcHNakcbz4iUcscfWgDU8Nacb2dePkH3q3fEN8ltGtparhFHIHer1jYrpGhghsTOOfpXJazciS4Z14PQ0AZM1y5kYoPmNaekWrNErFeSetZVsm+Vm6qOK7DSYittGoA25BzQBO1qYrBjn5vSudvd5BEi/LXYPGZFlV+GHSub1VQqnPUdqAONmj2SMPfIowcDPFWL6MicDHBqvuwpDcnt7UAKMA7v0pWUbST0NNQjfhulPwMMASQKAGkqseAaaSGGAOlDhS3yk9KUYOABzQAI25Sh4zSHoMjFNOScEYxTiAQBmgBp5YY/GldBkA0RHEh9BSMdzc/WgB/H3VPWm/xYPGKNu/p25pduTzxigBFQsCec1IgwoGeaSSQAjb0xg0xCQSQaAJkYKXB7jGfSoXUbuCT70uSecfjQCAnqaAHoimXDHHFRqP3px0FCnkljz0oAxyPWgCxBzJhVJXqa6AMn9n74wQV6GsiwuVtXDsofdwRXRSCC60V54BtVD8y0AY7plVmz857VA8rSzZY8DtTjOGbZEMqB1pkaLHKHkbIPagCTC7f3gpWgJYY/KrDqrMojG4Dk4p4wxJAwRQBVMTxnavO6nhQD5ZXt973qzLITDhV+b1qG7uESJQAC2P1oAzhH5bt5rZp8EmXwgypqMqbnAwdxNSQRSW7EsMIKAJ4gbiQRlcY71BOskMxUL8mavMxhjWRRlW6GoQJZW+fgdqAIkty2A+MHkVp20Z2EovAGMVYtNNa5tS6Zwn3q6Gy0SRLaK5dSLdjt3HpmgCpa4trQk9xnNVoUWWJbh+5wtLrUo+aGL7xICgVPqoFjHaW+P3iLkigDM1t45LoW45VB8x965icBpSFGD61s3LYtZGkOJJDkmsZ3JJKjIHAoASJGUZ7g12vgu0Et1FdzRkwxHJFc9pNkbqdV7dTXqOj2y6fpm3ysCUbRkUAYvia8UQ3LHIRh8lectLIzfPyc10/iu9E8/kx9FNYVjbmQnIyc0AXdKt9wyR15xXWaOqtAQ33h0FZ1vYSi1V1Qhh14qzY3DWdy28ZBHFAEz3rieQ4yy8YrH1R42UsfvGrcDNPqT46Hk1l6yu4kjjnFAHNX0j+eSTwelVuCeasXmXbHpUMa724x070AKu1Rnr6UBeWxkZpMDaOcn0o5JIHY0AMWM78Z5p2WQHjHpSqcHPemvlmJzmgB2cKMjml8oqW54oUgQncck9KVmULgnNADcrtPB3e1Ea5POBSRD5unBokbGMcD0oAXhZO+31oPz4x69aQHI9ac2VXBHHXNADepA9aMbWxSplXDDnHNOBRuW6k0ANjbOQw4PepIQGUrgEnpURHy4XpSqCuXz0oAJc+bt70rrhloXBbPU0kjfNkcqKAJQR5ozwa3tPP7trYc+dwBXPKqyMCGwe1dNo17a2NuZWXfcL93PY0ATDw/cQWxlnXy4lPfvWXLHH5b45IPFbGo6tc6rpTeZJgg/dHesNoZFAYngdqAJoJBA/ydxV+0KoAXA+eqCsrqNo+cikaKUxqwc5B6UAdSmlC8s824BcctiuXubZxfFYELuOCK3NC1GaGXYuVTb8xq55kEk2+3AEmeT60Ac7HavbuJJE2mpUEcs5En3D0Fb8tqb+3clh5sfJUd6x5rYrJvj+96UADWzOgiVeAcqKdDa+ZOIwv7zpj3qzZtJIyM+A49K3b6KC2W3ukGJuC3FAGz4A0c2120l8g+x7fnB71r+K7+0i0OW3s1UQ7yyDuKx9Q1WX7HBLbNiFgAwHrXF6ndXRnfzJCY27DmgC/4UtLfUfEdv8AbXCwIdzk+mKg1aT7frN5cpzEjYT6Vl28vkPuVioP61dtZYzE204zyaAMbWVfcuFyOnFZhXbhQOc9PetGa7dpmKgEK2Bn0rS8PaU2qaoIkQl34UAd+1AHUfDDwhc6zeoIkO0/NIcfdWu3+JDwaPZi1TaGjXapFe5fD3wba+D/AAOpkUNdvFvmcjpkdK+YPizqKaj4gufIfMSMVAoA86vJA0jOBkk16V8JPAUviCQzygiBT6dTXHeEtDm1rW7ezjQtvcDjtX3F8OfCVv4b0aKPy1EhUZBHSgDybxB4Mit7CRUgCugwOOteNeIdFuLKcO0bBH4HFfcGo6VbX4/fJz6ivM/iV4FSexEsABVDxgdKAPkUFrG6eEH944z9BVS7Pn2xx1Vjmun+IOhS6dqYnxhVHJrlZw/2EuOC56UAYdzFlzzgGqLArjHWr9yCWVCfxqnIAs3J4FACFduQTz6UR8EHFLyzuScZPWjABwDn1NACttBIxnNNyvQdaOMEd/Wk+4+c57UAOjUEMG5AppYFCD26U5RlDzg00j92DQAdeOhpSvRT1PekLHBP8QNP3BgcjLetACPhWx2HGaa/zvluAKQ7ieKfIS6gYw1ACqwCkEc1GG46cUZ55x61Iu1UJbr2oAblivygYxSEHZn86AW+6Oc07B2qB170AMHJ9KcrDaQV5NISN5x+VKPm5yKAADaVyMEVcgcOxK4461TY8Ak8mnIfLIwep5oA292LdEizlutS28BmiZicuOoqnayFZtxPyAdK0IHSGbcWx5gPFAEcUQSVmi5AFWLZRLKkhBEX8RpluGS0lkKEbjtGasW1yPI+yMm1epagBlzcf6QViXanrjqKhZvKUupIzT5yCVjh+bnAIqtdRyNEY+hHJoA09PvEt7uFmkLM/DCtDXII7G78qZiBKAyEVyk2IwhUEsO9d7ps9h4g0aN7xSbq0Hy+9AFaxaCJEPlM57cVoag00kAf7I/lnqQp4qD+1IrZI2jhUSA9CK6C18aGCBo57WN0k65XpQBzmipM80lvegx2UinBPY0strpum2sn2qbzpSx24wcL2qPXdXkvHZ4VCQL/AAiuWO+Yu8hJJ6A0AW7iWG5YtGm1B92mNKoPlIu3jk0knMSeUORT9RkjgtYiRh2HNAGYqh5xBGPmJ5NfQf7OHhMX/iRry4iJtbOPJJH3n7V4d4fspLu93qmQCFHvmvuj4WaHD4b8F225QkkkYmlPvigCj8ZvE8egeFp4Yz/pE67FA7Cvi68M11qDFgSzHNezfG7xCdW1WZYzmFWIHPSsT4SeFV8R+ILdJVzGGyx9AKAPWv2e/AEOmaYutX0Qa5mH7sMPuj1r201FZ20VnaxW8ChYo1CqB6VLQAVBfW63VpLC4yGUip6KAPl/46+GpBHawwrklvnrwTVfMhUwgfcO2vs742WsVvoM2okfNGpJ/CvjLUPNmnMh/wBVI5NAGFeJtQNg+9Zrbd/JNdLbWNxrGoLp2nwGa5fhEBAyfqa9Q8Ofsz+M9VZZNWk0/R4WxkSy+dJj2VMr+bCgDwyRlHT+IU2FNwK55PNfU3iX9mGDTfBF9Jod3fa34mURi2jLRW0LZkXecMf7m48v+deW/wDCgviYPu+GcH1+32v/AMcoA8rI25J4I7GhmBQcYOa9Sk+AHxOfk+Gsn/r/ALb/AOOUN+z/APEsqB/wjOD/ANf9r/8AHKAPLsYUNjimqxOMY9ga0NY0y80bVLvSdUi8i+tJWhmj3BtjqcEZUkH8DWY3BA5yKAJZ1AbgjJpgyG+XuKcQCpcdOgpVK429D2NADEzuJPUClJLDJ6CnN933B5NNyApBFACuittC9QOaUgA4AzxSrlGbI5PApELRzA4yO9ACKGWTPSkbIclc/jSkFjk8c0jMGPHWgAVRvySOaGIUkEd+tHSMH3oOXbsM0ANYBjkHtTdpUAk55qZRh8AdBUcjlmzjAHagC/bZcjnbx+ddd4O8OyeItbitozmNBud+wAGa4q3OZATkKK9I0vU7fRNFNvpsmLq5GZJM8gelAFXxdd20Wpm0sIx9ni+XPqaxLhTNHuTiknPnPvU53d/WkV3SMqBkigCtbuY7oFOg65qeVWMjSF857VXdT8pX5cnmpLlDDwrbgRQBDuLEAD5Sea3tDU29pc3CnaoA49azUEbbSowQORVyyYJaTrNkRyfdoADci5COW2sOtMNxJJOsfJQ96hS0+UMrcKOnrUolZbcELhxxQA3ULsxxmIH61DZjzThjziqrDzHfzDlicmtGCNIwjKckjFAEkAAdw3CCoL+SK5mjDDO3gVclcJpkjOBuY4HvVPSoftN2kYGQvJNAHe/CzR5dT8XaVY26/LvEkg9gQa+vfHF+mleG5I1YKWTYoHpivnb9my08zx1c3jH9zbxlc+hP/wCqvRPifrX9o3D28bYjQ8UAeE+KZw0kj5ypbJz6179+zfoi23hqTVXX5rhtqZHQDrXzvqKNqWvrp8YPzuEH1zX2f4J0hNC8K6dp8YH7qJd3uSOaANuiiigAoopRQB5t8drmKLwe8U+NkpKmvkPxJNZmdEsvlgRQCPevo345x6j4k8QW2gaewKKocgetfPXjbw1N4euBDdjErcAetAHJ3nlxQmTGS3erXh7xz4p8M7P7C1/UbONf+WKzEx/98HK/pStPDBbLFMm5up9qydQe33/IMMRQB6B4o+OfinxX4D1Lw5r6WF1Bd+WDcpF5cqlJFf8AhO052gdB1ryRc45FSS7QMKeCaHCjbs645oAbznjpSFW3Z9eKeRggHuKkcgYA60AIB8rAHkUJyxZhk45poJAfH8VJltpx070AKmfKJwcZocBmDA9f0pxDCMrxioj8pGaAHI2X2npTTneQOgqxlVK45PWoTJlzx160AKNzAH3pEZmbbnkcinRhkOGPemkHce2aAHFiwVegzTHVVIHrTiuQR1IpzBQEJ5b0oAZghj7U6QYQHoTSFckgHjNPcFByc56UANYgRBgct0qJV3KzHinHlcYwc0dMDPvQA8HaB3zWjYXKmHEpOSeD6VltkNipbfhRjkk0Ab0WBNjP7sdDWhEjNETEuR3NULMqQhcfL0Na1lI63BiUYgA6+tAFW1s1lmxI2F6mm6osUJBt/n29RV2WKJmxCSGY81nv+6lbI9uaAKUUrySkhdpPQVop5k9oYQuAnOabAkaxNNIQGqcHyysiN8p6igBlhDg73c7fSoLp91ztB4BovblRMRFwDRZ23mrukODnigCC6XawwOSOatWSlVBYEg/yqWSJIwS/JHSqE926ybI+4oAnvHM7CND+6BrT0iNbVpJm4AGPrWNBE5ZSemea2WPnKsWNqqM5oA9U+EGqRaFpV5NvHm3Ui8Z5A5FXfGGr/JNOGHAIBz1NeSaFqYiuDF5hAB9aZr+sXNzOYUkzED60AemfBjThrnjOO9nTMNr+8c+9fVqazZlwgcAdq+N/ht4rfQdH1ARJiV1PNblt8TZorRZHJMo96APriC6gnGYpVP41NXytYfEue52hZPJI7k16x4N8bobWM3EvnSy8ctQB6j2yeBXO+M/Fen+GtGnu7m4TzAh2IDyTTdb1iGbSJAknlFhyc9BXyp8VPEUGq3EljbTMfszFQxbhqAPQvhr4o0y31TV/FPiO+UzOh8mJjz64FeQfFXxG3ibWGvkXYpc7F9q5idj9njCsxZeSM1BcyvOyt2xgigCncAyowxlxVC9jWUKCpBxWtEFBDE/Nkiqt0zZdZE+YUAYQVUUqwzimZXkjuatyqCzkDANUpFKcdqAArlsk44oGWYA07Ibb+VIfvHHSgBcHYQOoPNMYlCMjrUoB+8G+U+tNBVlw/XPFAA5PXP4U1wcK2OKdLGFbI+6aRslV5z7UALGuRlulNPU4H609GG454A5x70nHJPNAAfmb5s5PSkYnPP0pqNznGQOMGnqFkcs3AoAZ8xPBxToiNxB60AnzS38I7UmCSWA4HWgBDnkE8igbuD6CnKoZTk4xSoGDbQc4oAaSSenWnbdsnbgZpgysh9cVJGgOWdjQA1Duk+bpSwt5WWUcihPmDKvT1oVtsbgDpQBpafMxZjIeDzit+1l3WhZm46CuWs3DZGcEVvWJUpGrc45xQBoKmFRhweuaLsRT2ol6MpwR61KjRuH+bHbFKbfEwijXdxk0AUbu1SOFFccMM1AJIxCxJwR0FXrmXzT5jAbV+UCsm8hV2DA4x1FABxI6v1pZro+ehGQq9qrxEqrKOq9KkwJSEI+dhmgBTdvNcdfk7VSxI1yW5IzWpZaex4ZSADyaWCMR3TZG5QaANCwjFrZyzznc5A2LSSXRhsSWHzuOParDYkkE5H7lRgL6GsG+lZ58KeBQBDZDbvznzCetTxZDk5JGc01Yvl81T81SEmNAdvJ60AX31FktyU4GMEetU47xnRQBwTk5qBmBLe/anRpIUHy4U96ALt3ffuSBkNgYxXQ6N4uurKGIxyEOg45rj5InV8kZFLhihJ4cdqAPR9S+J2q3dgLZZjlhgkVwz3Be6eSRsk/zrLKSIQI25qaNirHjLH1oAuLdMCwxjjmoI3kDBkycnpUanlt/JPBqwQURSgwR+tAEskIKhs4PX8ajYGSQSsd3Y0seGYFnyT2qa1sbl5WSJC3cD1oAx7lVLOp+XB6VnOioCTyuePaugv7K4Nwwa1cP/FxWPdK8ZbzIWWPpyKAKBXdnbQThcdKQHnIOBSqM53fhQA0E45JwKANw6daejfw4GKMMqAnH0oAcmd4DHJAqPG3nvTtzbgVznHWmyLxgHPfNAAp+bJHWnIqHdnj0pCTsGR09Kbt+bOcCgBzKFXIx700gkAfjSjDcDvSqApAz81ADQSrYYVKjAbgTjPpTeeOhz0pQDl1I+agCNPmYjOKeQY2Heo9pMgUDBqQErNye1ACAnzASM0pHJ55JqTzFDdMnFR5yW45oARW2grjGe9IcKh5zuobBUY60qLuNADoCIfnbv2rcsJt8obpuFY2M/NjpVqyuP3oB4weKAOjtFUTlnyVHWuiZBDCkgH7yTgfSudsmKliAGyc4rt7+2jtdDgnuP9bKuEHpQBw13AVuSm/EWc/jUElupIG47vStqWyFzG7A/MoziqsNvnZhSWzg0AZNzZnzxsPuavQ2aiAuSPNFSXMSpeMMnaKntLKS5Plxt1PJoAcZXfTwsSfODgnHWq0EG5mVRl+p9q158WtgyxgebGcfWqTSLbWrOxH2iQdKAKuqXyW9strGPmPWsy3hWQ+Y5wB1qM7prtQ5zz1q0qBFIkP4UANKDzQI+YxzUcshmYgL04FHmMinHQmrMG2BSWxlhxQAyKIKgLjLAdKcZPMhO3jb2p0Iw/nSHjpimEJ++KcA9qAItx25bpQuHfLnFNK4IGc5puMLlqAJCieYSG4xxUUW7LFuMHinFcx8df5Ux2aNCQNwoAV8pIBjIbnNXo48qsrN8nTFVNxdUOMEilid0yucrnOKAJY1VDMQSWHK1ctNVurIRXEQBKnkVnpLglscUKxWQsT8jdqAO+X4gK1pltLt3lPDsU5rkvEWtpqkZiFnHEvqq4qKMbYSeA3pVO8j2lCCCDyaAOdmiCyFBwMZpYl3KOnB61oahFH5YmX6VS3J5Z2kbqAI9g3kBhkdxQcZCknNMfj2oVepHagCQgpgKevBz2oVQN2CM4pZHDKjd6ZIc5IH4igBDwPelCF4PoaRRub5uM0jfKSvQUAC4UY9OaQ8kHvTnTKMxGOaVcZ9sUAJGwU5AORTpMtJnpTY8+YT2oJHmDcKAD7s3JpHYEjH40Lyxz1pQFJwRjNAAMBQAO9ALB/l4zTmVQcLyaa5xH/tZ5FACEH+HvTRlumRT4xuU4+8e1OiYIcOMigBrEHA6CliIRwe+aSQ5XO3GaXjcmaAOo0OYS3EaKec967rxc+LSyt5Dhiox+VefeGMHUoRKuwFhzXp+m6WPEXiiBZpALaADPuBQBl6ZYytdIwQiIgBiaj8RmytbvytPYHA+Y+9d78RdR03RbAWVntE+0YC15FDCxheaYnzXPGaAEciYEyHmtfTBi9soU+UNgsfxqnBDGMb+W9K1NHVFuvOnICxKSKAK+qqkdxeLn51Y4rlLi4dpjuO5sYrQ1S7Z7ueR/uuxwarQIglBRcnHJoAWzgAQSHuaryAmbLHNWL66GwLGu3mqYBdgyk4oAma338q3C9adK6uVVuMU1SEOCfdqZIQwLDqD0oAkDhWIbPWrCRK6OR0K1CWVoS2PnIxT7dnEGF5J4xQBE0Xl24lP3gahRWYEmr14rCLb1I7VUBYQnZ9+gBivtT5f4qlUb028VUWNiqsTg5q1hSCQcMBQA1yVKqByKZNHIr8Hlqfbgtye/AqSJwWZJBlu1AESFUU7jxjH40i5aHa3VTlTTGiEe/zD8pPAqSL5dpbnFAFiKXcAWBJ70NGJ1fAIHanRlftGR9zGcU5ZdzF0GBnGKAMu4VfKa3deeo+tZUbKilWX584NdFfruYSEfd/WsbUEEMokA4YUAUDlmJI4HSlOVGKRiSMZxmj5sdaABwpQY60DKDGeDTSCXxnGKcRljvHFABuIPH504AFssaawOAB+dIMA89RQBIC3kFTjO7kU3O0n1PanEljgjBJzmkA6YPNAB904bv2pyKoAJ59fam9QSSS1Nwc4B5NAAceYMHnuaeygNjPbNNLAP8Ad57UkmSfQ+lABKu3aQetOVQQSetLkNgMMYFNzsJFADTuQ7h+GKfIR94fiKjJIOD0p/3ArEZBoAQksp55FORSWXofSmjb16mhCQ4PagDodHu0CESgAp0IrpPDmp3T36taSkMvv1rgoiS0m37uOK6/w4EtJYJQfmbrg0AdNqlmGkF1qEpknY8L1rPuF3yH5RtXpire2Sd5J5vur0BqOaDERMbZ3DmgCtDBvZZweo4FWorbOj6g5f5w3yj8KcESHTocHLCq9+Xgs2lyR5nO2gDCaINbqZTkgdPelKlYAsYwT1PtT7JBNG5Zuc857UXhEcLBW7YFAGfKCIzJIOOi02JsMqgYHWnAmSMFj8q9qhG8k5HSgCbytzMS2MU5ggX/AGh29aYrAqMZJNIXAkBI5xgUASF1aRWAwBwRVq2QvfRJAchjz7VSeWOT5VwNvWtPSmWKB2wRgZ3YoAgu2ENxIm/c3eqLqyvnNJMgeWRtxyx609yxiQenGaAGgFzg8Y6Um75jgcd6cQVbmhCpJJ6UALGSGGPWnSgqST9/tUcTGLPHU8U99xYZ79KAGBDLIQ/UAYpJuAroMnoRUgcCRXUc9DTZhIki+h60ACNtdfSraKAwHQE81RjIjc5+bPQVPCzSS4YYA6UAWp4A+7nOOlZupxq1kMjLKeQK6COFVUbj171Xn04fYrm5XmMDnNAHFM4YDApp5Tg1NcRjfu6Cq46Y7UAPgCbmLnpSv8wzkYqMDnjNOBIPT2xQAqnkkZxSqoBLPwD2poY7Sgz1p4CmP5jyDQAhAaM4PzA/pUQzzingBxgHHFNbKcAfWgAZiHBpyuFwcc0FCAC35U0A/wAY47UAOVXkkzxmlAO4lvvdKagY8jt3oLsxPpnJoAfIpByTxUb/ADEnvinM24daWMjDgjnHFAAOWBcdBTMggbs4qXzNzZZe3aogMnb0xQAEkgNgAUgyx+tPY/LgDgUiH5eOGH60ASRqdpw3QdK6fQHKkM+SAK5NWIJOK6Xw6WZwj9DzQB2Pms6KrnCN0xQU+UYYgj+VQKvmlAh+RamuigK4zz1oARTuYxjlCcD2o1+VEFtbpyET5j75qWDaqnHJU5NZGpXa3N1IFGAgNAFKRhHA/lnG5uTVaeZSgJB2YwKdG/mB93EfSq04K4TgrmgBH2xrhTnNRRs7MBj5jTztYHnpUUMreaSo59aALFudkbE/e6CmkBjtboe9DOv3TwfWmuN68HpQBBND5UuVOcnsetbcdwTZxxsgHPNZiL5oyOq9PerEMjPKd5ACigCOV0aZ9vQUhJwBngU1EVEkzzuOQaaJC2d45oAnQeYxGc4FRqoiJ3c45pYjhiY+cimnPRjn3oAlUhwZHPHQCmMXb5lPQ03ywXC7/lWnoVETgZyaAFGI3GQCTzRdMHAKnmnWkfmXGWPQVHIFDFSRjNAEM0ZBRkPNTRmQOVJGfvZqN1dJmcn92egqa3QxnfI2dwoA0rKVpFUSnjNdBcw+T4VnYj93IxCn3rl1O4DyOorc1O8e40e0slOArbm/KgDhryL5OnIrKJzgeldRfW2wOW+7iuadNhJ2nGeKAEDHfx260gJeQ0p+V8469qULhjsoAecMMKOc8moz0wOQD3pyMVLbSCe9EpJUAAA96AGEc4Whc8lhkdKljUAbs5PQUigsSG470AGC7Z7dKSTIY5HyiljIBY9OOlJJ8pZRzuoAXOIyFOSelEYUIzMcdqbE5VfWg4bkeuKAGZw3safE/wB7jgc0rqMhF60qqFfA6DrQAiuGbpgYoThS3Xmmt0BI60+IbnC5wuKAHTBQoC9+tQvtDcHipHZdqmh23R9B1oAiI+YAHrXS6F98J/y0YYFc6NqcsMmtTSZZDIGB5zxQB2Vq/wB0K2NvWliLM5EgzzxUNnsIeNidxGc0okaWDYgwynrQBfgDrJcN/B2NYN2rRuXI5ataS43WMq5IxWNNNviBfqg4oAqXDCCPA69apRSM7Mc/Megq1dTZAcqMGqnnKH+RfmPFAD2Zo12uOD3odwIwI+v86bMHbagI5pu0pMqN/DQBNG/mY3DGOtPd0QAD8agaQAEnhiaRlLgMeDQBaVmVsgYQDNNklUWzEH5nPFNldgAFPAXmi0TzEGQCc0AW7hFW2iHqKrwguxWi5Z8gDtwKQPkAnhhxQAAeSpZfpTclThzweaS4BUZz8vpUasJGDN90UATkKy7weDU0ePMRSvFVIm+cqB8vXFPknYycdhQBZUt86gYJ6VCAqvhjk0+Bi0wDdMVAcISe+aAJSu7JZuB2qGS4OwsoyBS/dkz1z1o8vezBeFbmgC3ps7QtHKR8rHFbULB7lpAcrjpXNruC7CeBwKv27tGiopO7qaANDWLCSVcjiM81x12hiBVx0PFd2JTNB855UVyWtRlpGJ7dKAMV2zyetPBwg7Maaw7Ub/mBNADlAw/96iJhv9sUikJJu6ikkA3FhwDzQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This sagittal short tau inversion recovery (STIR) magnetic resonance image of the knee shows a high signal fluid structure posterior and medial to the knee joint (arrow) consistent with a Baker's (popliteal) cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD, and Celia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28304=[""].join("\n");
var outline_f27_41_28304=null;
var title_f27_41_28305="Candidal hyphae in cord";
var content_f27_41_28305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candidal hyphae in cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 256px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEAAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6jU7tzqG3crh8gcE/5zUhpBk8kAUevXrWdxi0hIAyeAO5opHUMrK4BU8EEcEGkBFeXMdpA80zAKoJOSBwOT19Bk1OfxprosilXUOp6gjINVrazS3u5pYliRJEUbFjAIILZOR1zkcdse5pgW6Q9P8A61Jzt65PqKdSAa7hNoIb5jgYUn88dB7morW4W6h82NZUXcybZY2jbKsQeGAOMjg9CMEZBBqYmjNACEZGOo64pe/JooJwRnqaADk9KWk5A55pRQAUlFGaADvR3oJx1xSZ4pXAXpR2prOqsoZgCxwBnr34/Clzg4OfagBaTPbmmqzF2DKAuflOevH6Up59KVwEVmLNwuzsQ3J9eKceehxR6UZGcZ56470AMgDiFBKwaQKNxHc+tSUx22gEIzZIHHbPf6U7tg0ANO5UXaDI2QDkgHryfy5p2eaWkByB/wDqoABnnIA54xS5pPWjpQAAhuhB7cUtIPbFFMBT3zxRR+NH07UAHekP5H1oyc9sdqKYCn24pDz+dAGKarZGRuxnGCMd6AFZiFLYJIBOAOTTJB5qbFkaNhhtyY3DnPcdDjFSDnuaQ53AHof8/wCNAEV1FJNGyRXEkDFSN6BSVJGARuBGQeeRjjnNSKdy/KcgcZ96d+dRJCsYYRjapOdo4HJyePUkk596AHlu/p3pikSBMq+GG7njbjHB56/4GmsdgckuwByDkc5P3R+g5/OpSPmBPI6Y9TRYBOBk+p55/pWbeQ294ksckUM9tsKvEy556Dv+H+TWJrl5PbuzSTtFEuNxxg5PYDp04rkbTx+CDBZ2rS+W4wpyN/oCefzrWFKUtYnRGhpc6bVNHzpVxBZQxRxtzGsZ2gHHQZpJ73R0sLa2nitLy6jhC7SgcBwOm/8APitp7+GeCGBz5NxPgiKQfdJHTiueu/DM39i3MVjEiTSq2GHDbsc8/wCH/wBeqUukivi+PQxvD+sanrDzpaRpbQRNgRwALjtjgcD3rpYbO/iDbmmRmbcQP/1Vi/Dfw9qOjS3eoa7sieaNUSMYKooJJz7+9bNzqk11MzpMLdAcKjJzj15q5u8rRsaRk2/cR2w6d/xpe9FFcpwjQQQCCCDyCKXvRQP1oAKRc5bIGM8YOcincUUAJR2paSgAoFAA7UYpAHaj0oGDyKPXtQAopKM9aTuKAAnBxxn0JxUTiZ3wDsXOdynnGOmCOuf5VN2pOc9qLgL9KKTPcHrQefpSAKQEHjuO3pS5pKVxjWTLK2TkdgadnPtRxjrxR3oAUUgzk5wPTnrSZPbpR1PFACg9qMdOtA9O9Ge2RnFAB3peOtIMY/pSg5x6+lACDOTkd+Pel+lGePajvyetNAFI3Q4JBPoKWg88E0CDij86TkjuKRWV87DnHcdKYDv5UenJpATuIxhRjn1o5A6D86AF/Wjt1o570fWmAgbdggVl+IpTFp21JY45mYeVvBwWByPfjGfwrUIDAqeh4xVLUrW3uVjiuoy8ZbaMA/KTwOR0oTV9Rq19TlofEF3Y6jp2myyR3ktwCzyDPyjsR/8AXrtCVzu74xkDtXlPjjUtL8L3r6jZO1xqPlkJb7gEVQeT/wDWrs/CfiFdW8O2t/eKLZ5I9xXbwB0z9DW043ipJaG04pq8TpSeQMdfakPBOOo7dM1knVfNjla0eGZVUbdh3Ek47CjSmuVDmYu5dtwBH3fUD0HGay5WR7J2uReKI4f7LuXmtxMFTefUY7iuG+HFzpl/f3MFvbRi5gxIsirnIJ6k16KuBc4ebeGBxuxg56CoNO0nTtMuLi4023jheT/WrH3I55Hrz0q4zUYOLLjU5FbuZ+q6NPdeILS/heJUiXLr0zjsfUVq3Gp2tudnmB5Onlpg5/wrM1vWfKjeOGRVXHzydNvsP85rh457MazFJHf5My4VAQU7/jmnGLmtehtSoOaXPsdFcXNze3TCR1SBdwMRBODkbec44GeMenQ5yiwSTDeoDDpy2Me2MGp5AscRjDxsiN03YJyOfr/OtK3SBogRGW9wKq9tjobjBWS0OmNJR60v61geUGaQdBnrS0nX60AHQj3opCQv3jgdOaAPmJ4ye9AAFUEkAAnqaWj3o7UAH1oHej9KKQCUdu/0o9+aRiQpIBPfA60AJIzKuUQucjgH9eadz+lH8qOD0xSAPyoopPbrQMOvX8aCcnB6+lAPGevpQeT0pAIRkds9uaO3alPTtik6E80ALn8qTPBoPXHBoye3agAGCA3PrzR0YelICSO/+FRE3Bu4vLEX2Qxv5hYnfvyuzA6Yxvznn7uO9AE/PSkzxjpz1oHOaAPTjPpQADOecAdqU88UmPy9qADwfbkUAKe1HX1o4o4/HvTARuwGMZxSYIlLFyQflCgcD3/Wn5x65pmPxxzQAo47nFLz7Zpv3uTkcd6XqMnpQIDkDgZwOPesvStVknleC/hFpcByqIWz5gHpWmRkjk5HPp+dc54x0e5v47e90xiup2bboVyAH56HPpzirhZuzKjbZnSDpyapanqlrpvlNeSeWsjbQ2CQD7+lcn4g8Q6vZppnl23lvOMTZXo4xnHt15qDxHquo/2P5ItQwmfG9xu4A9/fHNXGk21fqaRotrmOsfWbUhRbzJM5OPkOQPrVC58QSrr40qzt/OdYvMeQnAXI4H8vzriLW41fStGvbq2tl+UqIy3PB+9hevB/yaWPxHdxaVfSMZpr3yDJGXXBVeAdzD9K09j21NfYroWPG+g6bqF7Zvc6Yrtj5miY7d3Ug/Q1ftbPULrw6ltpiW8EUbeWUkUsGj78CuM8Haws8F9JPct5aSqQrH77nrXotprlnY2kYRJZGbJyo6Vc+aNo72NHT5YaasTQdFh0+7Z7ZPssZ6IHJ3e59D1rrYtoRQo47VzNv4gjvLryoI5FkxlcpjHqKtx66SWH2eTaowHKnBNYTU5O7MZwlKxN/bFm2ota/vROqksxiIBA9DWZdarc3JdNot4gcbQeW/H/AAqBb955Wcv8+PTgD2qndPI8REQyWGBu7ehFNQSOmlhuXWW5zPjLxBZabarbXAaa4I27UfBfjBPrwSOvc1leHPCuravKmoT2/wDZ9gP9WAcyMD3B/n+gJrf0DwpBBqMmoas32q8c5XPIT6D1967p5mjgMciSrEwZfnYjAPYEYPTgd/fNbup7NcsNR1HJPQ5WDQr7S7GSVtRkuQOSsnBPoASeual0/wAQXVpC0V1bySOGyG3IOMD1YGt2dZNQMbyENHG+9UI4Bwec+3Nc5e6/pkM7RzxCWReGJ7e3WpUnLdXHeTWu56f3opCCSMEjB/Ol9BXMeWGc+/bikPUYBJ6UvNFIBFJI+YAHnvn6UtAwQP60UAB+ho60f/qzR244pAFIKWikAn4c0e9A+7R04oARAQo3YyPQYFHc9/alpP50DDv9aDxS9/Sk79qVgDHPPJpABj5fwpfpRQAhOQe1HOcYOMdaOcjOB9aOo6Y9qAAY9B+FBpCOAMYHt2pR/WgBOxyfY0p4OccDnijHBx9aQfd4PI4zSADnggdf0pR19aQgZGSeenJ601lIyQxB+g/woAfg4/8Ar0e4pAD6DigdMk5z6UwFbv159Ka3HJ5zx0zTs96Q9evagCN0bcHjYgYwyk/KR7eh56//AFsO3YIXGCRxznpSkEgjrn/ClI575A/z/Ki4Dfn4O1Txg80pU5DccA8DPWlUcc8Eeh6UAALgcgcAZoAbIWEbEDzCASFH8RHbk1BeyvFZTSIVOxCenXHXj8DU+07iUPpkE9hXLfEfVF0zQfLaQRfaW8vf6CrhHmkkhxV3YoSR6nPoJa2kEskzEnI25H0ydo64FcNJ4b1yNzPqGpZt5HMfk797r3H06da6zw/f215oWnpLcmOYLnOeGAJxnn8ann8P2tvCy+dLm7O7cDnp0AP/ANbsa64y5G1+h2bHIeFb+78Q2Nna+W4t7e7CTMWziMe/516Fqt9Z2VrN9mtkuHdNrg/cC+h/wFcJK/8AYvk2doCIYW33D4++3Un+laei3N/rVnI8VlKC74jzxxjqfanUjze8ti3FNXkctqmlWFxdQRafZzIZT5myPhN2eAT15H9K9G8PaDcYWWfMKbQNh6g+gqfQdBTR3mvdWnSSVjuXH3V4/U1YutWmfPkfuV/h3feAHtU1Krl7sfvBNy0p/eassNrZxAOW2Dk/Ng//AKqyNQvUlV40Z2QnoWyBjsKqF5rkYPmvk53FtoHOeorE1XU47KfbKlw4J5KElR/Tv2rOMG3bqXToKOs2Xks1BLI7opbO3pz169e9XrOJmbe42BT2wc8+tMshE0PmSOohI3Fi+Mj3zXA+MfFzajNFp3h8y7FYq7xj7+eAFPUD1P5VcYSqOyNJzS0R6q95BCY7e3lia5k52BwSvOMn2qvfLkMZpZHGCq7Dznpke49a5XwTo39jWn2i8YSahcqNy7iTGOwrpFDyy5eQFARxtOAB1B565Oc+n51MoKMrJ3MYwtqyJ3uJEaFWCQsuNoU5ySc859O2Px7VzD+B7WRi/nSDdzgYP8xXatCoj3NxsOc5IA/D6VOm1VAK/mOacZuPwjdSK2R0mePekzilpO9YHmB3xQeh5xRRSAQDAAJJPqepoJAIBIzS0mAdpOCfXFAC0UnX1oJ9aQC0mcDJIA+tNcMxTY20A5bK5yMHj25xTuvBFAAeetDHAyBnHYd6PrR78/lSAT160HvkdulC4KjAOMd+KD6GgYi4KKQ27jr60uaAAAAD04ozjtSAWkI55zil70nWmAg6ccfWkAwuBn0GeTTiM460d6QDfrS/n+dGPSkcsoGxAxyARuxgZ5P5UrAGPXt+VKfwoPXt9KQ/iOKADPHTrQc8bQMZ5zQT+NIxOMryeOM470AO/GkHI45A49aO/SkOCuGGR6Y9KAHHv/SgfiPegDHtR+dMAHQZ7daTJ3Y6YpCTu+YcdcilOcgjpjGKLgL9earaleJYWNxdz8RQo0jEegHSpy6qDyeOTWDfz2+tWt7ZQs+MFGJ43dMge1VFXZUYuRc8O61b65piXluGVSSGV/vKR1BrP8WaLH4hsxb3YC2qHfvXGUOOeDwar6HGmnWwjto5JRJhifkUZ/76q/rcb32i3doyy27SJjcwDA88j5SfT8j9av4Z3iaOPJLQ8e1ee1m1GPT9BdHuEdYt4JxleNvoRx1rr/CUVz4f0poLucSbpjKmWLLGT1Ck9BntUOh+Gbewu5LiKEm5lJyxXGD7Vv6hokN1pcq6k5ihIydp+f14/wA/4V1TqRaUOh3SjFL3itBov9pzCaT5IefMYD74PUH1rWivbXSbCO00/fO8eRk8YGe5xj8qz5LhjF5EbyJaZG1Hbk8AflxnHPU/QT2dg9wQYU4HHzDAP+NYvVa7BKmn71TRdiHfLcyebO4JBJyW4UfyxVmCNFXdBH9pb/no/C/h61XvL60srv7GkS3l7xn/AJ5xfX368VYitp5lDPJIGPVen6UWK5k1poi/aaU0kYluZTIMcJ2FOnSytY9t2EyRwu3PHpVHybqFd0VzIO/yjAx/k1WlheRi0hZ36EseePaptd7mag5PWWhg+Jon1YNZQbks5Rjco2kHsKl8N+GrTSLRFiUPLgbpCoyfx9OlSaQJrq9kkmdykZ+RRwuD6+pqO1m1ePxGRqPlJp+dsSYyWPTI/PrXR71uVMu6WxphbhL1AsK/ZsZeQNg59Md81Pb31s9y8SSxFx8oTJ5PfNRarfwafaSSSMEiVSxLdh6DHc15pqXiDT5/E9rfQ3MkZXaXXZjJHH+FKFPnE3zbnry3TfaxA4KNs3Z55HT+tVH1e2eR/JmhmVWK7kZSOO3FU5Zl1nTnt0mYW80B8uYcMOCOvse1cJB8Or7yx/xMYsdtqNyPf3pwpxfxOxjaz1R70wypDdDwaU9KWkPauQ4DO17WrHQrJbjUJGRHcRRoil3kc9FVQCSTUNn4i024sxczTGxUyGIpfKbdwwAOMPjsR+dUvGWh3erLptzpc0Eeoabci4hWcExPxgq2OR9RWL4l8O+JPEFrai7k0gMvnLJDG7qoVlUKRJtLHBBJHyg8elYylNN2R6eHw+GqQhzzs3e+u3bS2t+99ztJ9RsYNv2i8tot2CN8qrnPTqe9Utc8Q6fo7Qx3k6maaVIlhRgXy52g7c52571xA+Hl3Np00V2NOlnOixafC0mW8uZc/MCV4HI5HPHSnT+BNVN6xRtMkjku7W7e4lZ/OXygoaMfKcrwSOR16VLnPojeGDwXN71a9vlfb/g/cd3DrFo1rJczyLaRJM0O64dUBYHHBzjnt3qrpnifStR0uyvluo7eK8BMK3LrG7YJHTPqK5VPBWpQPYzIdNuXtb+7ufs9wzeU6TfdP3T8y+mMcnnvWVdfDvXJfD2n6YLjTXSCye3cF2TbKZGYOGCbmXBA2nAB55pOc+xUcHgZaOra7+5e9/kn87HpOnatbahqGo2kAk82wkWKXcMDJUMMeowaraP4i0zUvNS3nWOSKSSIxysFY7CQzAZ5GQeao+EtEuNEudWnvJrdku3hZCjk42xKhzkDuOK5208FFJ7Kcf2e86atNdzTRhizwvuwm4L15GQePeq5p2Tsc6oYRymnPZKz8+W7/HQ9Ba+tFUM1zAFKeYCZBgrnG76c9aoaj4h06wit5JJ1mjmu0sg0LBgkjHADc8Y7+leVf8I1fxeEPFQa1v55x/xL9Nja2fzPsyTbxgYzgk5/4CK6SXwNeXdzNPcrpUXn6jZ3UtlDuMKwwggjlRlmBORgDjrUe0m9kdLy/CUnedW6Tt6/C/1fzVup3Umqactqly9/aLbM2FmaZQhI7A5xTptQsreKKSa8t40mIEbvKoDntjnn8K4SfwPqccNxb2bactpJq0159myYx5LoqqoYIShBByFGCD1rP/4VvqX9m6VHJLY3L29i9lPC8zomDIzBkYIT0YAjA6Dmm5z/AJTOOCwbs3W6/hr/AJemp6ZqF6lkLcujv50yQDYBwWPU5I4/X2ojv7OW48iK7t2nILeWsiliBwTjOeKxNb0C6vtK8P20EkKvp95a3EpdmwVi+8FOCSfTP4msTRvA0+n3ei3RFgtzaX1zcXE0ed8kcm7aoO3JIyODxxVOUk9Ec9PD4aVJylUtLXT5O35JfM7xp4UfY8sauFLlSwBCjqfpUEuoWa7EN5bK8m0IDKBu3dMc857YrmfFnh3Vr7XGv9IlsQJ9Nl06VbouNodt25doOTn1rAvPhze3OnTwyf2c9ybCwtYZHydjQkeZg7cgEDAx174pOcuiNKGEws4xlUrWvbptrb8NzuNQ8R6ZZCzaS4SSK7nNuksTKyKwBJ3HOAAAadfa5aW0YcM8sLW8lwJoSrrtQZODnk+nWuOuvA19HcPJYRaU0C6v/aEVtIzJH5flbNpAQgHPPAIotPAeoW8NuDcWZZbW+SRFLKiPPyoQY+4Pz9qlyn2NfquBsn7T+rN/LojstM1y11BInhWSOGS0jvFkk2qoRxkZ54OOtSNrOmCBJ21KzEDsUWTz02kjqAc4zXD3HgHULiyaBrq1T/iVWdl1ZlaSFgzBhgZQ4x6+1Sa34S1rVbaNFt9DtF3y+bb27MituRFVvM8vcTlTkYUEBR2o5p22F9Uwcpq1Wy/LT8b7fLXc7ODWLabWptLjLm4igW5LYGwoxIGD+FWXvbVLtbV7qFbl+VhMgDn6L1rlvBvhe+0XUIbi7mt3VNLgsSI2YnehOTyB8vPH8qhPhS9TVtWKrpsttqNw032uYN9pt8pt2pxg4xwdwxzxVc0rXsYyw+G9pKMamiS17vr/AJ2+R1kd/ZSpLIl7bOsJAkZZAQh9G54P1qDVtb0/StOmvLy5hWONHcAOpZ9gyVUE8tx0rz6T4earJo95bGTTIJjpsenRCEsFl2yK/mynbw3y4wAep5rV8T+CJri8lfQ7bSY7aTTZbAQTKY1gZmJ81AqkbueenTrU807bGywmDVRJ1bq7+5JdfO/4dzt7C5S9sre6hDeVPGsi7uCFYZH481Pk4FUtGtHstGsLSYqzwQRxMVztJVQCRntxV0n61qtjyqiipNR2DvxkGgDHU0H8aTnnHA5pkCg9uf8ACgkDOcD1zTJWVE3bc89hk5rDvtQluCLeGM/vPl388Z/rVJNlwpub0E8Y6nJYaLd/Zhmfy/lbsuSADXH+GI9bttEiuokjea4bc7vjaEz3z689P/1aWuxPKzW8sjEAKrBjwSPQVpaKJbmCOCNgkMP8IGQVxj8utbxajCx2Ol7KnzdzCu49RtpftrbZLdnCloQcIPp7c13umYktopo5A6Ogwytke1ZmvR3MFpGbHYYllHnRsAN6HryaqRahaaTZ/Y9OBZFJ2DdwuSTjNTJ88VYybnWSSRu6jdw2MDSy479BXA65rDJE13ebs7sRwjue3HrVq6lmvLkmdgwU/dBzz2p8GijUdQikmAeCJHDoRwGPT9MVUIqO51U6SoR5pbjfC+kT6kIr6/kBVvmWNeFA7Aep9Sf/AK1dLrMtxDbG201USQj5pCOFHt6muV8Eam6adc2gyqW8pjQ9sc+tdIiy3Tru3IvXOev+eadRPn16GM05vmk9DL0PSYYFzHGwXOW34JZz1yeh/CuiEagLlgWzxz/OmxLHFFhFIIxnAqQuMZ2nI59/zqJSb1MpzcnoRY6pjtwcdqrTocs0arvYjfuGPTn8qsySADd05+97HvTGdWA3EsDwAT/MUkEW1qcReWV7pUcxtgULyb2b7wJP/wCuqceqXUcptlSOW527leQfL7cnv9a7HUf38DBZGhkJCb2HIH+c1xlhZeIrrXLm5nhghteYvJlbhoweAMd+M/jXVB8yuzdT0szDu9fu4b77FrFjOiSnAbPyAdiB3A9jVS4+HtxLK0mn3EBU4Pzs2R+nSu/fS7yO6jd5YJLVeTFIu/Zn0JrYSW182IG4TJXITOHPviqdbl+ANLGX4Y066sdJtLO6eORogW+705z0x24rWnsgJWKsoDc/Mc0+AbS4Z8q5wq46D0/rSTy+U4XG7Kg55/xrCUm3clys9DrSoPUA855oPTpR+dGc9KwOAQnkDBOfTtSmj+VA7nPBFIAoNGeetFAAaB19qKOmBmgCIxx+UEAVUUfKFGNvGOPSpD0NKaBSATgCjIBA5JPtQeoNH60AQ3dxDZ201zdzRQW0KNJNNK4RI0UZLMTwAAOSalVg6hlIYEZBB4IqK9tLe/s5rS9giuLWdDHJDMgdHU8FWB4II7GvKx4H8SfD4vc/DG8bUNHBBfwxqcxMYG4ljbTscxnno2VJJJJ4FNID1rp9KQAZ75x61xfgf4jaP4ouDpsyz6P4jhUG40bUV8q4jOCcoDjzFwCdy9iCQM4rtceuMUmrAJznNJ04zx/WnUmQSRzkVIwxwR/9ajsM0hPb+VHJxgDHrQAv86Me3FBPHag80AH5UnOOKOnTNKM0AIaQnAJ6genJpfpRn8aADjcfXriob2dILaSWQMyoCxxycAc1PnGPaqOqME0+dFaNXeNkjMjYG7HGTTQ1uV7PU2ntvPMLBexb5Tg9CKzrLxQuoajJaW8DKkYO6YkFc+3NcJN4g1CaCHTL25Eca4SSWEEBhnoufWtSxjFrciKCynk/h5bCEnrn3rp9iknc640E9Wd6l6ZEUxgsH53n09abG0VpJGlwQJZWwp9faq9xJFo9nCZnf5iBgkE7sdB/hXKeK7p5fFWm2iMSsce+QZ5UnHX9KzjDmduhEY875Y7MueKtYg+2m2hjfzCCRMo64PNVIruZYYzFI8SkBlwcduKow20Mt1dEeb5hxu56ewrRcRww5LIFQZyecfStLJKx6EaahG25DJI8uDczSyY5wxJ6/wBaIX3fNFEMZxu7U+3tmufncERdBjjdXRaZpgUo0uRzwo/z/OiTUSpVY00UrTSpXgLYVc859a1btl0nRppSVVguAT3JrSkMVvA0k5VUVfmY8CuY1O4/thYkEZitYm3Lu6lu3HpWa9967HDzzxD8jil1TT9AtUsrjzZJyPNZI2AIJORuOe/t2rvtB1AX2lWs67E82INwc/hj0rHvtC0qdJzJZR7rhNkkiIN7jOc59c1q2YstFsIIDtggVdqKx59q2m4yWm5VV8yJLa5kluNxJ8oH5QTnPbgZq6GLt2APPH6Vm2MsN2jvZtkgnBP8PtVzLiMEhScZO3tj/Cs2jNpPYnZhyGwfX/PrVbeSsR2sHPQZ7fWhLgEqNwDdevWmzXZaMiEqX4OQcd+tFhJNERVprlonbzEC5dT3z6GodYvNM0iBZ76UQqflBbn8qS1mZATI5Y5yMHOTn+X+Fc/4z8PR+Ifsc0sk4a2JBiQjBXPPX+L3q4pOVpPQ1ad9Dnfi34qu9BsbA6Y5iW6BlEgAznjH061j6Prcuu6LB4kmAXUtPcQS8/LKrHg7fUEn866LxV4ZXxNDDYzJJbGAA28mQ25SOjL2xx61b8KfDm30fTZoJ5WuTOwZ1cYTjoAPqAT/APrrpjKnCCvuJpxep0Nvdx3mm2zQk7GwX4xyQep/L/69XLaKUwgPuYrxwasWmn/Z4FXYfLHHTHb09OaY4AYjKp7Dmua62Q+dLRHWBgRlTkdKMZ6/pS0jA9iPxFYHnh+YpaQgHr65oPQ96AF/OikoPIFIAoo78UgIOeckUAL1o60UZpAJnNFLSAY6dOtAC0wxqZlkZF8xQQGxyAcZx+QpwJ5yCMH86B+dAHM+NPBGheM7aEa3Z/6Xbnda31u5iubV+zRyDkEHDAHIyBkHFcS2p+OPhqZDr0c3jHwhCGK6haoDqdqgAx5yZAlA6FhzjczEfdr1wUChMDH8LeJdG8WaSmp+HNRg1CxZim+I8q2M7WUgFTgg4IBwRWtg7w244AI29j7+v/66898V/DG0vtYbxB4T1Gfwt4mIO68sVHlXWW3H7RD92XJzycHJBO7AFZ+mfEvUPD15HpfxX0uLQppGEdvrNszSabdsWIAD4zCSBnD9lJO3gU7dUB6l1GOopOmM9TSQyRzRxSwSrJFIodHQ7lZTyCD3GKcRkjPY9KiwwY/T8aKOw4ozyO56daADqB70isCocZwRuGRg4+hqt9rP9pC02Y/deaH3decYx/WoJtXt4b4Wr7gxOC+OM07MqMJS2Ro87j3HajPqcD60hIxzj1pTjNIkZJuIARlDE8cZ7Vx2q6FqmssHur4QW6tkxgc4B/rj9af438U/2XCkFkiTXDt84Y7QF74NGjawup6hFavJuYR+aVBJUe2e9bQjOK50dFOEkrmbp/h2wl1HmOeXLEgu33e/HpXY6fpUNgSYgWA6BuSD9a0I0VAMKF+grO1rVrTS9PuryeWPbABuUHJ3E4UfUkgVMpynoKdZz0jojM8WNpsJtLzUpJd9ud8UKHIc9twx0469K59poL+YXottsrDeHI+Ykf8A1v0rmLaDUte1htR1WSVIgNoizjfjoPp1rrbeExxbI1JAXnnNbuPIlG92duGouK5pC2NxHcWzzIu1s4Y+/SmPYG+WSNCVKgkEfyqC3V7SORFBAZyxPpntW7DIlpoz7eJZWA68+9J+69Dacmlp1IoysMMEQUh0jAZe4bNWptVkSARQH970L8EL9PesrLD5MEE/eJ5IFadpbBZIw2A5HyqfSpaXUznCMUufUrNBdTp5l9PI6k52k9R/TrVyC3zCIxGu3BwDnP0q9KqqCzjKjt/9apI8BRngkZCnjFLmOeVW6sUZ7ZtrEOisANgK8D9az9T0aDVDBJK8qNGpXB/i5649eOtaUpuJLtERSsRb5nAHGBnn8aWeIlgFYkqcn69+KqLa1RF29yhpECabH9mI3nduEgHX/wDVXJeOrnxDJqdsNFaZbYNteOMZ5Hc8dK7pG8tckEnoOcnms7UJRFDc3IUFEB+bOASBn+lVCVpczVzRJN3ZwPjPxXq2iRWqLaw+eFLTNt3qfxPT8K6rStRXU9Csbq0iEJuYd5+bGDjkH6HNef8AivUH8SeG0utKhku2S4CTxhSdpwcZ9jXSeDYLjRvDLLeQZkUeYEPB46j+dbyglC9rM0T1NrwfaXVnZuk9wjgkkfLyM1syWxe2MMrBom+8O7DuPauT8Ga3qGqyXRmtmhhjAEZkH3s9ea7GW58myEg2glScN344/UY/lWVW8Za7kyfYfawxQuZMkM7fLubt7fWlu9UtbSXypDtf+FcZIBzjPtXinifxxNa6oYZbgxOJMoAxyoHTj09q6LQ4L25ZTeTSln2urSKSZMjjn36Vp9XduaTM5q7u2eq2zSS2wd5dqn+4OCOo59ufzrMllAkYKJGA49cVPaTTCxjR8EhcEdPb/P8Ak0Q229WZgpcsckLnPofyxxXOlZkx91ts6rFJTY1KxqruZGAALMBlj68cU7vWRxh3AwaKMCgdO35UgAccUHpzS/hSHjtQAUUhHpjP0peAelABjI5FIGG4rkbh1FLj8aO/WgBCeecCjIyORS5opANOMdcZ44qnbTP5/lMp2AE7iw656Y69Of8APN3rWXruq2miWUl9eMyoOOBk/gKLX0RcddDJ1DxOYZmW3QEKSDu74/lXQ2c7T20cjqI3YAlfQ15KPEr3uuNdRwWsdvz5e3ksc8E9q7zw7c6hNLsu5QwVSZFKgEehrWdJxR116cFBcsbHSAggnj86g1CztNSsprPULa3u7SVdskE8YkjcejKQQRU6qB069+aR3KsBtJBPJHb/AD/WsTiPKZPAniHwJN9r+Ft+sukKd8vhfUZS0D4yWFvMxLRMxJ4Py7jljgBa6HwP8SdI8T3kmk3cVxoniaDAn0fUh5c4JXcTHn/WpgEgjnGCQMiu2aRQoPJ7AAc+lc3448E6D4406O18Q2IlaLJt7hDsntmI+9G45ByAccglRkHFVe+4rHSg7V6kn1I5pjE7+449K8qW88dfDiTGpx3XjXwimQt1bpu1a1XgL5iZAnAPVh83LMSAMVJqvxt8F6bYabqLa1Fd2WoXIt4TaZaSLA+aSZDhkVcrkY3fMMA0uXsNE/j/AMQXllqbW9gvl33l+WsgU8oTxj3zXQeHdIe30eJdRYzXagszlz144z7c1oR2enX09vrEey7aWNXimjk3xupXKupHByp4I4q1OnmkRjGzqqjjPXrWrmuVRivU6YystCjqWoGVfs9uGaXttH05PsKsvdHTbUS3krtkBdqKSQaprf2mj6nb6fNBcG5uiCJVTMYPpnr+VReJJxPZKyBDi4jVT6jPPNSo7K2g3Z+7FaE1/pNpqF//AKTbI6bPmBGe/wBPesPwi1qniS/jtocJEvyKoOVGccj1rb8SeIbPQBG11IsQkbGWGScenvXG/DrVtPfxVqJN8HnmTCIQQcbun6VcFJwk+lh3fJd7WPS7ps20uDIgZSoKryue/wCFeJ6kl1p97PJCZ747XOLZdzS7QScKeCx6Adya9k16dI9LnVn2tIvlgA888ce/WvNrKxg0eHCtJKSSx5y7euB6U8O+VMvC0+a8nsa9ooMCgZwVz8y8jPr7jPT161pRNHGCep/WsSyu5b3aoXy06iNfTnnPeuitbQRoZLlSAB09T6CiStudsprluyi9us0vmohGRhj0/MU8gIExyVO7HYn1xVq+n2kAjB7Rrx170y2t3mk+fHvzxj0pX6slSSV3sO0+FpJvOmO5uvPQn1rScqiNu3OQCxCjJI9B6k9gKfGhSNVHG7P1zTLqNGjcO2ISCGCnHbn+dTe5yVJ87JLc+cXwuFDYUng/l2pNzrGGY72LcAt2qKyT5ThiRnP0/wA89aGQoW38sw3ZAzjrRbUzsr2J2kwPun5jg/j1zVC4kS3EkrKxVU3Y3AcD6/1qae5OwKvJK9uuPWs68h+0q0DRhoXTDg9MnHX0ppFQgcnB4+sZr77NdoVjJK5AyR1Ayc9K6kNBrmmy2GwoYgI3XgAgggd/Q15do3ww1S78QZu3jj02OcktuO51ByABjrXtK200epxYwLZEw3qSBwDxW9ZQjbkZUpJepy+gaPZ+CNBvWTcYUHn3Nw5ByegAGew6e5ritK8eWmv+IorCPT5G86QqHWTHH95l6dPevRPHWijX/D01jHcvbs8m7LAAsAehx/CeD+Vc34J8B2XhwpLCfOvZD/rnP3OOwHSiEotOc3dkU2279DpoIVs4DFbWsdvEv+78o475681JdZnj2oqg7MEt6HqM9vrUMtx8piaRQ3RiB1/CnRT2kVs0sriJEUs0kp4Hrk/jWfmbuNldnM6h8PNEnvIb57YtPEQzMZch8YxuHT/GurheSKMOyrvU7eD0FPjKXqLJbSh0b5lKH5SOh5/H/OKc1uI0xO48xsHA7D/OPz96pzcviZGmzII5WkZnZQEBJ5fHT8P881rQPGYlbecEZyATn8hWdLZtJ5agAruDEH29KuiRGAZJQqNyuDwR2I9jUNozqWeiOhUggEUvpSKMClrI4wOf8aSgHI6EexpRQAnPWmsCSuGwAeR69adgEc803L7vurtz6nOMfT1pAO+lH54opOcD19qAFFIBgcdO1L1pBzyKQC55780gAVcDPHvmgmjnFACE8VwHxVuYrW1txfFjayKUxtJ+Ykdh/nivQOMdKrXkMEsebhVKrzk1UJcsk2aUp8krnzDBL/YWq3W65VraM7mROctnhc/wn617h4J1WbU7qVoXMtpgEyOPbgD39a8e1LRrHRPEd60Es1xFdZwjdgSTtx/jXefDl5Yp2t/9RbON23dwCcd/6V21oqUeY7Zxcou56Nd6kEljjhw4ZtuV5yT2rC1wa+ttL/ZLyh9+VbOSo9Np611VtaxW64ijC564qc8YyOPWuKMlHWxyKajokcr4Y8Tx6hut9Q/c6hD8ro3y7j6iulSeJkyjqR14NZOp+HrO8u47wR7LlM/Mpxk+9SppzHImIweDinPkbvHQfLBq9yzJd4m8qPJZcFiMcA9DXx3+0F8OvFOofEG71az0zTZYL9i0FvphUShcnBlTarNK5yxI3ZJxkgCvpC5tZdL8Spb2l/ctJMoYecnmBQff8Kpa54Z1S68Zwzm1jn03cm7dgggYJyD06e9aQglu+g5U42VmfPnwS+LGrfDTUh4W8bwX0GiOwCpcwssunMTy4RhuMZJyy9vvKM5DfX7yq+nLd2MiXXnKrxSxMCHVsYZWGQQQc5pNS0y11y2ltNbsLK/09wpEF1EJVLDJyVYEccYP19qx7HQtO8HaNDY+HbeW2sWvA6WwmeRI2c5YIGJ2KTk7RhckkAZJrJtNmSunYr3moxWOqw6dKJka4baJnOQ+OCo9K2b7TRcQxxx5jWORXC4yWIzge1WdV0m21JFFwh3IQyOp+ZT7GrsKlFxkn5QMnvQ5KyaNZVb2aPOfE8cuov5OrWyyKjZRJE5Uev41reE/Cmj6d/xNo7URzyLli/RMHqM/SutntYJnVpoUcjgFlzXN+Kr0+cllG5UAB5cenYfjVKcmuVOx0+0VdRpwjZ9Shq942oTOxJjjIKxlvuj3qgtvDezOxMbiRBGVB3AYOcAj3ri/ix4hltbaDSLZ1S4cnesfG1cjgnuf8a6n4N+Hns7E6hK0h89cBW6HpyB9c81uoclPnZrKpGnGyWiOu0bRgkpmkXqc56EmneLNVg0e0aeTHyKdvPAPr710LERoT0UV89+OdZk8W+Pk0e1lf7FG4jO08Yxlj9aypQdWeuyOWM5VZ3Z3/hm+k1uxF48Zj8wnZk5yv96urgQRgbQNo45NZuhWkNhpcESJtjiUL64Hsa0p5dsQK5B7Y6mlJpvTY2qycnyk7PsQEgk9iOlVLghlAjXDKcY7f561mTaxYRX62Ul2qzkAGMk9+fT3rS3RsFCSYycqQOlHK1uZKNiTcsRCZIIGf/1/nTZXjKKOQe2On1wawvFF5NYxwtHIcYwTjk5NUvD2rSyh7VSgt4wTvbkgnJI98nNWqbceYpRb1OkuCFcL3xyc96fJG0JtX3KUJ+dmOMA+p/KoGaRozLIDnPPT9KtQXodE3LskX2yDgVOoSUktDTuECRhVG0D+EZ/SomlMUDNJxgkD39MVlRaorhx5LY52knggnr/n9KnyLl/MDMcD5Vydv6VPK+pj7Nrc878W+MTY+JoNNjjJQ4ExzkAkfdA/GuwsdRjltklC8OgIUnkZqpc+C9MutVk1G4hJnyGwzcA9On+elNvYLe2uPs9kpSGNQpX39D/hW7cGko7nTSSk+UyPGeqP4f0wajDaNOXkWMDsCR94kZ9KzPHEF/rHhGK105XJumVpApAOMdCPr/KmfE7V9S0yztINJshcR3BDSNIA4BHbB+ma8y1vxFqena1HMZJI7lGU4zwPwroo03JKSKnLmupbHsfwu07UNEtYbHVpI2nb/UANyF9/0rvp7QB9xYYXkYXrx+v/ANeub8F6yuoaPaanNAEnuUVXds7sZIJx68H64ro7lhMrtGxDEdRnAxntkep+tc1VtzdznqOXMOlIRd2AGHQsM/8A16zwpmAkV2yeWAO7B7jNLJKGjOAxK8rnHJ7fp1pIbGwnTfNZo75PLwgk/jzn61CdgS5dWdbSEfWo7oSNbyLAVEpUhS3QUllKZ7WKQqVLDJBrM4yakNKaKQCZz2IpAdw4yOSORilHSjPzEegBoAWk9cCij1zSAOQaDQeuaKAEBBHBz24opsqb43TLDcCpKnBGfQ9qVV2qF5IAxycn86QARzyOlIygqQRkdx60DjAyWIHU0vtQM881vwpO+tz30lvFdWbkuEX5WT296teFbIXOptcPEI4YxxGq4Xd2z712+eOeM1WjWG0QpCqquc4Faus3GzN1Wk48paPHaowERAqLtXsBVRrsZxnJ6c9zUDXWBxgMTjj2rKxKpNmiZRt+g5NNabHJ+prIlvlH3mwOcH+dUpdXtVJDzBRnJDHgf54pqLNFQZvtIu7dgbx0YgZ+mTTJbgnaAcKemOtYSXsboGidWTswOR60+G63P82AAcnP5U+U0+rW1OgjLTKCzYQ9Avf8aoeJHFvo8s4Ulbd0l464VgTU9rOGQbMkdAcdqnvohNYzw5BWVCmOO4xULR6nK1ZiRX9vIFKyD5gCPof/ANdTpKjIZEdWQ4IZTkH8a8/t47ppIdKZsGNT58g67Bwo+proLSJLO1W3tUKRDnB5rSVO3U6JYdK1mWo9Sk82ZLgBFUEqy1wdxqb3+pXVxGN2w7lxnkjgD6dK7CeRBBJvA2txkd65yyso0BSGPZvOePU1ULK52YeEVeS0PPfDnhfUvEvjOO/urd/scUu6V5eN3U4wevNfQVnbR2trHDCoVI1CqAOAAK5vRo7rQp5Ir8+bZztvSYZJjP8Adb2qXxd4tsPDscQuJf303C7RnA9aqtKVWSSXpY4ar55csdjT8QXHk6bKqH946lR7Z614n8PtEnh8WapNexESIxwzDg5bOQfpXpU1017jdhgwDD8fWo7gi1DTSZEcS722rknvxx7dKdOTgnHuddOiqcddzJ8d+KV8PWKGEwvcnGyKRyCF/vYHOP51N4P1W8v9Lt7nUwVupXYhAMcY469PWuO1DTh4lS98U25R2ilUwxP94BeOR6jPeut0e9g1azW5iBWUIyFc/wCrcj5m988VrKCjDz6/5EQVyCK2sNS8SBob9W1GJjuijAQHGMYJ5OP19u/T6mn7jy4/3c4B2lXxjnr618z+LbbWPCniIS3G/wD1geGdOhPtx1FfQei61bav4Ut9cndozJCDIXXAZhwen4/nTrU3FKSd0Qpa6nIateXAuTDPEzqrbCxJOPpV+xvl0+2kmbiSRsL2yAMcVqwWFtfTyzx5KJlwFOckn9eKwb61ebU4o1hcnPG3ptq01LQ30Ot8P3Ml9bSSSxMg+6A38XYkVo3P70gZGxR8oxjJpLbZbQJBGh8sAKQeen+f51Zj5Yq3Uev90Z/SuWT1uZ3tqzPKxkujEk45XJxirEcuMLBvQjHzL+uTVgxRttztCkZB549PwqjfXkVoE+6uw7i5baox26jrntxSuU5KQ97m4VmDzfL+Oc98+3T/AOvVJIFkkwDIzu3XHOa5nxjJqV3JDFp9u3nyEGORewPTBHGP/r1u3kOq6dbR/ZnE8rxAEgAbWAG5gfTk1qoaXvuNTUFotTYgkjnvlhlhV4duQGTPP1/p7Vj+KvCmi6jemXULLN6HDxvHxux2b2q94QMw0+W41BPKnZiNxb5sHtj1rSuXWeRTkMqdABk+lTdwnoZN3l5FDTrI2xiigSMW6KF27clAOw9+O1aUzkxMqHBJwOOg9fwrH8XeIj4d0qGeKPzZriQxR+YMrHxkntnIzjNR+D9Wn1nRobyWH7NO7MvQ4YDoQOwPP5U+WTjzPYlS5m/IvRQtviDzP5gdWwh+VsDBU9cKTyRTWnVwrThHcg8se2TirVorRtJIW2omNxIJ47/1+lXHtoQx8qNCpOc7yM+/Q1N7FOcVLU6F22jLEgUo6DHSgZG4liQTnp09qTByc8g1keeKVBIJHIo/OlozSAQn1FKKMDOe9J25oAWkpe/1pO9IApD0oJA60EgZORx15oAUn86jYASBixAAxjPHJ/nxQTsX524z1/Gsy7vNwIUgL3PtRuXCDm9DRMyD+Pn8qikuVGeeOuc1jB2b+IkdyTmq1y5QrKGbcAVA3HbyRnI6ZGOp98d6rkOiOH1sac+oYJAPAOKoT3v+0TmqJDvnLAYPOTzS+Tkk4BB6+lPlR2QowiON0T0OD0x/T9TWJ4n1qayt4kj4MhbLZ5AGK2lhyegHH6VT1XTVu41XO2RclWAyOeoI9DVx5U9TS0ehwM2tzynK3I+0A7lDZKnnofQ1UjuL6VpWmVmCffUtwB2wK2rnwzcQ7xHGjqTuDA4Yeoz6fypLHQLlLslhGgKDhiOQDj8ccfpXXzQWw1Ev+F7qUzhAHETD7uemK6ZGy/pkfw96zNO06OxUBFBJyCc5x7fSr4bcVByfXvXLNpvQ05dDZsbnaBtwzgce9Wry+jtbOW6eT93Ghy3949sfjWVZtwd4DEj+L/PWsTxbqEWm+HfIfzHV3BcRkAqM9B+NZKN3Y4Z0k5D9KupvMnklGZpm3OfQ9l/D/GtE3RVjvPX34rh9RvbuK4aBXxG4DKycHaRkfhWppVzcSxYnkLkjAJ6gY4reUNOY7FTTZu3FwXI2n6r2rQ8N24kud7jKr8w4yKxhhs4yMYHJrZ0q9mitWjihCgE4Yjr9aze2gq6apuMTotQnW2tJJX+baDhOu49q8G1DSNW8YeKZZb6KW3tkYgFl6AdAPrXrdxcvdOBcHAHBweF+tVptgYpBjt82PvU6UnTvbc5KNHk+LcrW4S3XCkbjxwOAMfr9K0LeMumZMDauAuOf/wBXWq0EH8cvQNn5jx9ayT410ttYSwspWmkDlGCcJnHY9+9Llb2RrUld2W5leJ7weGtVtJ7DQHvo7snzZIX2gMcjGACM455q9cquk6Vc3ek243Rx71TB3EkdP1reZ0vFLr8jdeE3DHYfzrO1SSa20yd3XLjJT0Bx1I9K0Ur2X9MmMX1OR+Gus3Xj4apYeJdPR7SMAiSWPjJOMKf4X5PI/Wu71SzsYvDz6JpyRxQiHylVFztHYk15no+s6gRuaZYrcNjZENoLEg5x6+9elaUhuNsjsxYEA98k9zVVo8srrRdjFUvtNmXo91Y6Npsts05eSHqG4zxjoe3vUuh3q6tcNNIrJcJ8uCedvbn69qm1bSLXU7+UOMhcK+0cuDyR9P5VHpqWypJHpbgQ5xlD828dz+dK8Wr9TS3U10eVFLkuTjhccE89DSSXqRxtG8ZEjDLA8/XJ9vSsRLDUCzPLqckqushAX5gDg7SMehOeKxvBel6/bavcQasd1uyF1zJuXPqM+o6g0vZqzdydHueg2wCXMfzHEqbiAensK88+J/hW88SPBDp10YlRiWiPIIxwwwetd9AWAVYwC3Xn2/z+tJF8txI0igv03deamEnCXMhW3ucZ4T0fXNM1OK21Cf7Tp0URjLM25SR93A6g12l7IyqoiCKq8nbn5sf57UltzNIMAIFwPc5znFTvE8seGJIzg+v5+tE58zuyW7NXOB8WeO7fw/cRW8sT3U0hyyxsF2L0B6fXjiux0TVLO50mG4txvSYblKnk9hn8e351w5+H9vJ4mury9uPt9pOQqRSrnY+euc9B/WvRbKytLCFIbZYTDHnGE4HbP4flWk/ZqKUdxTkranCeJodSvtPkjkljtS77JV8rcz54GMng45BHrXW6HbsmmwJLJ9xQu+TG58KBk0+7gN4w3EFM55HfPpVyy226CAjDqCSPY/49qmU7xsiXK0fMUKqlon3cDld5OB0J9j70unz+XYwJcDdKqAE7DzjvgdPXHvUjD7uFB7AAcHsBmjYcDKEnHOSP61kjK9zdcsANihuR1OOO5pQwIyDxSmk+mfpUmIvWikyCOKX60AIO+SOtLimsu484I4IGOhFDZx8pAPqaQBgEYpfrRzj3oPrQAVVury3gidpJFwvDc9/Q/pVXXdQNlau0PzSqM4HJH4d68N8R6te32oyqxe2gZt+0nG4nq59ea1p0nUN6VBz1ex2/iX4g28d09vZjznXqckDv09ah8Ja3ca5cSpeqEdAHUqpwRnofeuK0fQ7y+m8m3jJOfnmcHH4n9fWvTPDegxaRZ+XG4Zyd0kjfxNjH4DrW1SNOnGy3O2MVBaG/GwXhQMjg0twqSIwYoD2zUbQAj52OOOnf/OaGtwwCgnd9P5Vymel73KzWyqPv5Oex4FJGNoBPK+4q2bZSGXeQx6YGT9aWbaCSygHGAB0p3K9pfQrK8akEDJAODjJ/Khwmw/KSQOcAd6U4TJ6DPYVHNLtV2ycLnI9/8aLFehXmHBP6Hr/nis6VlEoYn5lBUqPQ4P8ASpr+4FtbSyMrbEXcdv6/T8a8w13xBfSSkpM4QjKqnAArWnTczpi+VanpCyoTgg47USEeXmPAxySTivOdDvtRkdZFumOOoJzXdxu8sQQk+YByzDgHpn6U50+V6lqV9URSvMZQQxY9FAFZHinzme0tY4/NlmkG7MmMZzg/ln8q2JSkJZQ4Oxf3jAnBJ681i6NLJqWvSXMuUitQFVDg/NggZ9OCfzpLv2Kk7ot3saf29o24Fm2up4wO2B9K1Y4ljD+UDszj+lU7u5hfVrWNQRKuSDjjkcDP+e1btra5t2d0JOcKvQk+mfeiT0QuZR1YQLBAqy3DDjjavOT6Y+lNfVX1CXyLcKigAhAuMj3q7b6Zl2mv9oRFz97H4frWXYW7rcTytKzmaTIyoGxeMKP896lWd2Yc0ZSvu0aMcCyHMzOQDn2Ppx/KpY4suWKhAcBVHGAKRFCkJuI5I/P3qwgDXGwYcDPHbNSRKTKeqyyz6fdw2UXmsIWYKeMnGea8PtLO4h8UwRmA20hlGfmwBnHGK9sv2vU02/XTUQ3kasUDHvg+3X2+lcN4D0HUDqLavrqSPIj5jSUcl+ece3FdNGShGTZlaz0O5sUkit0EyOUPqPmznjisLxvrttoNiI5Eed5MnyV+YuT/AErfTWLdL2a3eOVSp+Z2HAPpj096yRfw3N8n7qOW4fKBQcHIJxk+4rKKd7tDbb1Z4x4t8aaeNNtLG0R4boShymPuAn1969Ps9VlitJLpIVjVo0BkbID4GB36c9sV5746+FGq3/jVptHsG+xvKsrZPCg4J75xnNej+KNKnsvDdpaRncYIh5mz+PGB+VdU3TaiovczhJuTuUYteuLq+aOF1DSNgEHr/nmuhvfJlWC2hgDwzq3mvEdrknscV4lczahYapA1v5pAcsDt9eoNe1eHLUwWhudXuYreNvumVgm04+6CeM0qsFBJmjaS94ludRTw/oskzWscdnBGBGYvlbHoB+fNN8L+LtM1pzbReakqplfMXG4egAPvUuq6xo+qWMkDvBcwyx4eMPkFe/I/p+lct4M0qyt9dkuLATGDlY/l3eWDn5Qc8msowUotyTuL4nc7e81qHT9VtrIW0lxJLHuLKcEDOOnfvV3LXEu1No6BgxPyj/69JcxRyzGQxolyOAzDlEz09uKvaZdwmCUSBY2UYwerAf06fnWLtbRGcnyq/UiuIXtwvQntzzVV5JZXjizsB/u8Hv8AlUWoXjSXDiORtvRQB0x6fT+lcn438bSeFtRtbP7A91JPCGZl+XaCeNvByep5pwhKbslqL4UnLcv674gt9OlWHcrujAsOp9uen6da0tK1s6/FviSSKJcoMjAP/wBYetea6XplzrHiAxXNrcG0KlhOcjAOCOeh69K9e0DSksLLyUUjAyOwz3/Hj6+tbVYRgvMqo4xjd7lmzhyd6Y45X6/5/nVpbdYwFXOOWVSOOeTUphcsMMUwVPAByAenI6Hp/UVME2jkDgDiuZu5xN3KccbCUuEIQDDAdunQ1NJG5I8vBGP4hUyMrIT8xB6D07dv8/ypkj7GxlQepH+cUrhc0Tz9KjSLbKzl2+YAbc8DBPOPXnGfapF3c7iOvGPSkVQowOg9TmpJF96O2e1JnnGCR6jtRwRyM80AKM4G48+1IV3Lz1pT9aQZxyR74pAISRGSMZA79KydY1qGyhfy/nl6D0pL+aSUlUbC+x+7zVBtOST94wBAGeen0qopbs66VGPxVGcpYXOs6rfu72ojtSp2kP8AMT75q7beGw0yvqey4lzkAgEdeOa3yUiKIoCt6j/P0qRzHBEZriWOKJeTI5CgfrWrqP7Oh1SqWWgtnawwIFjiRQBjaoGKnMbBF2gb2x370+3ninhjlhmjmifOyRGyG9SCOKJ+V2EZPUEDj/8AXWVzlc+ZhHGC/msoDkAEjow7fXFSbCRt74J6nNNjQRyHKqpb5iD606RtjfM+0H25pEEEjBdxyAEGSe9VftEYmaMyb5gobbg5CnIB/Eq35VWvI3Ny0yqWGzEeegGeeP8AGgylyq5P3ffiqtobwg3qK+8rkjCkY45xVK7cBtrnCHkn096W8lLABCwIGSQayb5xbqHl3YbBB7E+1NI7acOrLclzFsKom5T1DA4Of8/rXGX/AIbMt0xjKrESCOM4/wDrVg+KPH9xbzNbaXFyuQzfxH/AVj2vjXVyyfaI5AjAZ2v39DXTCFSOqG5wvY9Fs9Git41+d2cDBKgfUfXrV0K6pInIPGFUnGMCuSj8TS/2aLkpi4BI2+YV56/jXL3njXUoZpcyIA2QTgkge3qfoMUuSpMp1IxO38QXMtzcnSLAlppceay/wDHPtW7olnFYWcdtAoVVOOn3j3J9z3rhvCM+pagzyWdkYEcgveXIOWHoB6d/evU9LTyIooZWEwx88r4Gec9BipmnDRh7TTmGab4d+0amtzLuUqMlQfwz+WK6q7S2sIkeZtsQPHOeT6VlXGuw2iSC2aKSXJGcnC46D6c1kyXSXLG8vbpDGedzH5QPQegrF3nuckozqu8tEac9816zKiuE55Yj19KfaxYijZVZkwQMDOeKydF1bTdSklgsZ1lkjHLYxkdMj2rH+IVzqiaNI+kySwRx4Z/KO07R159vQVcYNvl2Hpy2gXfEkrrrOkRPlIpJst7kYxXUWSlTl9+S2R2IHbkVwWr3d1beH9LlW6Etz5CByV3FmIHzrn+L3ra0a8vhpiyzMXkOCd5yPXH1qpRfKhNOSOia4S2muJGAKuBg9CT6D8KjjlE9lcSM/llwVQDrn6/1rxzxT4h1G71qG2uHMPl427jtycH5j2z+lbXhPxrY3MzW+s30MMsTKsQP8fXOT+VN0JKNyNOp3tnBIgjSeNNzDDMzZOPXPWsfSVW38QXZj2+czEbXOMgHqPpisD4i/EiDR1j/ALP/ANInZCFkIwuM9Vx1+teU3PiTUdTv7fU4vNjlBUgKSBwe1aUqM5K+yZXOpbn03DdSLGwlILhyGY4yF6/4dKh8n7TId3+tlyAvbA9T2+lZfhyWXUNOtzeGRLsxrvLjjJ5/MV2FnaIoyoLMBjee+e36fyrmfuvUipal6nM3Pg9PsxaJws45DsvfOfwHuK4LxN4B8VeI5oZbzULeUQ/KkYmwFX1wOM/rXssksUCs7ttjVS24n5Rgc15fc/EmzsfFotbezmZJcIWH6cfjWtGdRv3Vcy53PRmNoXgPU9C1Gd76REtJ12DbICSw5+UdvxrudCWHRYJri6ASOHh2PCr7g9/510X2rz41kaJQyDcEP8Oc964y81q2nnubW6iieN2wEYHB57g1TnKrujSLbXK9DO8NePDrfjRtKe1VYblm8qYZ3cAkZHpgV3ZsSLgyyyRyQsoMZHp1HH9a5O00HS9Pu11Cw082922cbWJ2KSc4+o9K62yheSwjjnbJCksUyAD+ef1pVeXeGiJbceoQ2i3r3TRM8RGBHIpxk46jvjNeKa9rmsQeKNQ07VtdjeEyNGzCMsFOeFxj5R0z2r6FtBHGm1dgwC3y+mTz9K4XX/A2gX+tnVbkSRyyPvkhifEcx7Fhj8eCM0qE4qT5jJSvO5c8B2lyLEm9iVNrFF2vkHaOo9q6kRbF2r15OQfXmqNsViESRSkIeRzgjH/6xV8uScJgbvQ+g7VlOXNK5NRuUrj0ZlCgdG/MfX3/AK/nTDc7dz7T8p5x/Fk8Y9/8aVI8qMnjHODio7oFCsmAVGcgjmla5noSGcFtyhsHG0k4B9vXI46+tZusfbjen7Nbl4tow2BzVxIRPIRlwAe/T8v896sMVJGZMHHYZzQnYasaACs5PdeOtBwDuJ9uTxQjEqu4YYjJFLmoIAmk3AHkjJ6UjttGQCcdh6VVvSWAQZDE4XAJHTPp6d/60hpXdmW/Qjn0OaZIwCNj36Vy097d205Cs6hT6cf/AFxVuLW/tETJNEI5OnDZU+n0quVo6XhZrVaohluP35w6nDYOSMD/AOtWpfOEhAAOMdRyDWCSWuH2nkgnj/Pfmr0hklhw23g54qmjonT1RyHjPU9VsZ7FNHilMTuDNMqbwFB5B9Biqek2ba7ZtZ6m1wY/MMkEm4LvPOD7kd/au5ls4rqCSKZQyPwQKh1Pw/FdacqWDJaTwYMUiDHP+0K1jUikls+4pTSepU8K6PN4e0y5ia6S4jMu+MgHIzwcj8K34xEoMzOBxz6jvWIuu2djILDUbmCG5TAIf5QfcD0PPWtveHXe2Dj9eKzndu8jBkQKrgAkjJbLHkk9KVVknulCRlkXncfu59/1pCC7B+TjGB/ntUy3kcMWAyZPIBbBz71DB36GfdJcLcyDzPlYEnOMDnFckPE8U3iSfSjbFDEhYEt8zkAdB7gmut1J4lglkmn8kN0YsB/n/wCtXmviCaGfUFvtMjga7JxJMFG9x2A9a1ppS0Z007tXNuXX7eVpUgjlI2j5uwBPce1VbdpdXkLPIPsKcbsYDewpnh7w1KI1uNSnZ5JMs0Ck4yezfQen612FrpIMS8bV9FHAx2HtTlyx2N+dJe8zy/XvB0oSSPSVikhZgyqx+dT9e4rBs/B2tTT4lEUSHrvP+FepeLNc0nw0sIvpsSyttSNF575J9AK89uPifAviAxQxGTS87fMI2tnI5+lb051ZLRXJ9pTudFZeEdPNrFFdxC4lDbt25h+mfStOy8PWFpgWlnEjbhyBn/P1q3o93DqyJPa3ETQ5I3A5Ax1q9ot7pl3NdyWNwm6BtspxkBsd/wDD3rJznrc0lVjHYrXSpaQgXO5GbkN2Pt0x17V5j4l8WXel3DW10VmJXchTGQD0r1nWrD+1dECPchH3jJA6YHcevWvDbu50hdR1M3aPNBbRFwufmlIPG0n7ta4eMZJ3VzGVV9Wc1qHjW+S7kjuEkwDuV5DhOe/HWug8O3d34u0m6hg1KFfKdW8t4iDj2I7D0rkfFdnFrMlidBjnkhaESNEeSpIGRx6YNdd4A0250WyVTYzT3Uxy0Ma9B23EZ59q65RSjdLUyi3KWuxc0zUboXK6LpkckbyyYlkAw8pxjcSOij0rqNcvNe01Z7KCI30bwgH5ckMevPpwPyr0SOztorSGaKzjSRI/nJUDqAeTjPFc/wCLPE1joio08JaYjd5a8ZA9eK5PaqctImsbJXGeHI5j4asDq0JMuCJPl27CTxU3iHUJ4LCJ7VZfJDAOypk49B6dag8AeLovEDXouLBF2uuwj5lw3Qc960vHl94dtbeXQdW1ZdNm1FdsbKfmjBPX6Zz196zbanaSIqVYqJ5r4xvvD1yLcT3D3F4qkqbSRSo5/iPQEelIPh5p2q6PY31tPLbPPEWbzRnknjOOnHP4ir9p8E5BHFbWusLPMt35kz+UQrRYGFByfc/j9M9Z478J6xH4TlgsGEsIxvWPOURQAABnp0/Kuj2sVaMJmUZ3+Lc4vU9D0LQPCDrqwOqXVoQsCB8feP8AF7DOa6f4Z3Wi6rptr5tpawakp2xRr3H95QT1PSsjwz4C1e60oNLjgcCTtnpnNYHiDQtQ8A+JLHVpZC0TEOIlONxzyAaGlO8ebUuemz+R75eS22mJsKJETnDdQD/dzTNL1KO4UBJA5fjIbgcn/GvL9b8VyeN/DMS6faPFdW8wkkRHDnYQRnI684z6Vj+G/E+o6J4msNHv7KeaK4ZVPm5BO7gEDHQd/wD61YLDScbvczjt7yPdr6OG+s2guNzCXjYXAwfTI715Z4u8IWdsZr7T1dNSWPbFukOST/ER04BP/wBauxXxr4c/tiHSItRSTUlk2rGnKlwp+UuRgY56c5H1FeVfFzxbr3hrxcTYzMoMSTK20MGVuwyDxRQU+a0TONRK52Hww1t9M8OGzv5hLeiRtiHkopHyrnvk8/54xdX0zWJvEjSy2spaRiylR8qr6A/StD4Yyw+MIINY+xm2vMDzwFwjMDjKjtnAP416np9nCt04eE5RRh36k89Pwq5zVObdtS1KMFzGLpsVzAkAuIC0hyCwbGzA9O+a1rUpHArRhFtFTIwRjA7j2xUutW1vJpFzpxllto5rd4vMhba8akEZU9iOx9apWGp2r7be1RIoUAVVB6DsAce1c13LWxDqOfQ0n8qaIZcFCMjJ6/j27VE1rGiM+ZTtG7ao545wo9+/epSUUYwRjGCO31qHzRGACCck/e6jv3qdehHoWzDEwzsVk5GM1TuFlEkQJDQhvmVvboPz9akZgzsRISpULs6qPf1phmGJDJnYy4O7lcA/zOT+VCI16lhNqtmMckbgcY3Drx+tSBgRudsKpGfxPeoEeIZJVAytkquPn4/mff0qOX7RDPLIHDwlcZ7j/PXjr3pMmxbVRlRtIYcg/hjGfXB/GkLYOOR9MCqa6nbfd85SynlTjIPvj+tSfb7Y/wCsc7u/B4oswsyNtaMLDzl4PQAcn6fnV231SCVBhvmJ7VzEV9cCOOJodwVcCcsGVgDgE5O7cRgnIPJPJ6mIOk5YmIKecg5Gf8/lVciO/wCrxktVY7VZ43YbXAxzz0p4ZQeMkH0rikaWMOY3lDAcDOcDsAKy5rnVg4MN2hJ+XaScYwcnPY8/56VKp36kPBvozs9UtkeNmjGGA9OM+4/w5rnpEkhIEiqeOWzgE/T09qWx1S9k8q3nt2jIUYc5P1ANWLmVpmLGIAHoSeB7gVSTjozooqUNJDbEo5ZFAyox05H1rTjCvGAvYcnr+dZMUW3c6nDYx0xmprOeS3KiQIVJ5IPOD0/Wm0OpG+qN22hT0HU9P4jUjAPl1AA5+ZSOf84qvBKsceMcHpgVaaVVXgYHXp+NZ9Thle5z+oaPp+q3SS3tmjvE23cwOcdce471qPGMrtGRx8o4x7U6WQNuz0zx7/8A1qrzX0Fug+0SIqgdzg/56VTk3oVqy6se3LFjuHPsBXPa7q9ppcKyz73nfAiRVyWPYY6/5+tYut6rrd/qDWHh23LIkSyyzOdiYfIUBumRg571oaDoUtiBPqVw95enJEjH7pPXaOo5pqFtZFRVnqzEOj6vqzpJqF6baLcpa3X5gcZwD7jj24re0/RbKyiVo4gJeSJCuG798cfQVrlUAO8gc+tMMzBSMjPUjrTc29Ebc/YgiREkChQM9sYz/wDXqY32HSFNq7uEDNgsQMkAHuByRTNzOxZM545U5/Ouc8R682hXNpALed4biQLmKMkjkZz75NEYubshy11Z5r4k/tDxd4hljubN57KylaP5OGJ9Cfwrz3S/tE8Wp2n2aOOKMMTK+XMIz0Huema+nTHIs8s8arEX4ZkQKT/9f3rznxskdpNbWWj+VbM2ZJnjcLiTIxuI7AEmu6nWT91ITp2VzmPhbrN/DNfW0VtIdMVG2seWTP8AEcd/w9K6yHw7dWsLS6LfSwsHEsonGN+ScH3wM9a8q8SapqkuofZdKllisoJCqHft3+rfTOcZr0bQdKvdR8Of8tWvpQGmkkBXOOcZ9O9VOLXvbX/rUIPS1js9R1ia40KSGwLvcJErrJG5jMj8cZ+v51y2n+F4ri2e81K0jt7hw+VRQ0ZHYEemc1v6dbTWtnaWssJluE+66LgEHoCPT3p/j+6n8PeHPtPkPKzNtIySFBGCfbp+tc6fI+WHU0SjuypoPhjSsoq20GYAp3INrbupyR26cdMV0eqa1oXhWyjl1NltEc/u4448k+uAOw9a4j4Tajc+JZ7hbeDyxEB5jkcDJOCPyqH46+D5/EUFne2F1CLiwi+zzRSuFDLu3BgfUZPFKUeaooTZnVn7v7s9A0bxPpviuGRdDl3kNtcsCNoI54OD0+tcV8dbcWkWl2ygeWzHdIB1OPlBPfHNcr8F2n8O+GvEWo26i6vIjGBGoyAqtyfcc9vSt5/ijBrF8LK+06LMq4Bf5ir49MdM1UaUqdT3VdIyTeiOg+FXh+HTdCTU7hgrzHeVzkbR90kevJ/+v28f+MlnqWufEycQ75vMVBbhuAExkAen+NfSunXby6IUukVf3IA2LzkDoBXkXhfUYtQ+IkrTXbSy7Jom3Q7VBGNuD2GcjHb8adGb55VGhNKT949C8G6hB4K8L2um+Ir+W51JAZXwpcgNyq7vQDA5rduddGu+Gbm50FGlkIKbZk2kDvj1/DNQnTdKurhtQvbXdeMAZSwJHAxnHTsK8e8c2esXPjhptNNyI7V8WixEoqJgYK445J5rKEI1ZX67+Rn7N82iPWtKubwWaQSt5Mjgb1HJUj09uKw/ip4dm8SaDb/Z8vd25G1c/MwPXnufatjw4t4bC2bVFBvfKXzSo2gH6Vevrq3050e4dbeBedxXC4z3/wAajm5Z3W6OiSTex5x4I8O3nhi1v5p4FN0IMQRuBguOQfwxWtP4hg1jRIrmUKl8qsjyPEFmjIAyUJ6ZxXNfEY3V54taCG9VosK1sUPykbRwecdc1NpEC2FvcnXoCsWzHmyH5Qfr+vFdNlJc8tw5VL3mefQeG7q58SxtaXTgJNvW5ycqck8Y/ir3Z9G0y90pJNVtYJIrdDia4G5lQZOOc8DLYHYcCqHhbV/Dl08MOnsJpVGxgF24OOvvU3i3Tv8AhJdPntLO6iMaNn5W3AkZ4P09KVSo5yS2sFlb3UZvhzxpoemXlxDptuU0+BSWnVNqKo5Jx+fbrUSfGrSrrU/sVgkpLEqnmLs3N2+btznr+Fc/oPgC5GgarpU0zubpAPNix36Z9s9qwLT4O3uiTrqN8xuY4jvEMSndntn6dar2VGTd3r+ZnODck5HT23xdvbrxedK1K0iS2ml8kMoO5QTwevrWp4pvv+Ecuo5LWeU5BLtnjJH5kZxXR+DvCWhS3H9qPbNLfrmHdMP9WcdQPUZPP5VnfE7ws40uSW2V5o05IX7yjHP1FJSp86jFWEuWLcUzQ+H3imbxJvtpFBeMrJ5qEjA56/4f/WrtmtJWXBKlsE89Qf8A9VcB8GvC0ujW8l5eq8c1wAEjZcFVHcj1JNeorg4I5GOc+tc1fljNqJlUfK7IyXt5Vf8AeOVHTcvb2+lQSyNHL5RYnaNxI4BB7fy4rXu22LkHP+f5Vg3khkRtrqoYFRn+v+f8KiLbFG8iI71tlxMzzFMBxgZ46nH8hWPevdFiZ57gRRjIRW2qfrg9cYGTWtbKqo6YcFDtPy4BJ5AB/qKb5MjWyPMuw+uOR/k1d7HRBKLuyG0sgF3LGByCBjr/APX5q6LK9UABOPqKn00r5YZCTwTjspq9cXsiOFjAUAd+uaTkyKlR3sj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28305=[""].join("\n");
var outline_f27_41_28305=null;
var title_f27_41_28306="Ossicle histology";
var content_f27_41_28306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Otic embryology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial histolologic section of the temporal bone at 12 weeks' gestation. Note the developing incus (i), malleus (m), stapes (s), facial nerve (7), external auditory canal (eac), and mesenchyme in the middle ear space (mes).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28306=[""].join("\n");
var outline_f27_41_28306=null;
var title_f27_41_28307="Hexachlorophene: Patient drug information";
var content_f27_41_28307=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hexachlorophene: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/62/33763?source=see_link\">",
"     see \"Hexachlorophene: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/54/9059?source=see_link\">",
"     see \"Hexachlorophene: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      pHisoHex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      pHisoHex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691488",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hexachlorophene or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694517",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on healthy skin only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696242",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash and rinse affected skin with warm water, then pat dry.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11755 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28307=[""].join("\n");
var outline_f27_41_28307=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179113\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179114\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019119\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019118\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019123\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019124\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019126\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019121\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019122\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019127\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019128\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/62/33763?source=related_link\">",
"      Hexachlorophene: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/54/9059?source=related_link\">",
"      Hexachlorophene: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_41_28308="Early lesion in PHX";
var content_f27_41_28308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early lesions of pulmonary Langerhans cell histiocytosis appear as cellular infiltrates along small airways.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28308=[""].join("\n");
var outline_f27_41_28308=null;
var title_f27_41_28309="Pelvic vertical shear fracture";
var content_f27_41_28309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Pelvic vertical shear fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three images of a vertical shear fracture: (A) Schematic; (B) AP radiograph; (C) 3-dimensional reconstruction from a CT scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28309=[""].join("\n");
var outline_f27_41_28309=null;
var title_f27_41_28310="Complications of procedural sedation for gastrointestinal endoscopy";
var content_f27_41_28310=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications of procedural sedation for gastrointestinal endoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/41/28310/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28310/contributors\">",
"     Jonathan Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/41/28310/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28310/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/41/28310/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28310/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/41/28310/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 29, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of gastrointestinal (GI) endoscopy has greatly expanded the diagnostic and therapeutic capabilities of gastroenterologists. Adequate patient tolerance is essential for successful completion of a safe examination and compliance with subsequent follow-up. As a result, endoscopists have developed skills in administering a variety of sedative and analgesic agents to facilitate procedures and enhance patient comfort. However, a number of complications related to procedural sedation have been described.",
"   </p>",
"   <p>",
"    This topic review will focus on the complications and adverse reactions related to procedural sedation for GI endoscopy. An overview of procedural sedation for endoscopic procedures, issues related to endoscopic procedures without sedation, and the management of patients who are difficult to sedate are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42694?source=see_link\">",
"     \"Sedation-free gastrointestinal endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=see_link\">",
"     \"Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARYNGEAL ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main concern related to topical pharyngeal anesthesia is inhibition of the gag reflex and the risk of aspiration. Systemic effects such as arrhythmias and seizures due to absorption of the topical agent have been observed, although they are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/1\">",
"     1",
"    </a>",
"    ]. These drugs have also rarely been associated with the development of methemoglobinemia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/7/6264?source=see_link\">",
"     benzocaine",
"    </a>",
"    more than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of methemoglobinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Significant methemoglobinemia may be clinically suspected by the presence of clinical \"cyanosis\" in the face of a normal arterial PO2 (PaO2). The blood in methemoglobinemia has been variously described as dark-red, chocolate, or brownish to blue in color, and, unlike deoxyhemoglobin, the color does not change with the addition of oxygen. Pulse oximetry is inaccurate in monitoring oxygen saturation in the presence of methemoglobinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SEDATIVES AND ANALGESICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Phlebitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous administration of sedatives and analgesics is associated with a small risk of phlebitis. The risk appears to be higher with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/4\">",
"     4",
"    </a>",
"    ]. The risk of phlebitis from diazepam is increased with injection into a small caliber vein and increasing duration of infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/5\">",
"     5",
"    </a>",
"    ]. Administration of medications through a running intravenous line may reduce pain at the infusion site.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    can cause pain on injection, particularly when administered through a small vein, but does not cause phlebitis. This may be averted by the pre-administration of a small amount of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (10 to 20 mg).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiopulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent and serious complications of procedural sedation are cardiopulmonary. Risk factors for the development of cardiopulmonary complications of endoscopy include advanced age, underlying comorbid illness (especially pulmonary disease), dementia, anemia, obesity, and endoscopy performed for emergent indications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/6\">",
"     6",
"    </a>",
"    ]. Adverse events resulting from oversedation include hypoxemia, hypoventilation, airway obstruction, hypotension, vasovagal episodes, arrhythmias, and aspiration. The frequency of such unplanned cardiopulmonary events has been shown to be associated with increasing ASA scores [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall incidence of cardiopulmonary complications is low but important. In a prospective survey of 14,149 upper endoscopies and a retrospective study of 21,011 procedures, the rate of early cardiopulmonary events was 2 to 5.4 per 1000 cases and the mortality rate, which included cases of aspiration pneumonia, pulmonary embolism, and myocardial infarction, was 0.3 to 0.5 per 1000 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the potential causes of cardiopulmonary complications is arterial oxygen desaturation, which can result from oversedation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Reversal agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hypoxemia is common during endoscopic procedures. This was illustrated in a study in which arterial oxygen saturation was measured in 236 consecutive patients undergoing elective endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/9\">",
"     9",
"    </a>",
"    ]. A drop in the oxygen saturation to below 90 percent was observed in 40 percent of individuals having an upper endoscopy and 54 percent of those having a colonoscopy. A similar incidence of oxygen desaturation (41 percent) was observed in another report of 103 consecutive colonoscopies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/10\">",
"     10",
"    </a>",
"    ]. In the case of upper endoscopy, oxygen desaturation is largely related to the use of sedation rather than the passage of an endoscope along the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some degree of hypoxemia can be noted during endoscopy even in patients who do not receive procedural sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In one study, for example, 9 percent of individuals undergoing unsedated flexible sigmoidoscopy had an episode of hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other risk factors for hypoxemia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      , which significantly increases the risk of hypoxemia compared to midazolam alone [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A high frequency of oxygen desaturation (up to 50 percent) is seen with procedures of longer duration, such as endoscopic retrograde cholangiopancreatography (ERCP), providing a rationale for the routine use of supplemental oxygen [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/14,16,17\">",
"       14,16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Active bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other patient characteristics that may increase the risk of sedation-induced hypoxemia during endoscopy include older age, underlying lung disease, anemia, and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast, patients with cirrhosis do not appear to be at increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine pulse oximetry is suggested in all patients undergoing endoscopy since the variables discussed above are not sufficiently precise to predict which patients are at risk for becoming hypoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/9-11,14,20\">",
"     9-11,14,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potentially important limitation of pulse oximetry is that it does not detect hypoventilation and the resulting hypercapnia and respiratory acidosis. This becomes important in patients receiving supplemental oxygen, since hypoxemia may not be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\", section on 'Monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of hypoventilation is increased with obstructive pulmonary disease, dementia, and the use of high doses of opioids or benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/16\">",
"     16",
"    </a>",
"    ]. In addition to their sedative effects, opioids and benzodiazepines inhibit the central responsiveness to carbon dioxide, leading to decreased respiratory drive.",
"   </p>",
"   <p>",
"    The degree to which different benzodiazepines inhibit the respiratory drive is variable. In a comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    for procedural sedation, the rate of respiratory depression, as indicated by elevated end-tidal CO2 pressure, was slightly higher with midazolam during the first 45 minutes after drug administration, but higher with diazepam during the recovery period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cardiac arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of cardiac arrhythmias during endoscopy depends upon the patient's age, underlying medical conditions, the incidence of significant arterial oxygen desaturation (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Hypoxemia'",
"    </a>",
"    above), and the type of procedure. Some of these issues were illustrated in a study in which Holter monitoring was used to detect cardiac arrhythmias in 164 patients undergoing elective upper endoscopy who were randomly assigned to one of three groups that differed in either endoscope diameter or use of sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall incidence of arrhythmias was significantly higher among individuals with prior cardiovascular disease compared to those without cardiovascular disease (30 versus 6 percent). The most common arrhythmia was sinus tachycardia, the presence of which significantly correlated with patient tolerance of the procedure. Among patients receiving sedation, arrhythmias were more common in patients who experienced oxygen desaturations than in patients who did not experience oxygen desaturations (75 versus 46 percent). There were also more electrocardiographic abnormalities during examinations with larger endoscopes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration is another adverse consequence of oversedation. This is particularly important in the management of patients with acute upper gastrointestinal bleeding. Endotracheal intubation for airway protection should be considered to prevent life-threatening aspiration in patients with active hematemesis. It may also be advisable to avoid topical inhibition of the gag reflex in such patients and in other individuals at high risk for aspiration (",
"    <a class=\"graphic graphic_table graphicRef56501 \" href=\"UTD.htm?10/14/10475\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=see_link&amp;anchor=H2#H2\">",
"     \"Aspiration pneumonia in adults\", section on 'Predisposing conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     REVERSAL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversal agents are usually given for oversedation during endoscopy, which can lead to respiratory depression. They have also been looked at to reduce recovery times.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     For oversedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversal agents should be used when patients exhibit signs of respiratory depression, such as hypoxemia or decreased ventilation, despite supplemental oxygen or gentle stimulation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    is given to reverse the effects of opioids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    is given to reverse the effects of benzodiazepines.",
"   </p>",
"   <p>",
"    With both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    , patients are at risk of resedation, since the half-lives of these medications can be shorter than the medications that they antagonize (",
"    <a class=\"graphic graphic_table graphicRef65736 \" href=\"UTD.htm?32/6/32877\">",
"     table 2",
"    </a>",
"    ). This requires post-procedure monitoring if one of these agents is used. We recommend that patients be monitored for a prolonged observation period (at least one hour) after receiving one of these medications for the treatment of oversedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Naloxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     Naloxone",
"    </a>",
"    is an opioid antagonist that is used to reverse the respiratory depression and sedation caused by opioid agents (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    ). Appropriate additional supportive measures such as fluid resuscitation and even vasopressor agents may be required to manage cardiovascular compromise resulting from opioid overdosage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link&amp;anchor=H14#H14\">",
"     \"Opioid intoxication in adults\", section on 'Basic measures and antidotal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    causes the release of catecholamines, and thus should be used with caution in elderly individuals and those with cardiac disease, to avoid cardiovascular complications. In addition, administration to patients who regularly take opioid agents, prescribed or otherwise, may result in considerable pain and precipitate an acute withdrawal syndrome.",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    given to reverse an oversedated patient with respiratory depression is 0.2 to 0.4 mg given intravenously (",
"    <a class=\"graphic graphic_table graphicRef65736 \" href=\"UTD.htm?32/6/32877\">",
"     table 2",
"    </a>",
"    ). Smaller doses may be used for elderly individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link&amp;anchor=H14#H14\">",
"     \"Opioid intoxication in adults\", section on 'Basic measures and antidotal therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    may be cleared faster than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , individuals who require naloxone reversal must be observed carefully for a prolonged observation period (at least one hour) to detect the development of resedation. Recovery room personnel should be alerted when naloxone has been given so that resedation will be detected quickly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Flumazenil",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benzodiazepine antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    is used to reverse sedation induced by benzodiazepines, but it has limited efficacy in reversing respiratory depression. As a result, patients who develop severe respiratory depression after being given an opioid agent and a benzodiazepine should generally receive the opioid antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    &nbsp;",
"    <strong>",
"     before",
"    </strong>",
"    being given flumazenil. In addition, flumazenil should be used cautiously in patients who chronically use benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , or high-dose tricyclic antidepressants because it may induce seizures or withdrawal.",
"   </p>",
"   <p>",
"    An initial dose of 0.1 to 0.3 mg is given as an intravenous bolus (",
"    <a class=\"graphic graphic_table graphicRef65736 \" href=\"UTD.htm?32/6/32877\">",
"     table 2",
"    </a>",
"    ). This can be followed with additional boluses or an infusion (0.3 to 0.5 mg per hour) to prevent resedation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link&amp;anchor=H14#H14\">",
"     \"Benzodiazepine poisoning and withdrawal\", section on 'Antidote (flumazenil)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The average duration of antagonism is one hour. However, the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    may persist for 80 minutes or longer, so, as is the case with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    , patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    must be observed carefully for signs of resedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     To reduce recovery times",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    electively to reduce recovery times remains, at best, marginally supported by the literature and is rarely done. In a placebo-controlled randomized trial of 69 patients, flumazenil was associated with significant improvements in recovery time (8.3 versus 23.5 minutes) and the proportion of patients in whom sedation scores quickly returned to presedation levels (84 versus 24 percent at five minutes and 89 versus 58 percent at 15 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/22\">",
"     22",
"    </a>",
"    ]. Similar findings were noted in another trial of 60 patients in which all patients treated with flumazenil returned to presedation status within five minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these findings, it remains uncertain if the reduction in recovery times is cost-effective, as the cost savings may be balanced by the cost of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28310/abstract/24\">",
"     24",
"    </a>",
"    ]. Neither resedation nor seizures were a significant problem in these trials, but they remain theoretical concerns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of procedural sedation for gastrointestinal endoscopy include phlebitis, hypoxia, cardiac arrhythmias, and aspiration. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Sedatives and analgesics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       Naloxone",
"      </a>",
"      is an opioid antagonist that can be used for opioid induced respiratory depression. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Naloxone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"       Flumazenil",
"      </a>",
"      is a benzodiazepine antagonist. It can be used to reverse the sedative effects of benzodiazepines, but it has limited efficacy for reversing respiratory depression. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Flumazenil'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients who have received reversal agents be observed for a minimum of two hours to monitor for signs of resedation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Reversal agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/1\">",
"      Patel D, Chopra S, Berman MD. Serious systemic toxicity resulting from use of tetracaine for pharyngeal anesthesia in upper endoscopic procedures. Dig Dis Sci 1989; 34:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/2\">",
"      Khan NA, Kruse JA. Methemoglobinemia induced by topical anesthesia: a case report and review. Am J Med Sci 1999; 318:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/3\">",
"      Collins JF. Methemoglobinemia as a complication of 20% benzocaine spray for endoscopy. Gastroenterology 1990; 98:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/4\">",
"      Kawar P, Dundee JW. Frequency of pain on injection and venous sequelae following the I.V. administration of certain anaesthetics and sedatives. Br J Anaesth 1982; 54:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/5\">",
"      Morgan M, Thrash WJ, Blanton PL, Glaser JJ. Incidence and extent of venous sequelae with intravenous diazepam utilizing a standardized conscious sedation technique. Part II: Effects of injection site. J Periodontol 1983; 54:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/6\">",
"      Sharma VK, Nguyen CC, Crowell MD, et al. A national study of cardiopulmonary unplanned events after GI endoscopy. Gastrointest Endosc 2007; 66:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/7\">",
"      Quine MA, Bell GD, McCloy RF, et al. Prospective audit of upper gastrointestinal endoscopy in two regions of England: safety, staffing, and sedation methods. Gut 1995; 36:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/8\">",
"      Arrowsmith JB, Gerstman BB, Fleischer DE, Benjamin SB. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. Gastrointest Endosc 1991; 37:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/9\">",
"      O'Connor KW, Jones S. Oxygen desaturation is common and clinically underappreciated during elective endoscopic procedures. Gastrointest Endosc 1990; 36:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/10\">",
"      Bilotta JJ, Floyd JL, Waye JD. Arterial oxygen desaturation during ambulatory colonoscopy: predictability, incidence, and clinical insignificance. Gastrointest Endosc 1990; 36:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/11\">",
"      Lieberman DA, Wuerker CK, Katon RM. Cardiopulmonary risk of esophagogastroduodenoscopy. Role of endoscope diameter and systemic sedation. Gastroenterology 1985; 88:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/12\">",
"      Yen D, Hu SC, Chen LS, et al. Arterial oxygen desaturation during emergent nonsedated upper gastrointestinal endoscopy in the emergency department. Am J Emerg Med 1997; 15:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/13\">",
"      Barkin JS, Krieger B, Blinder M, et al. Oxygen desaturation and changes in breathing pattern in patients undergoing colonoscopy and gastroscopy. Gastrointest Endosc 1989; 35:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/14\">",
"      Reshef R, Shiller M, Kinberg R, et al. A prospective study evaluating the usefulness of continuous supplemental oxygen in various endoscopic procedures. Isr J Med Sci 1996; 32:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/15\">",
"      Jurell KR, O'Connor KW, Slack J, et al. Effect of supplemental oxygen on cardiopulmonary changes during gastrointestinal endoscopy. Gastrointest Endosc 1994; 40:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/16\">",
"      Freeman ML, Hennessy JT, Cass OW, Pheley AM. Carbon dioxide retention and oxygen desaturation during gastrointestinal endoscopy. Gastroenterology 1993; 105:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/17\">",
"      Freeman ML. Sedation and monitoring for gastrointestinal endoscopy. Gastrointest Endosc Clin N Am 1994; 4:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/18\">",
"      Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy, Lichtenstein DR, Jagannath S, et al. Sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2008; 68:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/19\">",
"      Iwao T, Toyonaga A, Harada H, et al. Arterial oxygen desaturation during non-sedated diagnostic upper gastrointestinal endoscopy in patients with cirrhosis. Gastrointest Endosc 1994; 40:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/20\">",
"      Bell GD, Reeve PA, Moshiri M, et al. Intravenous midazolam: a study of the degree of oxygen desaturation occurring during upper gastrointestinal endoscopy. Br J Clin Pharmacol 1987; 23:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/21\">",
"      Zakko SF, Seifert HA, Gross JB. A comparison of midazolam and diazepam for conscious sedation during colonoscopy in a prospective double-blind study. Gastrointest Endosc 1999; 49:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/22\">",
"      Chang AC, Solinger MA, Yang DT, Chen YK. Impact of flumazenil on recovery after outpatient endoscopy: a placebo-controlled trial. Gastrointest Endosc 1999; 49:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/23\">",
"      Bartelsman JF, Sars PR, Tytgat GN. Flumazenil used for reversal of midazolam-induced sedation in endoscopy outpatients. Gastrointest Endosc 1990; 36:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28310/abstract/24\">",
"      Wille RT, Chaffee BW, Ryan ML, et al. Pharmacoeconomic evaluation of flumazenil for routine outpatient EGD. Gastrointest Endosc 2000; 51:282.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2599 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28310=[""].join("\n");
var outline_f27_41_28310=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARYNGEAL ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SEDATIVES AND ANALGESICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Phlebitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiopulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      REVERSAL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      For oversedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Naloxone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Flumazenil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      To reduce recovery times",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/14/10475\" title=\"table 1\">",
"      Predispositions for aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/6/32877\" title=\"table 2\">",
"      Meds for conscious sedation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43049?source=related_link\">",
"      Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8729?source=related_link\">",
"      Clinical features, diagnosis, and treatment of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42694?source=related_link\">",
"      Sedation-free gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_41_28311="Botfly extraction";
var content_f27_41_28311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54606&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Botfly extraction from nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. Extraction of",
"    <em>",
"     Dermatobia hominis",
"    </em>",
"    larva from a nodule on the scalp. The lesion was anesthetized with lidocaine intralesionally and then gently extracted in toto.",
"    <br>",
"     B. An additional lesion from the same patient contained another larva.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Peter Lio, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28311=[""].join("\n");
var outline_f27_41_28311=null;
var title_f27_41_28312="Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura";
var content_f27_41_28312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Daniel H Sterman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Leslie A Litzky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Larry R Kaiser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Steven M Albelda, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Arthur T Skarin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28312/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/41/28312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant mesothelioma is a rare neoplasm that typically arises from the mesothelial surfaces of the pleural cavity. Mesotheliomas may also arise from the peritoneal surface, the tunica vaginalis, or pericardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17754?source=see_link\">",
"     \"Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6789?source=see_link\">",
"     \"Testicular sex cord stromal tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"     \"Cardiac tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural mesothelioma has a poor prognosis. The median survival of patients with mesothelioma is between 6 and 18 months, and the outlook has not been substantially affected by newer therapeutic interventions. However, carefully selected patients with localized disease who receive aggressive multimodality therapy may be long term survivors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are only very limited data from randomized trials for patients with disease confined to one hemithorax. Local treatment approaches for malignant pleural mesothelioma and for fibrous tumors of the pleura are reviewed here.",
"   </p>",
"   <p>",
"    Other topics on mesothelioma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiology (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=see_link\">",
"       \"Epidemiology of malignant mesothelioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pathology (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29204?source=see_link\">",
"       \"Pathology of malignant pleural mesothelioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Clinical presentation and staging (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=see_link\">",
"       \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Systemic treatment of advanced disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42329?source=see_link\">",
"       \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PLEURAL MESOTHELIOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single best or standard approach for patients with malignant pleural mesothelioma, and treatment may range from simple tube thoracostomy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    to control a pleural effusion to radical surgery or combined modality approaches. Operation may be part of the initial treatment for carefully selected patients, either alone or in combination with other modalities. However, no randomized trials exist that have demonstrated a survival benefit for surgical resection, although a number of observational trials have suggested such a benefit. One pilot trial conducted in the United Kingdom (the MARS trial) has at least demonstrated the feasibility of randomizing patients to radical surgery or to nonsurgical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operation for malignant pleural mesothelioma can be done simply for diagnostic or palliative purposes, but in selected patients, it may be done with curative intent. Although potentially associated with substantial morbidity, resection may be useful to palliate the major symptoms of the disease, which include pain and dyspnea. Whether resection actually is responsible for an improvement in survival in some patients remains uncertain due to the lack of a randomized prospective trial.",
"   </p>",
"   <p>",
"    Video thoracoscopy has allowed for earlier definitive diagnosis of mesothelioma in more patients at a time when they still may be candidates for aggressive attempts at surgical debulking. Despite this, surgical resection as part of aggressive multimodality therapy is only feasible in a small percentage of patients. Most patients have locally advanced disease, advanced age, or other comorbid medical illnesses, precluding aggressive surgical intervention.",
"   </p>",
"   <p>",
"    Pleurodesis, or obliteration of the pleural space by causing adhesions between the visceral and parietal pleura, is used to control symptoms from pleural effusions. Procedures used in an effort to alter the natural history of localized mesothelioma include radical pleurectomy and decortication and radical extrapleural pneumonectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Pleurodesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large pleural effusions can cause persistent dyspnea, which, along with pain, is the most common symptom in patients with malignant pleural mesothelioma. Complete drainage of the pleural effusion by tube thoracostomy or video thoracoscopy followed by introduction of an irritative agent into the pleural space to produce pleural symphysis, or obliteration of the pleural space, often provides palliation in this setting.",
"   </p>",
"   <p>",
"    The most widely used compound for pleurodesis is sterile, asbestos-free talc, either insufflated as a powder or instilled via chest tube as a slurry [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/2\">",
"     2",
"    </a>",
"    ]. Thoracoscopic application (poudrage) may be more successful than other methods of pleurodesis (eg, tube thoracostomy), but the presence of bulky tumor in the pleural space or \"trapping\" of the lung by a thick visceral pleural peel of tumor can preclude successful pleurodesis because of the inability of the lung to completely expand to allow for visceral and parietal pleural contact. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of malignant pleural effusions\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Pleurectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parietal pleurectomy and decortication allows for expansion of a \"trapped\" lung and is more successful than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    in producing a durable pleural symphysis and reduces the likelihood of a recurrence of the pleural effusion. However, data from observational series suggest that neither open parietal pleurectomy or thoracoscopic pleurectomy alone results in improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/3\">",
"     3",
"    </a>",
"    ]. Similarly, observational data do not provide evidence that adjuvant RT following pleurectomy offers a survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Adjuvant RT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is some evidence that parietal pleurectomy and decortication may be as efficacious as extrapleural pneumonectomy (EPP). Multivariate analysis of a retrospective series from three institutions that included 663 patients who underwent either",
"    <span class=\"nowrap\">",
"     pleurectomy/decortication",
"    </span>",
"    (PD) or EPP found that patients who underwent PD actually had a better survival than those who had EPP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/4\">",
"     4",
"    </a>",
"    ]. PD patients had a higher rate of local recurrence of disease, while patients undergoing EPP had greater surgical morbidity and mortality. Although this study was retrospective and may have been influenced by selection bias, it raises important questions regarding the risk and benefit of each surgical approach.",
"   </p>",
"   <p>",
"    A retrospective study from England demonstrated the feasibility of an extended videothoracoscopic (VATS) pleurectomy for palliation of dyspnea in patients with locally advanced mesothelioma who are not candidates for more extensive surgical approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/5\">",
"     5",
"    </a>",
"    ]. An ongoing randomized trial in the UK is comparing the palliative benefits of VATS pleurectomy versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    in patients with malignant pleural mesothelioma (NCT00821860) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Radical extrapleural pneumonectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical extrapleural pneumonectomy (EPP) entails the complete removal of the ipsilateral lung along with the parietal pleura, pericardium and the majority of the hemidiaphragm. Based upon results from observational studies, EPP is the only intervention that has been demonstrated to result in long-term, disease-free survival in highly- selected patients with favorable prognostic indices [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EPP achieves the greatest degree of cytoreduction and allows higher radiation doses to be delivered safely to the ipsilateral hemithorax because the lung has been removed and it is the only procedure that potentially allows for removal of all gross disease. EPP is the favored surgical procedure when a thick tumor rind involves both the parietal and visceral pleura, as it potentially allows for removal of all gross disease, including tumor extending into the interlobar fissures.",
"   </p>",
"   <p>",
"    EPP is technically complex and associated with significant perioperative morbidity and mortality, even in centers with extensive experience. In an analysis of 328 consecutive patients treated at a single institution, the overall incidence of complications was 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/8\">",
"     8",
"    </a>",
"    ]. Atrial fibrillation was the most common postoperative complication, seen in more than 40 percent of cases despite prophylactic antiarrhythmic therapy. Other serious complications included herniation of the heart due to failure of the pericardial patch or herniation of abdominal contents into the pleural space secondary to dehiscence of the diaphragmatic repair, vocal cord dysfunction secondary to recurrent laryngeal nerve injury, bronchopleural fistula, empyema, and prolonged respiratory failure. Meticulous attention to technical detail has reduced morbidity and mortality, but even with extensive experience, the early postoperative mortality rate approaches 4 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32329?source=see_link\">",
"     \"Sequelae and complications of pneumonectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    EPP can palliate the profound dyspnea and orthopnea associated with the severe",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    mismatch resulting from lung encasement by tumor. However, EPP alone does not appear to prolong survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/9\">",
"     9",
"    </a>",
"    ]. In most EPP series, median survival is less than two years, but 10 to 20 percent of patients are five-year survivors. Patients with sarcomatoid histology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymph node involvement have an even poorer prognosis and should not be considered as candidates for EPP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Efforts to improve outcomes following EPP have focused on multimodality approaches that include radiation therapy (RT) and chemotherapy. Because of the morbidity and mortality with EPP, patient selection is a critical factor. The ideal patient is younger than 65 years old, has pure epithelial histology, an absence of lymph node involvement, and is physiologically able to tolerate pneumonectomy. Although EPP is most effective in this carefully selected group of patients, it should not be considered the standard of care. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Patient selection for a combined modality approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesothelioma is sensitive to external beam radiation therapy, but the dose is limited by the need to treat the entire hemithorax and by the sensitivity of the heart, lung, esophagus, liver, and spinal cord to radiation. Although treatment of the entire involved pleural surface is technically difficult, RT can provide symptom palliation in up to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/11\">",
"     11",
"    </a>",
"    ]. Intensity-modulated radiation therapy (IMRT) can improve local control while theoretically offering decreased pulmonary toxicity, if correct treatment algorithms are applied [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there are anecdotal reports of long-term survivors following high-dose external beam irradiation, most studies have not shown an effect on overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adjuvant RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant RT has been tested as a way to prevent chest wall recurrences as well as to improve survival following definitive surgery.",
"   </p>",
"   <p>",
"    Three randomized trials evaluated RT after thoracoscopy or thoracotomy to prevent tumor seeding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In total, these trials enrolled 79 patients and used differing techniques and radiation doses. There were too few local recurrences to draw definitive conclusions about the value of RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adjuvant RT has also been used following definitive surgery although there are no randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 123 patients who received adjuvant RT to the ipsilateral hemithorax following pleurectomy, the median survival was 14 months, and 23 percent of patients survived two years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/17\">",
"       17",
"      </a>",
"      ]. These results are similar to those with pleurectomy without adjuvant RT.",
"     </li>",
"     <li>",
"      Intensity-modulated radiotherapy (IMRT) following EPP was well tolerated and appeared to be more effective than conventional RT for local disease control in an initial observational series of 100 patients treated at a single center [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/12\">",
"       12",
"      </a>",
"      ]. However, a smaller series from another institution reported severe toxicity with IMRT, with 6 of 13 patients developing fatal radiation pneumonitis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=see_link\">",
"       \"Intensity-modulated radiation therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Chemotherapy-based approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even if disease can be controlled locally, most patients develop systemic metastases. The availability of active agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    , led to the integration of chemotherapy into combined modality approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42329?source=see_link\">",
"     \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemotherapy has been given both prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] and as an adjuvant following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, chemotherapy has been given directly into the thoracic cavity during surgery in an effort to improve local disease control [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of 183 patients were treated with EPP, followed by RT and adjuvant chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    for four to six cycles) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/21\">",
"     21",
"    </a>",
"    ]. At a median follow-up of 13 months, the overall survival rates at two and five years were 36 and 14 percent, respectively. Factors associated with a favorable prognosis included epithelial histology, tumor-free resection margins, and the absence of extrapleural nodal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter phase II trial evaluated the role of neoadjuvant chemotherapy prior to EPP and RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/19\">",
"     19",
"    </a>",
"    ]. All 77 patients had histologically confirmed clinical stage I, II, or III, malignant pleural mesothelioma (",
"    <a class=\"graphic graphic_table graphicRef81665 \" href=\"UTD.htm?43/19/44349\">",
"     table 1",
"    </a>",
"    ). Only 57 patients (74 percent) completed all four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and underwent surgery. EPP was completed in 54. RT (planned dose 54 Gy) was initiated in 44 and completed in 40. Among patients completing therapy, the median survival was 29 months and the two-year survival rate was 61 percent.",
"   </p>",
"   <p>",
"    In another series of 60 patients, the median survival was 59 months in a subgroup of patients who had epithelial histology, completed trimodality therapy (neoadjuvant chemotherapy, EPP, and then RT), and had node negative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, the median survival was less than 14 months in those not completing the treatment regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intracavitary chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative intracavitary chemotherapy has been used in an effort to improve local disease control. In a series of 92 patients, hyperthermic intracavitary perfusion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (225",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was performed following EPP [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/22\">",
"     22",
"    </a>",
"    ]. Recurrence of pleural mesothelioma was seen in 47 patients (51 percent), and was ipsilateral in 16 cases (17 percent).",
"   </p>",
"   <p>",
"    The value of these combined therapy approaches remains uncertain, due to selection bias and the lack of randomized trials. These combined modality approaches should be restricted to clinical studies at centers with extensive experience in these approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Patient selection for a combined modality approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the critical role of nodal status and metastatic disease in the success of EPP, patients being considered for an aggressive, combined modality approach should undergo an extensive evaluation. This should include thoracic imaging with sagittal views to assess mediastinal and diaphragmatic involvement in addition to PET scanning. Pulmonary function testing with quantitative ventilation-perfusion scanning for patients with borderline FEV1 should be performed, as should echocardiography to evaluate mediastinal invasion and ventricular function, which is crucial before treatment with anthracycline chemotherapy. Patients more than 60 years of age may not be candidates for EPP even if they meet other criteria, because of the increased perioperative mortality rate in older patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32329?source=see_link\">",
"     \"Sequelae and complications of pneumonectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, more invasive staging to search for mediastinal nodes and intraperitoneal (IP) spread should be performed. This may include laparoscopy and mediastinoscopy or endoscopic ultrasound-guided fine needle aspiration of the mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination of multiple expressed genes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteins within individual tumors may eventually prove useful for estimating prognosis and response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. As an example, a recent study that included 120 patients with mesothelioma found that a ratio based on expression of four genes distinguished between patients at low risk from those at high risk for recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The localized nature of mesothelioma, the easy access to the pleural space, and the development of distant metastases late in the natural history of the disease make mesothelioma an ideal target for other therapies focusing on the intrathoracic disease.",
"   </p>",
"   <p>",
"    As an example, intrapleural instillation of a replication-deficient, recombinant adenovirus has been used to insert the gene for the herpes simplex virus thymidine kinase gene, thus making tumor cells sensitive to the normally nontoxic antiviral drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or to deliver the gene for human type I interferons",
"    <span class=\"nowrap\">",
"     (beta/alpha)",
"    </span>",
"    to induce anti-tumor immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. A number of long-term clinical responses suggest that this approach has some promise, and also has the capacity to induce significant humoral and cellular anti-tumor immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SOLITARY FIBROUS TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solitary fibrous tumor of the pleura (also called pleural fibroma or benign fibrous mesothelioma) originates from a submesothelial mesenchymal pluripotential cell [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/34\">",
"     34",
"    </a>",
"    ]. Although older reports referred to these tumors as benign mesotheliomas, they are distinct from mesotheliomas and have malignant potential [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. These tumors can be quite large at presentation.",
"   </p>",
"   <p>",
"    Solitary fibrous tumors have also been reported to arise at extrathoracic sites, including soft tissues and muscle, pelvis, and abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of patients have symptoms at presentation, usually due to the local compressive effects of a large mass [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Paraneoplastic syndromes, including hypertrophic osteoarthropathy and hypoglycemia, are frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=see_link&amp;anchor=H13#H13\">",
"     \"Malignancy and rheumatic disorders\", section on 'Hypertrophic osteoarthropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrous tumors of the pleura are managed surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/37,40-44\">",
"     37,40-44",
"    </a>",
"    ]. In a retrospective series of 84 patients treated at the Mayo Clinic over a 30-year period, the five-year, disease-free survival rate following resection was 89 percent in the 73 patients with benign histopathology and 46 percent in the 11 patients with malignancy identified in their original resection specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/42\">",
"     42",
"    </a>",
"    ]. Most recurrences are at remote sites within the pleura, although distant metastases also can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. Pleural recurrences can be managed with surgical resection.",
"   </p>",
"   <p>",
"    Preclinical data and one case report suggest that inhibition of platelet-derived growth factor receptor with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    may have clinical activity in patients with recurrent solitary fibrous tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28312/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/15/33010?source=see_link\">",
"       \"Patient information: Pleural mesothelioma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no completely satisfactory treatments for patients who present with malignant pleural mesothelioma, even when disease appears to be localized to one hemithorax. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=see_link&amp;anchor=H24#H24\">",
"       \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\", section on 'Natural history'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For carefully selected patients with localized disease who are seeking aggressive therapy, we suggest a combined modality approach including surgical debulking with pleurectomy or radical extrapulmonary pneumonectomy, radiation therapy (only after extrapleural pneumonectomy), and combination",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      -based chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Such approaches are associated with substantial morbidity and potentially mortality, and such treatment algorithms should be restricted to selected patients who will be treated in clinical trials at centers with expertise in the treatment of mesothelioma. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Patient selection for a combined modality approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are not candidates for aggressive local therapy, drainage of pleural effusions (with pleurodesis for those with lung reexpansion), VATS pleurectomy, or the use of systemic chemotherapy may offer significant palliative benefit. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pleurodesis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42329?source=see_link\">",
"       \"Systemic treatment for unresectable malignant pleural mesothelioma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/1\">",
"      Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011; 12:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/2\">",
"      Cant&oacute; A, Guijarro R, Arnau A, et al. Videothoracoscopy in the diagnosis and treatment of malignant pleural mesothelioma with associated pleural effusions. Thorac Cardiovasc Surg 1997; 45:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/3\">",
"      van Ruth S, Baas P, Zoetmulder FA. Surgical treatment of malignant pleural mesothelioma: a review. Chest 2003; 123:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/4\">",
"      Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/5\">",
"      Nakas A, Martin Ucar AE, Edwards JG, Waller DA. The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008; 33:83.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. file://www.clinicaltrials.gov/ (Accessed on February 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/7\">",
"      Tsao AS, Mehran R, Roth JA. Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer 2009; 10:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/8\">",
"      Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 2004; 128:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/9\">",
"      Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 1991; 102:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/10\">",
"      Balduyck B, Trousse D, Nakas A, et al. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? Ann Thorac Surg 2010; 89:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/11\">",
"      de Graaf-Strukowska L, van der Zee J, van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 1999; 43:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/12\">",
"      Rice DC, Stevens CW, Correa AM, et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007; 84:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/13\">",
"      Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107:332S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/14\">",
"      McAleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2009; 75:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/15\">",
"      Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 1995; 108:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/16\">",
"      O'Rourke N, Garcia JC, Paul J, et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/17\">",
"      Gupta V, Mychalczak B, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005; 63:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/18\">",
"      Allen AM, Czerminska M, J&auml;nne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 2006; 65:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/19\">",
"      Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/20\">",
"      Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/21\">",
"      Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/22\">",
"      Tilleman TR, Richards WG, Zellos L, et al. Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 2009; 138:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/23\">",
"      de Perrot M, Feld R, Cho BC, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27:1413.",
"     </a>",
"    </li>",
"    <li>",
"     Mesothelioma Applied Research Foundation (MARF) information available online at www.marf.org, by calling (877)-363-6376, or by email (mhesdorffer@curemeso.org). Information accessed January 8, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/25\">",
"      Rice DC, Steliga MA, Stewart J, et al. Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma. Ann Thorac Surg 2009; 88:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/26\">",
"      Rice DC, Erasmus JJ, Stevens CW, et al. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 2005; 80:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/27\">",
"      Gordon GJ, Dong L, Yeap BY, et al. Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst 2009; 101:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/28\">",
"      Pass HI, Liu Z, Wali A, et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin Cancer Res 2004; 10:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/29\">",
"      Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003; 95:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/30\">",
"      Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/31\">",
"      Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998; 9:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/32\">",
"      Sterman DH, Recio A, Carroll RG, et al. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. Clin Cancer Res 2007; 13:4456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/33\">",
"      Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11:7444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/34\">",
"      de Perrot M, Fischer S, Br&uuml;ndler MA, et al. Solitary fibrous tumors of the pleura. Ann Thorac Surg 2002; 74:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/35\">",
"      Churg A, Colby TV, Cagle P, et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000; 24:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/36\">",
"      England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol 1989; 13:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/37\">",
"      Lococo F, Cesario A, Cardillo G, et al. Malignant solitary fibrous tumors of the pleura: retrospective review of a multicenter series. J Thorac Oncol 2012; 7:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/38\">",
"      Wignall OJ, Moskovic EC, Thway K, Thomas JM. Solitary fibrous tumors of the soft tissues: review of the imaging and clinical features with histopathologic correlation. AJR Am J Roentgenol 2010; 195:W55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/39\">",
"      Briselli M, Mark EJ, Dickersin GR. Solitary fibrous tumors of the pleura: eight new cases and review of 360 cases in the literature. Cancer 1981; 47:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/40\">",
"      Santos RS, Haddad R, Lima CE, et al. Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura. Clin Lung Cancer 2005; 7:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/41\">",
"      Sung SH, Chang JW, Kim J, et al. Solitary fibrous tumors of the pleura: surgical outcome and clinical course. Ann Thorac Surg 2005; 79:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/42\">",
"      Harrison-Phipps KM, Nichols FC, Schleck CD, et al. Solitary fibrous tumors of the pleura: results of surgical treatment and long-term prognosis. J Thorac Cardiovasc Surg 2009; 138:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/43\">",
"      Carretta A, Bandiera A, Melloni G, et al. Solitary fibrous tumors of the pleura: Immunohistochemical analysis and evaluation of prognostic factors after surgical treatment. J Surg Oncol 2006; 94:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/44\">",
"      Liu J, Cai C, Wang D, et al. Video-assisted thoracoscopic surgery (VATS) for patients with solitary fibrous tumors of the pleura. J Thorac Oncol 2010; 5:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/45\">",
"      Prunotto M, Bosco M, Daniele L, et al. Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. Lung Cancer 2009; 64:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28312/abstract/46\">",
"      De Pas T, Toffalorio F, Colombo P, et al. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. J Thorac Oncol 2008; 3:938.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4626 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28312=[""].join("\n");
var outline_f27_41_28312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PLEURAL MESOTHELIOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Pleurodesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Pleurectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Radical extrapleural pneumonectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adjuvant RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Chemotherapy-based approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intracavitary chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Patient selection for a combined modality approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SOLITARY FIBROUS TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4626\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4626|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/19/44349\" title=\"table 1\">",
"      TNM stage mesothelioma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7622?source=related_link\">",
"      Epidemiology of malignant mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35496?source=related_link\">",
"      Malignancy and rheumatic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17754?source=related_link\">",
"      Malignant peritoneal mesothelioma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29204?source=related_link\">",
"      Pathology of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/15/33010?source=related_link\">",
"      Patient information: Pleural mesothelioma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32329?source=related_link\">",
"      Sequelae and complications of pneumonectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42329?source=related_link\">",
"      Systemic treatment for unresectable malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6789?source=related_link\">",
"      Testicular sex cord stromal tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_41_28313="Salivary gland tumors: Treatment of locoregional disease";
var content_f27_41_28313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Salivary gland tumors: Treatment of locoregional disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/41/28313/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28313/contributors\">",
"     William M Lydiatt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28313/contributors\">",
"     Jeanne M Quivey, MD, FACR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/41/28313/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28313/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28313/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28313/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28313/contributors\">",
"     Marvin P Fried, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/41/28313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/41/28313/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/41/28313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland tumors include a wide range of tumor types, which can be either benign or malignant (",
"    <a class=\"graphic graphic_table graphicRef70453 \" href=\"UTD.htm?20/36/21069\">",
"     table 1",
"    </a>",
"    ). Approximately 85 percent arise in the parotid; the remainder originate in the submandibular, sublingual, and minor salivary glands, which are located throughout the submucosa of the mouth and upper aerodigestive tract (",
"    <a class=\"graphic graphic_figure graphicRef62744 \" href=\"UTD.htm?6/19/6449\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/1\">",
"     1",
"    </a>",
"    ]. Approximately 25 percent of parotid tumors are malignant, compared with 40 to 45 percent of submandibular gland tumors, 70 to 90 percent of sublingual gland tumors, and 50 to 75 percent of minor salivary gland tumors.",
"   </p>",
"   <p>",
"    Treatment is based upon retrospective reviews of clinical experience, and there are almost no data from randomized trials to guide treatment decisions. The published literature predominately focuses on the parotid gland, reflecting the relative frequency of parotid gland tumors compared to tumors at other sites. The treatment of locoregional disease, which includes stages I through IVB, will be discussed here (",
"    <a class=\"graphic graphic_table graphicRef61042 \" href=\"UTD.htm?34/52/35661\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other topics on salivary gland tumors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"       \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11816?source=see_link\">",
"       \"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H17#H17\">",
"       \"Pathology of head and neck neoplasms\", section on 'Salivary gland tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment and outcome of salivary gland tumors depends upon histology, the gland involved, and location within the gland. In general, when a tumor is oncologically completely resectable, complete surgical resection is the cornerstone of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with benign and low-grade tumors are typically treated with surgery alone, whereas patients with high-grade carcinomas and those with positive margins and other high-risk features are usually treated with surgery and adjuvant radiation therapy (RT). Patients with unresectable tumors may be treated with RT alone, or RT with chemotherapy for appropriate patients with unresectable tumors. (See",
"    <a class=\"local\" href=\"#H267154432\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Preoperative assessment of salivary gland masses guides the surgical approach. Contemporary imaging techniques such as MRI, CT, and ultrasound aid in evaluation of regional lymph node involvement and the extent of tumor invasion, such as facial nerve and skull base involvement with parotid tumors.",
"   </p>",
"   <p>",
"    Biopsy or fine needle aspiration cytology can usually discriminate benign tumors from malignant lesions and primary salivary gland tumors from metastases or lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link&amp;anchor=H6966596#H6966596\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Parotid gland tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection of parotid tumors depends upon whether the tumor is benign or malignant, its location within the parotid gland, its size and invasiveness, and its relationship to the facial nerve. The facial nerve divides the parotid gland into a superficial and deep lobe (",
"    <a class=\"graphic graphic_figure graphicRef66602 \" href=\"UTD.htm?15/13/15572\">",
"     figure 2",
"    </a>",
"    ). Adequate resection of tumor with preservation of the facial nerve is the prime objective in management of salivary gland tumors. Unless the facial nerve is directly involved by malignant tumor, effort is made to protect and preserve its function. This may result in a pathological positive margin however, this typically does not carry the same negative implications as mucosal disease. In fact, whole organ sectioning suggests that the vast majority of parotid dissections will harbor a pathologic positive margin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/3\">",
"     3",
"    </a>",
"    ]. The addition of RT is discussed below but is not mandated by a pathological positive margin. (See",
"    <a class=\"local\" href=\"#H267154432\">",
"     'Radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Parotidectomy is classified as conservative, superficial, or total, based upon lobes resected and extent of facial nerve dissected:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A conservative, partial, or limited superficial parotidectomy is any procedure that is less extensive than a superficial parotidectomy and does not fully dissect the facial nerve.",
"     </li>",
"     <li>",
"      A superficial parotidectomy involves resection of the entire superficial lobe and dissection along all branches of the facial nerve.",
"     </li>",
"     <li>",
"      A total parotidectomy involves dissection and preservation of the facial nerve with removal of parotid tissue in the deep as well as superficial lobe.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These procedures are in contrast to a simple enucleation, or shelling out of tumor, which is rarely indicated for salivary gland tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Benign tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial parotidectomy is recommended for most benign tumors confined to the superficial lobe, including pleomorphic adenomas (the most common benign salivary gland tumor) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Pleomorphic adenoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, a conservative parotidectomy has been advocated to remove selected tumors in the inferior portion of the gland, particularly Warthin tumors. For benign tumors lying deep to the plane of the facial nerve, every effort is made to preserve the facial nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Malignant tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For malignant tumors of the parotid gland, the extent of resection depends upon the histologic degree of differentiation, as well as the location and size of the tumor if known (",
"    <a class=\"graphic graphic_table graphicRef64529 \" href=\"UTD.htm?29/62/30699\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    High-grade tumors are often treated with a total parotidectomy. Lower grade malignant tumors and high-grade tumors located peripherally within the superficial lobe (particularly the inferior aspect) may be treated with a superficial parotidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/4,5,8-14\">",
"     4,5,8-14",
"    </a>",
"    ]. For deep malignant tumors, a total parotidectomy is typically performed depending upon the location of the tumor within the gland.",
"   </p>",
"   <p>",
"    For more invasive, T4 tumors (",
"    <a class=\"graphic graphic_table graphicRef61042 \" href=\"UTD.htm?34/52/35661\">",
"     table 2",
"    </a>",
"    ), obtaining wide surgical margins of normal uninvolved tissue may entail resection of skin of the face and neck, contiguous soft tissue and muscle, and mandible or temporal bone. Tumors that extend to bone may require a lateral or subtotal temporal bone resection, resection of zygoma or mandibulectomy. Partial or complete facial nerve paralysis occurs in 15 to 23 percent of malignant parotid lesions at presentation and is associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Total parotidectomy with resection of the involved portion of the facial nerve is performed for patients who present with facial nerve dysfunction or with clinical suspicion of tumor infiltration at operation. If possible, reconstruction of the nerve with an interposition nerve graft or static procedures to mitigate facial drop should be done at the same procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the facial nerve is functioning preoperatively, effort is made to preserve it. Prophylactic resection of the nerve, in the absence of clinical involvement, adds little to surgical margins or tumor control and results in substantial morbidity. However, even when the intent is to preserve the nerve, there remains substantial risk of facial paralysis with reported incidence rates of 27 to 43 percent for temporary paralysis and 4 to 22 percent for permanent paralysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although the use of an electromyography (EMG)-based intraoperative facial nerve monitor has not been conclusively shown to reduce the risk of postoperative facial nerve paralysis, many surgeons consider it a useful surgical adjunct [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk and the nature of complications following parotidectomy depend upon the extent of parotidectomy, pathology of the tumor, location of the tumor within the gland, and the experience of the surgeon.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of temporary facial palsy after parotid surgery varies between 10 and 65 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/19,20,22,23\">",
"       19,20,22,23",
"      </a>",
"      ]. Most patients recover facial nerve function within one year of surgery so that the rate of permanent facial paralysis is typically less than 3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/4,22,24\">",
"       4,22,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frey syndrome, also known as auriculotemporal syndrome or gustatory sweating, is characterized by sweating and flushing of the facial skin over the parotid bed and neck during mastication. Frey syndrome is thought to be due to aberrant regeneration of cut parasympathetic fibers between the otic ganglion and salivary tissue, which leads to innervation of sweat glands and subcutaneous vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Frey syndrome is reported by approximately 10 percent of patients, although rigorous testing may detect gustatory sweating in as many as 95 percent of patients after parotidectomy. Frey syndrome may occur from two weeks to two years after surgery due to a latency in the regeneration of parasympathetic nerve fibers; the area of involved skin may increase over time [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The incidence of Frey syndrome is reduced by minimizing the parotid wound bed, reconstructive techniques such as thick skin flaps, and postoperative RT [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/25\">",
"       25",
"      </a>",
"      ]. Intracutaneous injection of botulinum toxin A is an effective, well-tolerated, and long-lasting treatment for symptomatic patients; it may be repeated for recurrent symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Facial nerve dysfunction may also be manifested by sensory deficits around the ear and cheek. Additional complications specific to salivary gland surgery are sialocele and salivary fistula. These are uncommon long term problems but may occur in the postoperative period in up to 5 percent of patients. Numbness in the distribution of the great auricular nerve including the ear, especially the lobule and the face and neck is a common occurrence. Over time the majority of this will resolve but permanent areas of numbness may occur [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/28\">",
"       28",
"      </a>",
"      ]. Preservation of the nerve is best attempted when feasible. Bleeding and hematoma are also potential complications from any neck surgery. Finally, a rare but very problematic complication of deep lobe parotid and parapharyngeal space dissections is severe cramping or spasm in the parotid region with the first bite of each meal that diminishes over the next several bites (&ldquo;first bite syndrome&rdquo;) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/29\">",
"       29",
"      </a>",
"      ]. This is best managed conservatively using analgesics, antidepressants, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Submandibular gland tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Submandibular gland tumors, nearly half of which are malignant, are treated with submandibular sialoadenectomy, a resection of the submandibular gland.",
"   </p>",
"   <p>",
"    Anatomical considerations of a submandibular sialoadenectomy include the close proximity of the facial artery and vein, marginal mandibular branch of the facial nerve, the hypoglossal and lingual nerves, and Wharton&rsquo;s duct. It is the proximity of these structures that determines the major surgical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The surgical approach may be transcervical, intraoral, or endoscopic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. The choice of approach is based upon fine needle aspiration (FNA) cytology, imaging findings, clinical experience of the surgeon, as well as potential associated complications, including aesthetic considerations. Malignancy should be treated with an external approach to adequately address the surrounding tissue and nodes.",
"   </p>",
"   <p>",
"    Benign tumors are most commonly treated by simple excision of the gland. The marginal mandibular branch of the facial nerve, the hypoglossal nerve, and the lingual nerve should be spared.",
"   </p>",
"   <p>",
"    Malignant tumors are removed en bloc with the affected gland. This often necessitates resection of the surrounding skin, muscles, and nerves, although effort is made to preserve the marginal mandibular branch of the facial nerve, the lingual nerve, and the hypoglossal nerve, unless they are encased with tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Management of the neck'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Despite the increasing use of fine needle aspiration cytology for diagnosis, some patients with a submandibular gland mass undergo initial surgical enucleation of the gland before a diagnosis of malignancy can be established. In this setting, the necessity of reoperation to obtain adequate margins remains uncertain.",
"   </p>",
"   <p>",
"    In a single institution review of 87 patients, no statistically significant difference in locoregional disease control or overall survival was found for patients managed with enucleation of the gland alone followed by adjuvant RT compared with patients who underwent enucleation, definitive surgical resection, and adjuvant RT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/36\">",
"     36",
"    </a>",
"    ]. Based upon these findings, patients without clinical and radiographic evidence of disease after enucleation of a malignant submandibular gland tumor may be adequately treated with adjuvant RT, whereas those with gross residual disease following tumor enucleation should undergo definitive surgical resection prior to adjuvant RT. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Adjuvant radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sublingual gland tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sublingual gland tumors are rare but usually malignant. Like salivary gland tumors at other sites, surgery is the mainstay of treatment.",
"   </p>",
"   <p>",
"    Resection of the floor of the mouth and involved sublingual gland as well as the ipsilateral submandibular gland is suggested even for small tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Concurrent removal of the submandibular gland along with sublingual gland resection may be necessary since its ducts may be compromised even with a limited resection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/39\">",
"     39",
"    </a>",
"    ]. For larger tumors, en bloc resection may entail a marginal or segmental mandibulectomy and resection of the lingual nerve. Reconstruction, often with microvascular free-flaps, is appropriate to improve function with floor of the mouth and mandibular defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=see_link\">",
"     \"Mandibular and palatal reconstruction in patients with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite low rates of nodal involvement, an elective selective neck dissection is commonly performed for sublingual gland tumors, particularly when a free flap is utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. A more comprehensive neck dissection is indicated for the node-positive neck. Generally, elective neck dissection should be considered when the histology is known prior to surgery and is high grade, involves the medial mandible, significant floor of mouth structures or requires a free flap reconstruction. A relative indication for elective neck dissection of levels I-III is in a high grade tumor where adjuvant RT is to be avoided. Adjuvant RT may be added for patients with high-grade tumors, positive margins, or advanced stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Management of the neck'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Adjuvant radiation therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Minor salivary gland tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral cavity contains 500 to 1000 minor salivary glands, which are most common on the hard palate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/40\">",
"     40",
"    </a>",
"    ]. Minor salivary glands are also found in the lips, superior poles of the tonsils, nasopharynx, paranasal sinuses, oropharynx, hypopharynx, larynx, and trachea. Minor salivary gland tumors are staged according to the anatomic site in which they arise.",
"   </p>",
"   <p>",
"    Surgical resection is the mainstay of management. Postoperative adjuvant therapy is prescribed for the same general indications as a comparably staged squamous cell carcinoma. [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Occasionally, minor salivary gland tumors are treated with RT alone. [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/40,43\">",
"     40,43",
"    </a>",
"    ]. Although minor salivary gland cancers may achieve local control with the use of RT (or chemoradiation) alone, surgical resection alone or followed by RT is preferred. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Definitive treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management of the neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of patients with salivary gland tumors have clinically apparent nodal metastases at presentation and should be treated with a selective neck dissection of the areas involved and echelons at highest risk (levels II to III, for most parotid cancers, I, IV and V when indicated, (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"     figure 3",
"    </a>",
"    )) followed by adjuvant RT in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/41,44-47\">",
"     41,44-47",
"    </a>",
"    ]. At this point in time, there are no data on sentinel node mapping in parotid malignancies. &nbsp;",
"   </p>",
"   <p>",
"    The management of the clinically negative neck is more controversial. Occult metastases have been detected in 12 to 45 percent of patients with a clinically negative neck [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/44,47,48\">",
"     44,47,48",
"    </a>",
"    ]. Based upon this high rate of occult metastases, some experts recommend elective neck dissection for all patients with malignant salivary gland tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/47,49\">",
"     47,49",
"    </a>",
"    ]. Many however, reserve elective neck dissection for patients with features suggestive of high-risk for occult nodal disease: high-grade tumors, except adenoid cystic locally advanced disease (T3 and T4 tumors), facial nerve",
"    <span class=\"nowrap\">",
"     paralysis/weakness,",
"    </span>",
"    and advanced age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/41,44,45\">",
"     41,44,45",
"    </a>",
"    ]. Elective dissection of levels II and III can easily be performed with minimal additional morbidity at the time of parotidectomy and should be considered for high-grade salivary gland tumors where adjuvant RT is not planned. If RT is to be used postoperatively, elective neck dissection is less important given the equivalency in elective treatment. [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above recommendations about neck dissections are primarily based upon the literature regarding tumors of the parotid gland. Based upon comparable treatment outcome and behavior, these recommendations are generally also applied to other salivary gland tumors. Routine elective neck dissection has been suggested for all sublingual gland tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and for all nasopharyngeal malignancies arising in minor salivary glands however the lack of good data make a definitive pronouncement tenuous [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267154432\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Definitive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive radiation therapy (RT) is reserved for patients who are medically inoperable or who have unresectable disease, either by extent of tumor invasion or location such that resection would result in a significant functional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cosmetic deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/40,43,52-54\">",
"     40,43,52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The techniques, dosing, and schedule for RT for head and neck tumors are discussed in detail separately. Although the behavior and treatment response of salivary gland tumors may differ from squamous head and neck cancers, many of the principles are shared based upon the much larger body of data available for squamous head and neck cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=see_link\">",
"     \"General principles of radiation therapy for head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Definitive RT may be delivered as conventional radiation with photons and electrons or with high linear energy transfer radiation such as neutron or carbon ion therapy. Although heavy particle RT has been advocated as potentially providing better disease control, the data supporting these approaches is primarily from observational series and these techniques are not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. When conventional RT is used in a good performance status patient due to unresectable disease, consideration may be given to concomitant chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . Unfortunately, no data exists to either support or refute this approach. Therefore, it is best reserved for a clinical trial or a situation with full disclosure to the patient about the lack of evidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Adjuvant radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of local recurrence following initial surgery for salivary gland tumors varies depending upon histology, grade, and extent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign salivary gland tumors have a low recurrence rate and an excellent prognosis after adequate surgical resection; thus there is no role for adjuvant therapy following initial resection. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Pleomorphic adenoma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Early stage, low-grade tumors including low-grade mucoepidermoid carcinomas, acinic cell carcinomas, and low-grade adenocarcinomas are well controlled with complete surgical resection, with control reaching 85 percent at 10 years and adjuvant RT generally is not indicated if adequate margins are obtained [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with high-risk features, including high-grade and advanced stage lesions, positive surgical margins, skin and nerve invasion, as well as nearly all adenoid cystic carcinoma, appear to benefit from the addition of postoperative RT.",
"     </li>",
"     <li>",
"      Salivary gland tumors arising in anatomic sites not amenable to wide resection, such as the nasopharynx, also should receive postoperative RT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Retrospective data suggest that adjuvant RT improves both local control and survival for selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/41,58-63\">",
"     41,58-63",
"    </a>",
"    ]. As an example, the administration of postoperative RT rather than surgery alone reduced the incidence of local recurrence from 54 to 14 percent for patients with microscopic disease present at or close to the surgical margin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/61\">",
"     61",
"    </a>",
"    ]. For patients with stage III or IV disease, the five-year local control rate and cause-specific survival were both improved with adjuvant RT compared with surgery alone (51 versus 17 and 51 versus 10 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consequently, adjuvant RT is suggested after surgical resection for patients who have T2 or greater high-grade tumors, locally advanced T3 and T4 tumors or positive regional lymph nodes, positive resection margins in most high-grade and some low-grade tumors (instead of re-exploration), perineural, vascular, or lymphatic invasion, and extracapsular spread.",
"   </p>",
"   <p>",
"    Additional circumstances where routine adjuvant RT of malignant, T2 and greater salivary gland tumors may be considered include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Submandibular gland tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/36,37,62,64,65\">",
"       36,37,62,64,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sublingual gland tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Minor salivary tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/66\">",
"       66",
"      </a>",
"      ], especially of the nasopharynx [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      All adenoid cystic tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/67-70\">",
"       67-70",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal radiation dose for malignant salivary gland tumor depends upon the fractionation scheme utilized, but likely exceeds 60 Gy, and most use doses of 66 Gy at 2 Gy per fraction. The radiation treatment volume encompasses the original tumor bed and regional lymph nodes only if involved or thought to be at high risk. For adenoid cystic carcinoma, neural pathways to the skull base are also included. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=see_link&amp;anchor=H1493366803#H1493366803\">",
"     \"Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule\", section on 'Dose and schedule of RT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267154709\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of RT, either as definitive therapy or as a postoperative adjuvant vary according to the anatomic location of the tumor and are dose dependent. The complications of RT for head and neck malignancies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic therapy with either chemotherapy or molecularly targeted agents has been used for palliative therapy in patients with metastatic disease. There is not a defined role for adjuvant chemotherapy in conjunction with postoperative irradiation, although this question is currently being investigated the RTOG 1008 clinical trial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11816?source=see_link&amp;anchor=H2#H2\">",
"     \"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease\", section on 'Metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are only very limited data regarding the use of adjuvant systemic therapy in patients with salivary gland tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/71\">",
"     71",
"    </a>",
"    ]. Chemotherapy has also been combined with postoperative RT in the adjuvant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PLEOMORPHIC ADENOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleomophic adenoma, also known as benign mixed tumor, is the most common salivary gland tumor. The majority occur in the superficial lobe of the parotid gland. Pleomophic adenoma has historically been characterized as having a propensity for local recurrence and a potential for malignant transformation to the so called \"carcinoma ex-pleomophic adenoma\". (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H18#H18\">",
"     \"Pathology of head and neck neoplasms\", section on 'Benign salivary gland tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Superficial parotidectomy is the treatment of choice for pleomorphic adenomas arising in the parotid gland. The recurrence rate after simple enucleation is 20 to 45 percent; with superficial parotidectomy, recurrence rates are reduced to less than five percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. For most pleomorphic adenomas, a more extensive procedure (total parotidectomy) does not reduce the risk of recurrence further and is associated with higher rates of facial nerve dysfunction and other complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/74,76,77\">",
"     74,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positive margins, capsule rupture, and tumor spillage have been implicated as a potential causes for high recurrence rates, and these should be avoided when possible. However, positive margins are common after resection of this tumor; these occur because of an incomplete tumor capsule, a tendency of the tumor to form perforating pseudopodia, and close proximity of the tumor to the facial nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/3,74,78\">",
"     3,74,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, pleomorphic adenoma has been reported to metastasize to the lung, bone, and elsewhere. Furthermore, carcinoma ex-pleomorphic adenoma, an aggressive malignancy, may arise in a small percentage of pleomorphic adenomas. Evidence suggests that the occurrence of both is related to incomplete or inadequate primary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=see_link&amp;anchor=H267154018#H267154018\">",
"     \"Pathology of head and neck neoplasms\", section on 'Carcinoma ex pleomorphic adenoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent pleomorphic adenomas are treated with resection, but the likelihood of control diminishes with each subsequent surgery while the morbidity increases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. These include facial nerve dysfunction, Frey syndrome, salivary fistula, and necroses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/76,83\">",
"     76,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of postoperative radiation following resection of recurrences is debated, but improved local control with postoperative RT, particularly for positive margins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multinodular recurrence, has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/76,78,80\">",
"     76,78,80",
"    </a>",
"    ]. Although re-resection should be performed, if possible, for positive margins, many experts would consider postoperative RT for all patients with recurrent pleomorphic adenoma, depending upon factors such as rapidity of recurrence, patient age, and completeness of resection. Unresectable recurrences are also treated with RT. RT doses used for pleomorphic adenomas are generally lower than for carcinomas, 50 Gy in 1.8 to 2.0 Gy fractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumors of major gland salivary glands generally have a better prognosis than those of minor salivary glands, while parotid tumors tend to have a better prognosis than submandibular tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/62,84\">",
"     62,84",
"    </a>",
"    ]. Several factors have been identified as prognostic of both locoregional control and survival for patients with malignant SGTs.",
"   </p>",
"   <p>",
"    Negative prognostic factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/41/28313/abstract/84-93\">",
"     84-93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative facial nerve dysfunction",
"     </li>",
"     <li>",
"      High primary tumor stage (T stage)",
"     </li>",
"     <li>",
"      Positive cervical lymph nodes",
"     </li>",
"     <li>",
"      Perineural invasion",
"     </li>",
"     <li>",
"      Positive surgical margins",
"     </li>",
"     <li>",
"      High tumor histology or grade",
"     </li>",
"     <li>",
"      Older age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular posttreatment follow-up has become an essential part of the care of patients after potentially curative treatment of head and neck cancer. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding, and enlarged lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences of salivary gland tumors occur within this timeframe. Continued follow-up is generally suggested there is a risk of recurrence even beyond the first five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salivary gland tumors include a wide array of benign and malignant histologies that can occur in salivary gland tissue throughout the head and neck. The clinical behavior and management of these tumors depends upon both histology and tumor location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Primary treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Definitive therapy is indicated for patients with locoregional salivary gland tumors. For patients with resectable tumors, we suggest surgical resection rather than radiation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In general, simple enucleation is considered inadequate for treatment of salivary gland tumors whether benign or malignant. The extent of surgical resection of salivary gland tumors depends upon the histology and anatomic location of the tumor. For patients who are medically inoperable or who have unresectable disease, definitive radiation therapy is an appropriate alternative. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Definitive treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Management of the neck",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with clinically or radiographically apparent nodal metastases, we recommend a modified radical neck dissection (levels II to III, I, IV and V when indicated (",
"      <a class=\"graphic graphic_figure graphicRef54099 \" href=\"UTD.htm?8/3/8244\">",
"       figure 3",
"      </a>",
"      )) followed by adjuvant RT in most cases (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest elective neck dissection of levels II and III for patients with high-risk features: high-grade tumors, locally advanced disease (T3 and T4 tumors), facial nerve",
"      <span class=\"nowrap\">",
"       paralysis/weakness,",
"      </span>",
"      and advanced age (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When adjuvant radiation therapy (RT) is to be used, RT to the neck may substitute for neck dissection. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest elective neck dissection for all sublingual gland tumors and for minor salivary gland malignancies arising in the nasopharynx (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of the neck'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest adjuvant radiation therapy for high-grade T2 tumors and all locally advanced T3, T4, and node-positive tumors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adjuvant radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest adjuvant radiation therapy for patients with high-risk pathologic features including positive resection margins in most high-grade tumors and some low-grade tumors, as well as perineural, vascular, and lymphatic invasion, lymph node involvement, and extracapsular spread (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adjuvant radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest adjuvant radiation therapy for T2 or greater high grade submandibular gland tumors, sublingual gland tumors, minor salivary tumors, especially of the nasopharynx, and most adenoid cystic tumors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Adjuvant radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/1\">",
"      Guzzo M, Locati LD, Prott FJ, et al. Major and minor salivary gland tumors. Crit Rev Oncol Hematol 2010; 74:134.",
"     </a>",
"    </li>",
"    <li>",
"     NCCN guidelines file://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/3\">",
"      Lam KH, Wei WI, Ho HC, Ho CM. Whole organ sectioning of mixed parotid tumors. Am J Surg 1990; 160:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/4\">",
"      O'Brien CJ. Current management of benign parotid tumors--the role of limited superficial parotidectomy. Head Neck 2003; 25:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/5\">",
"      Lim YC, Lee SY, Kim K, et al. Conservative parotidectomy for the treatment of parotid cancers. Oral Oncol 2005; 41:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/6\">",
"      Hussain A, Murray DP. Preservation of the superficial lobe for deep-lobe parotid tumors: a better aesthetic outcome. Ear Nose Throat J 2005; 84:518, 520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/7\">",
"      Roh JL, Park CI. Function-preserving parotid surgery for benign tumors involving the deep parotid lobe. J Surg Oncol 2008; 98:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/8\">",
"      Helmus C. Subtotal parotidectomy: a 10-year review (1985 to 1994). Laryngoscope 1997; 107:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/9\">",
"      Leverstein H, van der Wal JE, Tiwari RM, et al. Surgical management of 246 previously untreated pleomorphic adenomas of the parotid gland. Br J Surg 1997; 84:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/10\">",
"      Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986; 8:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/11\">",
"      Guntinas-Lichius O, Appenrodt S, Veelken F, Krug B. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 2006; 116:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/12\">",
"      Laccourreye H, Laccourreye O, Cauchois R, et al. Total conservative parotidectomy for primary benign pleomorphic adenoma of the parotid gland: a 25-year experience with 229 patients. Laryngoscope 1994; 104:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/13\">",
"      McGurk M, Renehan A, Gleave EN, Hancock BD. Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. Br J Surg 1996; 83:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/14\">",
"      Wennmo C, Spandow O, Emg&aring;rd P, Krouth&eacute;n B. Pleomorphic adenomas of the parotid gland: superficial parotidectomy or limited excision? J Laryngol Otol 1988; 102:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/15\">",
"      Guntinas-Lichius O, Klussmann JP, Schroeder U, et al. Primary parotid malignoma surgery in patients with normal preoperative facial nerve function: outcome and long-term postoperative facial nerve function. Laryngoscope 2004; 114:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/16\">",
"      Terhaard C, Lubsen H, Tan B, et al. Facial nerve function in carcinoma of the parotid gland. Eur J Cancer 2006; 42:2744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/17\">",
"      Sullivan MJ, Breslin K, McClatchey KD, et al. Malignant parotid gland tumors: a retrospective study. Otolaryngol Head Neck Surg 1987; 97:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/18\">",
"      Kimata Y, Sakuraba M, Hishinuma S, et al. Free vascularized nerve grafting for immediate facial nerve reconstruction. Laryngoscope 2005; 115:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/19\">",
"      Meier JD, Wenig BL, Manders EC, Nenonene EK. Continuous intraoperative facial nerve monitoring in predicting postoperative injury during parotidectomy. Laryngoscope 2006; 116:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/20\">",
"      Eisele DW, Wang SJ, Orloff LA. Electrophysiologic facial nerve monitoring during parotidectomy. Head Neck 2010; 32:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/21\">",
"      Scianna JM, Petruzzelli GJ. Contemporary management of tumors of the salivary glands. Curr Oncol Rep 2007; 9:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/22\">",
"      Nouraei SA, Ismail Y, Ferguson MS, et al. Analysis of complications following surgical treatment of benign parotid disease. ANZ J Surg 2008; 78:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/23\">",
"      Beutner D, Wittekindt C, Dinh S, et al. Impact of lateral parotidectomy for benign tumors on quality of life. Acta Otolaryngol 2006; 126:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/24\">",
"      Roh JL, Park CI. A prospective, randomized trial for use of prednisolone in patients with facial nerve paralysis after parotidectomy. Am J Surg 2008; 196:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/25\">",
"      de Bree R, van der Waal I, Leemans CR. Management of Frey syndrome. Head Neck 2007; 29:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/26\">",
"      Dulguerov P, Quinodoz D, Cosendai G, et al. Frey syndrome treatment with botulinum toxin. Otolaryngol Head Neck Surg 2000; 122:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/27\">",
"      de Bree R, Duyndam JE, Kuik DJ, Leemans CR. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 2009; 135:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/28\">",
"      Ryan WR, Fee WE. Long-term great auricular nerve morbidity after sacrifice during parotidectomy. Laryngoscope 2009; 119:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/29\">",
"      Linkov G, Morris LG, Shah JP, Kraus DH. First bite syndrome: incidence, risk factors, treatment, and outcomes. Laryngoscope 2012; 122:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/30\">",
"      Ichimura K, Nibu K, Tanaka T. Nerve paralysis after surgery in the submandibular triangle: review of University of Tokyo Hospital experience. Head Neck 1997; 19:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/31\">",
"      Berini-Aytes L, Gay-Escoda C. Morbidity associated with removal of the submandibular gland. J Craniomaxillofac Surg 1992; 20:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/32\">",
"      Hong KH, Kim YK. Intraoral removal of the submandibular gland: a new surgical approach. Otolaryngol Head Neck Surg 2000; 122:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/33\">",
"      Torroni AA, Mustazza MC, Bartoli DD, Iannetti GG. Transcervical submandibular sialoadenectomy. J Craniofac Surg 2007; 18:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/34\">",
"      Baek CH, Jeong HS. Endoscope-assisted submandibular sialadenectomy: a new minimally invasive approach to the submandibular gland. Am J Otolaryngol 2006; 27:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/35\">",
"      Hong KH, Yang YS. Surgical results of the intraoral removal of the submandibular gland. Otolaryngol Head Neck Surg 2008; 139:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/36\">",
"      Kaszuba SM, Zafereo ME, Rosenthal DI, et al. Effect of initial treatment on disease outcome for patients with submandibular gland carcinoma. Arch Otolaryngol Head Neck Surg 2007; 133:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/37\">",
"      Yu T, Gao QH, Wang XY, et al. Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases. Oncology 2007; 72:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/38\">",
"      Perez DE, Pires FR, Alves Fde A, et al. Sublingual salivary gland tumors: clinicopathologic study of six cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/39\">",
"      Rinaldo A, Shaha AR, Pellitteri PK, et al. Management of malignant sublingual salivary gland tumors. Oral Oncol 2004; 40:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/40\">",
"      Parsons JT, Mendenhall WM, Stringer SP, et al. Management of minor salivary gland carcinomas. Int J Radiat Oncol Biol Phys 1996; 35:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/41\">",
"      Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg 2005; 63:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/42\">",
"      Chou C, Zhu G, Luo M, Xue G. Carcinoma of the minor salivary glands: results of surgery and combined therapy. J Oral Maxillofac Surg 1996; 54:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/43\">",
"      Cianchetti M, Sandow PS, Scarborough LD, et al. Radiation therapy for minor salivary gland carcinoma. Laryngoscope 2009; 119:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/44\">",
"      Armstrong JG, Harrison LB, Thaler HT, et al. The indications for elective treatment of the neck in cancer of the major salivary glands. Cancer 1992; 69:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/45\">",
"      Kelley DJ, Spiro RH. Management of the neck in parotid carcinoma. Am J Surg 1996; 172:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/46\">",
"      Terhaard CH, Lubsen H, Rasch CR, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys 2005; 61:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/47\">",
"      Stennert E, Kisner D, Jungehuelsing M, et al. High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg 2003; 129:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/48\">",
"      Zb&auml;ren P, Sch&uuml;pbach J, Nuyens M, et al. Carcinoma of the parotid gland. Am J Surg 2003; 186:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/49\">",
"      Zb&auml;ren P, Sch&uuml;pbach J, Nuyens M, Stauffer E. Elective neck dissection versus observation in primary parotid carcinoma. Otolaryngol Head Neck Surg 2005; 132:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/50\">",
"      Chen AM, Garcia J, Lee NY, et al. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation? Int J Radiat Oncol Biol Phys 2007; 67:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/51\">",
"      Schramm VL Jr, Imola MJ. Management of nasopharyngeal salivary gland malignancy. Laryngoscope 2001; 111:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/52\">",
"      Chen AM, Bucci MK, Quivey JM, et al. Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys 2006; 66:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/53\">",
"      Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer 2005; 103:2544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/54\">",
"      Wang CC, Goodman M. Photon irradiation of unresectable carcinomas of salivary glands. Int J Radiat Oncol Biol Phys 1991; 21:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/55\">",
"      Laramore GE, Krall JM, Griffin TW, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys 1993; 27:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/56\">",
"      Douglas JG, Koh WJ, Austin-Seymour M, Laramore GE. Treatment of salivary gland neoplasms with fast neutron radiotherapy. Arch Otolaryngol Head Neck Surg 2003; 129:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/57\">",
"      Ghosh-Laskar S, Murthy V, Wadasadawala T, et al. Mucoepidermoid carcinoma of the parotid gland: factors affecting outcome. Head Neck 2011; 33:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/58\">",
"      Schulz-Ertner D, Nikoghosyan A, Didinger B, et al. Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005; 104:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/59\">",
"      Armstrong JG, Harrison LB, Spiro RH, et al. Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 1990; 116:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/60\">",
"      Chen AM, Garcia J, Bucci MK, et al. The role of postoperative radiation therapy in carcinoma ex pleomorphic adenoma of the parotid gland. Int J Radiat Oncol Biol Phys 2007; 67:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/61\">",
"      Fu KK, Leibel SA, Levine ML, et al. Carcinoma of the major and minor salivary glands: analysis of treatment results and sites and causes of failures. Cancer 1977; 40:2882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/62\">",
"      Roh JL, Choi SH, Lee SW, et al. Carcinomas arising in the submandibular gland: high propensity for systemic failure. J Surg Oncol 2008; 97:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/63\">",
"      Al-Mamgani A, van Rooij P, Verduijn GM, et al. Long-term outcomes and quality of life of 186 patients with primary parotid carcinoma treated with surgery and radiotherapy at the Daniel den Hoed Cancer Center. Int J Radiat Oncol Biol Phys 2012; 84:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/64\">",
"      Storey MR, Garden AS, Morrison WH, et al. Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys 2001; 51:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/65\">",
"      Dai D. Postoperative irradiation in malignant tumors of submandibular gland. Cancer Invest 1999; 17:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/66\">",
"      Garden AS, Weber RS, Ang KK, et al. Postoperative radiation therapy for malignant tumors of minor salivary glands. Outcome and patterns of failure. Cancer 1994; 73:2563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/67\">",
"      Chen AM, Bucci MK, Weinberg V, et al. Adenoid cystic carcinoma of the head and neck treated by surgery with or without postoperative radiation therapy: prognostic features of recurrence. Int J Radiat Oncol Biol Phys 2006; 66:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/68\">",
"      Mendenhall WM, Morris CG, Amdur RJ, et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck 2004; 26:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/69\">",
"      Gurney TA, Eisele DW, Weinberg V, et al. Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope 2005; 115:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/70\">",
"      Silverman DA, Carlson TP, Khuntia D, et al. Role for postoperative radiation therapy in adenoid cystic carcinoma of the head and neck. Laryngoscope 2004; 114:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/71\">",
"      Triozzi PL, Brantley A, Fisher S, et al. 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer 1987; 59:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/72\">",
"      Tanvetyanon T, Qin D, Padhya T, et al. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg 2009; 135:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/73\">",
"      Pederson AW, Salama JK, Haraf DJ, et al. Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. Head Neck Oncol 2011; 3:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/74\">",
"      Witt RL. The significance of the margin in parotid surgery for pleomorphic adenoma. Laryngoscope 2002; 112:2141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/75\">",
"      Harney M, Walsh P, Conlon B, et al. Parotid gland surgery: a retrospective review of 108 cases. J Laryngol Otol 2002; 116:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/76\">",
"      Mendenhall WM, Mendenhall CM, Werning JW, et al. Salivary gland pleomorphic adenoma. Am J Clin Oncol 2008; 31:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/77\">",
"      Witt RL. Minimally invasive surgery for parotid pleomorphic adenoma. Ear Nose Throat J 2005; 84:308, 310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/78\">",
"      Liu FF, Rotstein L, Davison AJ, et al. Benign parotid adenomas: a review of the Princess Margaret Hospital experience. Head Neck 1995; 17:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/79\">",
"      Nouraei SA, Ferguson MS, Clarke PM, et al. Metastasizing pleomorphic salivary adenoma. Arch Otolaryngol Head Neck Surg 2006; 132:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/80\">",
"      Chen AM, Garcia J, Bucci MK, et al. Recurrent pleomorphic adenoma of the parotid gland: long-term outcome of patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006; 66:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/81\">",
"      Myssiorek D, Ruah CB, Hybels RL. Recurrent pleomorphic adenomas of the parotid gland. Head Neck 1990; 12:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/82\">",
"      Ravasz LA, Terhaard CH, Hordijk GJ. Radiotherapy in epithelial tumors of the parotid gland: case presentation and literature review. Int J Radiat Oncol Biol Phys 1990; 19:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/83\">",
"      Leonetti JP, Marzo SJ, Petruzzelli GJ, Herr B. Recurrent pleomorphic adenoma of the parotid gland. Otolaryngol Head Neck Surg 2005; 133:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/84\">",
"      Hocwald E, Korkmaz H, Yoo GH, et al. Prognostic factors in major salivary gland cancer. Laryngoscope 2001; 111:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/85\">",
"      Vander Poorten VL, Balm AJ, Hilgers FJ, et al. Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer 1999; 85:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/86\">",
"      Pedersen D, Overgaard J, S&oslash;gaard H, et al. Malignant parotid tumors in 110 consecutive patients: treatment results and prognosis. Laryngoscope 1992; 102:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/87\">",
"      Vander Poorten VL, Balm AJ, Hilgers FJ, et al. The development of a prognostic score for patients with parotid carcinoma. Cancer 1999; 85:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/88\">",
"      Carrillo JF, V&aacute;zquez R, Ram&iacute;rez-Ortega MC, et al. Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer 2007; 109:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/89\">",
"      Spiro RH, Thaler HT, Hicks WF, et al. The importance of clinical staging of minor salivary gland carcinoma. Am J Surg 1991; 162:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/90\">",
"      Le QT, Birdwell S, Terris DJ, et al. Postoperative irradiation of minor salivary gland malignancies of the head and neck. Radiother Oncol 1999; 52:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/91\">",
"      Poulsen MG, Pratt GR, Kynaston B, Tripcony LB. Prognostic variables in malignant epithelial tumors of the parotid. Int J Radiat Oncol Biol Phys 1992; 23:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/92\">",
"      Garden AS, Weber RS, Morrison WH, et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys 1995; 32:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/41/28313/abstract/93\">",
"      Lopes MA, Santos GC, Kowalski LP. Multivariate survival analysis of 128 cases of oral cavity minor salivary gland carcinomas. Head Neck 1998; 20:699.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3377 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-EE4A41C0CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28313=[""].join("\n");
var outline_f27_41_28313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Parotid gland tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Benign tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Malignant tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Submandibular gland tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sublingual gland tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Minor salivary gland tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267154432\">",
"      RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Definitive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Adjuvant radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H267154709\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PLEOMORPHIC ADENOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Primary treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Management of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3377\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3377|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/19/6449\" title=\"figure 1\">",
"      Salivary gland anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/13/15572\" title=\"figure 2\">",
"      Parotid gl facial nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/3/8244\" title=\"figure 3\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3377|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/36/21069\" title=\"table 1\">",
"      WHO class salivary gld tum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/52/35661\" title=\"table 2\">",
"      TNM stage salivary glands",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/62/30699\" title=\"table 3\">",
"      Grades salivary gland cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23446?source=related_link\">",
"      Definitive radiotherapy for advanced head and neck cancer: Dose and fractionation schedule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17525?source=related_link\">",
"      General principles of radiation therapy for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11816?source=related_link\">",
"      Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39815?source=related_link\">",
"      Mandibular and palatal reconstruction in patients with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12362?source=related_link\">",
"      Pathology of head and neck neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_41_28314="Warfarin: Drug information";
var content_f27_41_28314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Warfarin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"    see \"Warfarin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"    see \"Warfarin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coumadin&reg;;",
"     </li>",
"     <li>",
"      Jantoven&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F234877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Warfarin&reg;;",
"     </li>",
"     <li>",
"      Coumadin&reg;;",
"     </li>",
"     <li>",
"      Mylan-Warfarin;",
"     </li>",
"     <li>",
"      Novo-Warfarin;",
"     </li>",
"     <li>",
"      Taro-Warfarin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticoagulant, Coumarin Derivative;",
"     </li>",
"     <li>",
"      Vitamin K Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Labeling identifies genetic factors which may increase patient sensitivity to warfarin. Specifically, genetic variations in the proteins CYP2C9 and VKORC1, responsible for warfarin&rsquo;s primary metabolism and pharmacodynamic activity, respectively, have been identified as predisposing factors associated with decreased dose requirement and increased bleeding risk. Genotyping tests are available, and may provide guidance on initiation of anticoagulant therapy. The American College of Chest Physicians recommends against the use of routine pharmacogenomic testing to guide dosing (Guyatt, 2012). For management of elevated INRs as a result of warfarin therapy, see Additional Information/Pharmacotherapy Pearls for guidance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Prevention/treatment of thrombosis/embolism:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. (administer as a slow bolus injection):",
"     </i>",
"     2-5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Initial dosing must be individualized. Consider the patient (hepatic function, cardiac function, age, nutritional status, concurrent therapy, risk of bleeding) in addition to prior dose response (if available) and the clinical situation. Start 2-5 mg once daily for 2 days",
"     <b>",
"      or",
"     </b>",
"     for healthy individuals, 10 mg once daily for 2 days; lower doses (eg, 5 mg once daily) recommended for patients with confirmed HIT once platelet recovery has occurred (Guyatt, 2012). In patients with acute venous thromboembolism, initiation may begin on the first or second day of low molecular weight heparin or unfractionated heparin therapy (Guyatt, 2012).  Adjust dose according to INR results; usual maintenance dose ranges from 2-10 mg daily (individual patients may require loading and maintenance doses outside these general guidelines).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note",
"     </b>",
"     : Lower starting doses may be required for patients with hepatic impairment, poor nutrition, CHF, elderly, high risk of bleeding, or patients who are debilitated, or those with reduced function genomic variants of the catabolic enzymes CYP2C9 (*2 or *3 alleles) or VKORC1 (-1639 polymorphism); see table. Higher initial doses may be reasonable in selected patients (ie, receiving enzyme-inducing agents and with low risk of bleeding).",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Range",
"      <sup>",
"       1",
"      </sup>",
"      of Expected Therapeutic Maintenance Dose Based on CYP2C9",
"      <sup>",
"       2",
"      </sup>",
"      and VKORC1",
"      <sup>",
"       3",
"      </sup>",
"      Genotypes",
"     </caption>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <col align=\"center\" width=\"70\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         VKORC1",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"6\">",
"        <p style=\"text-indent:0em;\">",
"         CYP2C9",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Must also take into account other patient related factors when determining initial dose (eg, age, body weight, concomitant medications, comorbidities). The American College of Chest Physicians recommends against the use of routine pharmacogenomic testing to guide dosing (Guyatt, 2012).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Ranges derived from multiple published clinical studies.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Patients with CYP2C9 *1/*3, *2/*2, *2/*3, and *3/*3 alleles may take up to 4 weeks to achieve maximum INR with a given dose regimen.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"7\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          3",
"         </sup>",
"         VKORC1 -1639G&gt;A (rs 9923231) variant is used in this table; other VKORC1 variants may also be important determinants of dose.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *1/*1",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *1/*2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *1/*3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *2/*2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *2/*3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         *3/*3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          GG",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-7 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-7 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          AG",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5-7 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          AA",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3-4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-2 mg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F234898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=see_link\">",
"      see \"Warfarin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Labeling identifies genetic factors which may increase patient sensitivity to warfarin. Specifically, genetic variations in the proteins CYP2C9 and VKORC1, responsible for warfarin&rsquo;s primary metabolism and pharmacodynamic activity, respectively, have been identified as predisposing factors associated with decreased dose requirement and increased bleeding risk. Genotyping tests are available, and may provide guidance on initiation of anticoagulant therapy. The American College of Chest Physicians recommends against the use of routine pharmacogenomic testing to guide dosing (Guyatt, 2012). For management of elevated INRs as a result of warfarin therapy, see Additional Information/Pharmacotherapy Pearls for guidance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Prevention/treatment of thrombosis:",
"     </b>",
"     Oral: Infants and Children (unlabeled use): Initial loading dose (if baseline INR is 1-1.3): 0.2 mg/kg (maximum: 10 mg/dose); adjust dose based on INR (reported ranges to maintain INR of 2-3: 0.09-0.33 mg/kg/day). Infants &lt;12 months of age may require doses at or near the high end of this range; consistent anticoagulation may be difficult to maintain in children &lt;5 years of age (Monagle, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F234881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial dose &le;5 mg. Usual maintenance dose: 2-5 mg/day. The elderly tend to require lower dosages to produce a therapeutic level of anticoagulation (due to changes in the pattern of warfarin metabolism).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F3401678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment required, however, patients with renal failure have an increased risk of bleeding complications. Monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F234882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor effect at usual doses. The response to oral anticoagulants may be markedly enhanced in obstructive jaundice, hepatitis, and cirrhosis. INR should be closely monitored.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coumadin&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sodium: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coumadin&reg;: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coumadin&reg;: 10 mg [scored; dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jantoven&reg;: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jantoven&reg;: 10 mg [scored; dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088578.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088578.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F234853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with or without food. Take at the same time each day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer as a slow bolus injection over 1-2 minutes; avoid all I.M. injections",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W,",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, ascorbic acid injection, bivalirudin, cefazolin, dopamine, epinephrine, heparin, lidocaine, morphine, nitroglycerin, oxytocin, potassium chloride, ranitidine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, ceftazidime, cimetidine, ciprofloxacin, dobutamine, esmolol, gentamicin, labetalol.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ammonium chloride, ceftriaxone, metronidazole, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone, heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of thromboembolic disorders (eg, venous, pulmonary) and embolic complications arising from atrial fibrillation or cardiac valve replacement; adjunct to reduce risk of systemic embolism (eg, recurrent MI, stroke) after myocardial infarction",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F234913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of recurrent transient ischemic attacks",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Coumadin&reg; may be confused with Avandia&reg;, Cardura&reg;, Compazine, Kemadrin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Jantoven&reg; may be confused with Janumet&reg;, Januvia&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      National Patient Safety Goals:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Joint Commission on Accreditation of Healthcare Organizations requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bleeding is the major adverse effect of warfarin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the intensity of anticoagulation and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Signs/symptoms of bleeding (eg, dizziness, fatigue, fever, headache, lethargy, malaise, pain)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, bullous eruptions, dermatitis, rash, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, flatulence,  gastrointestinal bleeding, nausea, taste disturbance, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, retroperitoneal hematoma, unrecognized bleeding sites (eg, colon cancer) may be uncovered by anticoagulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis (including cholestatic hepatitis), transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Osteoporosis (potential association with long-term use), paralysis, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory tract bleeding, tracheobronchial calcification",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reaction, hypersensitivity/allergic reactions, skin necrosis, gangrene, &ldquo;purple toes&rdquo; syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to warfarin or any component of the formulation; hemorrhagic tendencies (eg, patients bleeding from the GI, respiratory, or GU tract; cerebral aneurysm; cerebrovascular hemorrhage; dissecting aortic aneurysm; spinal puncture and other diagnostic or therapeutic procedures with potential for significant bleeding; history of bleeding diathesis); recent or potential surgery of the eye or CNS; major regional lumbar block anesthesia or traumatic surgery resulting in large, open surfaces; blood dyscrasias; severe uncontrolled or malignant hypertension; pericarditis or pericardial effusion; bacterial endocarditis; unsupervised patients with conditions associated with a high potential for noncompliance; eclampsia/pre-eclampsia, threatened abortion, pregnancy (except in women with mechanical heart valves at high risk for thromboembolism)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity: May cause hypersensitivity reactions, including anaphylaxis; use with caution in patients with anaphylactic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding:",
"     <b>",
"      [U.S. Boxed Warning]: May cause major or fatal bleeding.",
"     </b>",
"     Risk factors for bleeding include high intensity anticoagulation (INR &gt;4), age (&ge;65 years), variable INRs, history of GI bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, severe diabetes, malignancy, trauma, renal insufficiency, polycythemia vera, vasculitis, open wound, history of PUD,  indwelling catheters, menstruating and postpartum women, drug-drug interactions, long duration of therapy, or known genetic deficiency in CYP2C9 activity. Patient must be instructed to report bleeding, accidents, or falls as well as any new or discontinued medications, herbal or alternative products used, or significant changes in smoking or dietary habits. Unrecognized bleeding sites (eg, colon cancer) may be uncovered by anticoagulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin necrosis/gangrene: Necrosis or gangrene of the skin and other tissue can occur (rarely, &lt;0.1%) due to paradoxical local thrombosis; onset is usually within the first few days of therapy and is frequently localized to the limbs, breast, or penis. The risk of this effect is increased in patients with protein C or S deficiency. Consider alternative therapies if anticoagulation is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atheroemboli/cholesterol microemboli: Warfarin therapy may release atheromatous plaque emboli; symptoms depend on site of embolization, most commonly kidneys, pancreas, liver, and spleen. In some cases may lead to necrosis or death. &ldquo;Purple toe&rdquo; syndrome, due to cholesterol microembolization, has been rarely described with coumarin-type anticoagulants. Typically, this occurs after several weeks of therapy, and may present as a dark, purplish, mottled discoloration of the plantar and lateral surfaces. Other manifestations of cholesterol microembolization may include rash; livedo reticularis; gangrene; abrupt and intense pain in lower extremities; abdominal, flank, or back pain; hematuria, renal insufficiency; hypertension; cerebral ischemia; spinal cord infarction; or other symptoms of vascular compromise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dietary insufficiency: Use with caution in patients with prolonged dietary insufficiencies (vitamin K deficiency).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heparin-induced thrombocytopenia: Use with caution in patients with heparin-induced thrombocytopenia and DVT; limb ischemia, necrosis, and gangrene have occurred when warfarin was started or continued after heparin was stopped. Warfarin monotherapy is contraindicated in the initial treatment of active HIT; warfarin initially inhibits the synthesis of protein C, potentially accelerating the underlying active thrombotic process.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Reduced liver function, regardless of etiology, may impair synthesis of coagulation factors leading to increased warfarin sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Use with caution in patients with acute infection or active TB or any disruption of normal GI flora; antibiotics and fever may alter response to warfarin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate-to-severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid disease; warfarin responsiveness may increase (Ageno, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly may be more sensitive to anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patients with genomic variants in CYP2C9 and/or VKORC1: Presence of the CYP2C9*2 or *3 allele and/or polymorphism of the vitamin K oxidoreductase (VKORC1) gene may increase the risk of bleeding. The *2 allele is reported to occur with a frequency of 4% to 11% in African-Americans and Caucasians, respectively, while the *3 allele frequencies are 2% to 7% respectively. Other variant 2C9 alleles (eg, *5, *6, *9, and *11) are also associated with reduced metabolic activity and thus may increase risk of bleeding, but are much less common. Lower doses may be required in these patients; genetic testing may help determine appropriate dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Surgical patients: When temporary interruption is necessary before surgery, discontinue for approximately 5 days before surgery; when there is adequate hemostasis, may reinstitute warfarin therapy ~12-24 hours after surgery (evening of or next morning). Decision to safely continue warfarin therapy through the procedure and whether or not bridging of anticoagulation is necessary is dependent upon risk of perioperative bleeding and risk of thromboembolism, respectively. If risk of thromboembolism is elevated, consider bridging warfarin therapy with an alternative anticoagulant (eg, unfractionated heparin, LMWH) (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient selection: Use care in the selection of patients appropriate for this treatment; ensure patient cooperation especially from the alcoholic, illicit drug user, demented, or psychotic patient; ability to comply with routine laboratory monitoring is essential.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F234911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adalimumab: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Androgens: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents: May enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Alitretinoin; Altretamine; Aminoglutethimide; Anastrozole; Asparaginase (E. coli); Asparaginase (Erwinia); AzaCITIDine; Bleomycin; Capecitabine; CARBOplatin; Carmustine; Chlorambucil; CISplatin; Cladribine; Cytarabine (Conventional); Cytarabine (Liposomal); Dacarbazine; DACTINomycin; DAUNOrubicin (Conventional); DAUNOrubicin (Liposomal); Denileukin Diftitox; DOCEtaxel; DOXOrubicin (Liposomal); EPIrubicin; Estramustine; Etoposide Phosphate; Exemestane; Fludarabine; Goserelin; Hydroxyurea; IDArubicin; Irinotecan; Letrozole; Leuprolide; Lomustine; Mechlorethamine; Megestrol; MitoMYcin (Systemic); MitoXANtrone; Nilutamide; PACLitaxel; Pegaspargase; Pentostatin; Polyestradiol; Porfimer; RiTUXimab; Streptozocin; Tamoxifen; Temozolomide; Teniposide; Thioguanine; Thiotepa; Topotecan; Toremifene; Tretinoin (Systemic); Valrubicin; VinBLAStine; Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antithyroid Agents: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bicalutamide: May increase the serum concentration of Vitamin K Antagonists. Specifically, free concentrations of the vitamin K antagonists may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Warfarin. Boceprevir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capecitabine: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloral Hydrate: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: May enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists. Cloxacillin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coenzyme Q-10: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products. Management: When possible, concomitant hormonal contraceptives and coumarin derivatives should be avoided in order to eliminate the risk of thromboembolic disorders.  Consider using an alternative, nonhormonal contraceptive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cranberry: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desvenlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dicloxacillin: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Vitamin K Antagonists may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received oral anticoagulants within 1 week or have INR 3 or greater.  Monitor for bleeding and immediately stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Vitamin K Antagonists. Efavirenz may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: May decrease the serum concentration of Warfarin. More specifically, enzalutamide may decrease concentrations of the S-warfarin enantiomer. Management: Avoid concurrent use of warfarin and enzalutamide whenever possible.  If the combination must be used, conduct additional INR monitoring as serum concentrations may be decreased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Ophthalmic): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Esomeprazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethacrynic Acid: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethotoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Ethotoin. Management: Anticoagulant dose adjustment will likely be necessary when ethotoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibrate: May enhance the anticoagulant effect of Warfarin. Fenofibrate may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenofibric Acid: May enhance the anticoagulant effect of Warfarin. Fenofibric Acid may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fenugreek: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Systemic): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluorouracil (Topical): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Warfarin. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the adverse/toxic effect of Vitamin K Antagonists. Management: Consider avoiding the use of this combination of agents. Monitor for signs and symptoms of bleeding if vitamin K antagonists and Ginkgo biloba are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginseng (American): May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucagon: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glutethimide: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May enhance the adverse/toxic effect of Vitamin K Antagonists. Particularly, the risk of bleeding may be increased due to possible antiplatelet effects of green tea. Green Tea may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     AtorvaSTATin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: May enhance the anticoagulant effect of Warfarin. Imatinib may decrease the metabolism of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivermectin (Systemic): May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lansoprazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetroNIDAZOLE (Systemic): May increase the serum concentration of Vitamin K Antagonists. Management: Consider alternatives to concomitant therapy with these agents.  Monitor for increased INR/bleeding risk if metronidazole is initiated/dose increased, or decreased effects if metronidazole is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miconazole (Topical): May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Milnacipran: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the anticoagulant effect of Vitamin K Antagonists. Multivitamins/Minerals (with ADEK, Folate, Iron) may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: May decrease the serum concentration of Warfarin. Nelfinavir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neomycin: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the anticoagulant effect of Vitamin K Antagonists. NSAID (COX-2 Inhibitor) may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omeprazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orlistat: May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Phenytoin. Management: Anticoagulant dose adjustment will likely be necessary when phenytoin is initiated or discontinued.  Monitor patients extra closely (INR and signs/symptoms of bleeding) when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phytonadione: May diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the anticoagulant effect of Vitamin K Antagonists. Note that the INR/PT might be unchanged in the face of increased bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranitidine: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: Warfarin may enhance the adverse/toxic effect of Regorafenib. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: May enhance the therapeutic effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Salsalate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sitaxentan: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May enhance the anticoagulant effect of Warfarin. SORAfenib may increase the serum concentration of Warfarin. Management: Warfarin dose adjustment will likely be necessary.  Increase frequency of INR monitoring during sorafenib therapy (particularly when starting or stopping therapy), and increase monitoring for signs and symptoms of bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists. Management: Administer vitamin K antagonists at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfinpyrazone [Off Market]: May decrease the metabolism of Vitamin K Antagonists. Sulfinpyrazone [Off Market] may decrease the protein binding of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonamide Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: May enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Warfarin. Telaprevir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tigecycline: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: May enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Torsemide: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: May diminish the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: May enhance the adverse/toxic effect of Vitamin K Antagonists. Specifically, the risk for bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vorinostat: May enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zafirlukast: May increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zileuton: May increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F234872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Acute ethanol ingestion (binge drinking) decreases the metabolism of warfarin and increases PT/INR. Chronic daily ethanol use increases the metabolism of warfarin and decreases PT/INR. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: The anticoagulant effects of warfarin may be decreased if taken with foods rich in vitamin K. Vitamin E may increase warfarin effect. Cranberry juice may increase warfarin effect. Management: Maintain a consistent diet; consult prescriber before making changes in diet. Take warfarin at the same time each day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications (eg, St John's wort) may decrease warfarin levels and effects; many others can add additional antiplatelet activity to warfarin therapy. Management: Avoid ginseng (American), coenzyme Q",
"     <sub>",
"      10",
"     </sub>",
"     , and St John&rsquo;s wort. Avoid cranberry, fenugreek, ginkgo biloba, glucosamine, alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose oil, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (Panax), ginseng (Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, omega-3-acids, prickly ash, red clover, reishi, SAMe (s-adenosylmethionine), sweet clover, turmeric, and white willow.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (women with mechanical heart valves)/X (other indications) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F234859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Warfarin crosses the placenta; concentrations in the fetal plasma are similar to maternal values. Teratogenic effects have been reported following first trimester exposure and may include coumarin embryopathy (nasal hypoplasia and/or stippled epiphyses; limb hypoplasia may also be present). Adverse CNS events to the fetus have also been observed following exposure during any trimester and may include CNS abnormalities (including ventral midline dysplasia, dorsal midline dysplasia). Spontaneous abortion, fetal hemorrhage, and fetal death may also occur. Use is contraindicated during pregnancy (or in women of reproductive potential) except in women with mechanical heart valves who are at high risk for thromboembolism; use is also contraindicated in women with threatened abortion, eclampsia, or preeclampsia. Frequent pregnancy tests are recommended for women who are planning to become pregnant and adjusted-dose heparin or low molecular weight heparin (LMWH) should be substituted as soon as pregnancy is confirmed or adjusted-dose heparin or LMWH should be used instead of warfarin prior to conception.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In pregnant women with high-risk mechanical heart valves, the benefits of warfarin therapy should be discussed with the risks of available treatments; when possible avoid warfarin use during the first trimester and close to delivery. Adjusted-dose LMWH or adjusted-dose heparin may be used throughout pregnancy or until week 13 of gestation when therapy can be changed to warfarin. LMWH or heparin should be resumed close to delivery. In women who are at a very high risk for thromboembolism (older generation prothesis in mitral position or history of thromboembolism), warfarin can be used throughout pregnancy and replaced with LMWH or heparin near term; the use of low-dose aspirin is also recommended. Women who require long-term anticoagulation with warfarin and who are considering pregnancy, LMWH substitution should be done prior to conception when possible. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Bates, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F234887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Does not enter breast milk/use caution  (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F234860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast-feeding women may be treated with warfarin. Based on available data, warfarin does not pass into breast milk. Women who are breast-feeding should be carefully monitored to avoid excessive anticoagulation. According to the American College of Chest Physicians (ACCP), warfarin may be used in lactating women who wish to breast-feed their infants (Bates, 2012). Monitor nursing infants for bruising or bleeding (per manufacturer).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F234861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Foods high in vitamin K (eg, beef liver, pork liver, green tea, and leafy green vegetables) inhibit anticoagulant effect. Do not change dietary habits once stabilized on warfarin therapy. A balanced diet with a consistent intake of vitamin K is essential. Avoid large amounts of alfalfa, asparagus, broccoli, Brussels sprouts, cabbage, cauliflower, green teas, kale, lettuce, spinach, turnip greens, and watercress; decreased efficacy of warfarin. It is recommended that the diet contain a CONSISTENT vitamin K content of 70-140 mcg/day. Check with healthcare provider before changing diet.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F234858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Coumadin Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $45.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Coumadin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $159.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $165.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $171.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $171.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $172.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $178.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (100): $229.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $237.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $246.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Jantoven Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $49.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $51.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $52.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $52.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $52.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $54.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (100): $70.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $73.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $75.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Warfarin Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $58.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $61.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $63.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (100): $63.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (100): $63.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $64.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (100): $90.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (100): $93.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $96.91",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F234847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prothrombin time, hematocrit; INR (frequency varies depending on INR stability); may consider genotyping of CYP2C9 and VKORC1 prior to initiation of therapy, if available",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F234850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     INR = patient prothrombin time/mean normal prothrombin time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     ISI = international sensitivity index",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     INR should be increased by 2-3.5 times depending upon indication. An INR &gt;4 does not generally add additional therapeutic benefit and is associated with increased risk of bleeding.",
"     <b>",
"      Note:",
"     </b>",
"     To prevent gastrointestinal bleeding events in patients receiving the combination of warfarin, aspirin, and clopidogrel, an INR of 2-2.5 is recommended unless condition requires a higher INR target (eg, certain mechanical heart valves) (Bhatt, 2008).",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Adult Target INR Ranges Based Upon Indication",
"     </caption>",
"     <col align=\"left\" width=\"350\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Indication",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Targeted INR",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Targeted INR Range",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Unless otherwise noted, all recommendations derived from &ldquo;Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.&rdquo;",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          1",
"         </sup>",
"         If coronary stent placed, triple therapy (warfarin, low-dose aspirin, and clopidogrel) is recommended for 1 month (bare-metal stent) or 3-6 months (drug-eluting stent) followed by discontinuation of warfarin and use of dual antiplatelet therapy (eg, aspirin and clopidogrel) for up to 12 months.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          2",
"         </sup>",
"         If coronary stent",
"         <b>",
"          not",
"         </b>",
"         placed, maintain anticoagulation (in combination with low-dose aspirin) for 3 months followed by discontinuation of warfarin and use of dual antiplatelet therapy (eg, aspirin and clopidogrel) for up to 12 months.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Recommended for those patients with nonvalvular AF who are at moderate-to-high risk of stroke (Goldstein, 2011).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Recommendation from Stein, 2001.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          5",
"         </sup>",
"         If at low risk of bleeding, combine with aspirin 81 mg/day.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          6",
"         </sup>",
"         Maintain anticoagulation for 3 months after valve insertion then switch to aspirin 81 mg/day if no other indications for warfarin exist or clinically reassess need for warfarin in patients with prior history of systemic embolism.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          7",
"         </sup>",
"         Treat for 3 months in patients with provoked VTE due to transient reversible risk factor. Treat for a minimum of 3 months in patients with unprovoked VTE and evaluate for extended anticoagulant therapy (ie, &gt;3 months of therapy without a scheduled stop date). Other risk groups (eg, cancer) may require extended anticoagulant therapy.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          8",
"         </sup>",
"         Recommendation from the ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension (McLaughlin, 2009)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          9",
"         </sup>",
"         Continue for at least 10-14 days; up to 35 days after surgery is suggested.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <sup>",
"          10",
"         </sup>",
"         Instead of adjusted dose warfarin, the use of dabigatran has been suggested. In either case, oral anticoagulation should be initiated within 1-2 weeks after stroke onset or earlier in patients at low bleeding risk; bridging with aspirin may be required.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Cardiac",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Anterior myocardial infarction with LV thrombus or high risk for LV thrombus (EF&lt;40%, anteroapical wall motion abnormality)",
"         <sup>",
"          1,2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Atrial fibrillation (nonvalvular)",
"         <sup>",
"          3",
"         </sup>",
"         or atrial flutter",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         LV systolic dysfunction (without established CAD) with an LV thrombus (eg, Takotsubo cardiomyopathy)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Valvular",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Carbomedics or St. Jude Medical bileaflet or Medtronic Hall tilting disk mechanical aortic valve in normal sinus rhythm and normal LA size",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Bileaflet or tilting disk mechanical mitral valve",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-3.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Caged ball or caged disk mechanical valve",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-3.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Mechanical aortic valve",
"         <sup>",
"          5",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Mechanical mitral valve",
"         <b>",
"          or",
"         </b>",
"         mechanical valves in both the aortic and mitral positions",
"         <sup>",
"          5",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5-3.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Bioprosthetic mitral valve",
"         <sup>",
"          6",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Rheumatic mitral valve disease (particularly mitral stenosis) and normal sinus rhythm (LA diameter &gt;5.5 cm), AF, previous systemic embolism, or LA thrombus",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Thromboembolism Treatment",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Venous thromboembolism",
"         <sup>",
"          7",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Thromboprophylaxis",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Idiopathic pulmonary artery hypertension (IPAH)",
"         <sup>",
"          8",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1.5-2.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Antiphospholipid syndrome (no other risk factors)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Antiphospholipid syndrome and recurrent thromboembolism",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Total hip or knee replacement or hip fracture surgery",
"         <sup>",
"          9",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Other Indications",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Ischemic stroke due to AF",
"         <sup>",
"          10",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Cryptogenic stroke (recurrent) and either patent foramen ovale (PFO) or atrial septal aneurysm",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2-3",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Warfarin levels are not used for monitoring degree of anticoagulation. They may be useful if a patient with unexplained coagulopathy is using the drug surreptitiously or if it is unclear whether clinical resistance is due to true drug resistance or lack of drug intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Normal prothrombin time (PT): 10.9-12.9 seconds. Healthy premature newborns have prolonged coagulation test screening results (eg, PT, aPTT, TT) which return to normal adult values at approximately 6 months of age. Healthy prematures, however, do not develop spontaneous hemorrhage or thrombotic complications because of a balance between procoagulants and inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F234862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aldocumar (ES);",
"     </li>",
"     <li>",
"      Befarin (TH);",
"     </li>",
"     <li>",
"      Circuvit (AR);",
"     </li>",
"     <li>",
"      Cofarin (TW);",
"     </li>",
"     <li>",
"      Coumadan (AR);",
"     </li>",
"     <li>",
"      Coumadin (AE, AU, BF, BH, BJ, CI, CN, CY, DE, EC, EG, ET, GH, GM, GN, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, NE, NG, NZ, OM, PH, PK, PY, QA, SA, SC, SD, SL, SN, SY, TN, TR, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Coumadine (FR);",
"     </li>",
"     <li>",
"      Dagonal (UY);",
"     </li>",
"     <li>",
"      Lawarin (CZ);",
"     </li>",
"     <li>",
"      Lennon-Warfarin (ZA);",
"     </li>",
"     <li>",
"      Mafarin (TW);",
"     </li>",
"     <li>",
"      Maforan (TH);",
"     </li>",
"     <li>",
"      Marevan (AU, BE, BR, CL, DK, EE, FI, GB, IE, LU, NO, NZ, SG);",
"     </li>",
"     <li>",
"      Marfarin (HN);",
"     </li>",
"     <li>",
"      Marivarin (HR);",
"     </li>",
"     <li>",
"      Morfarin (TH);",
"     </li>",
"     <li>",
"      Orfarin (MY, TH, TW);",
"     </li>",
"     <li>",
"      Panwarfin (GR);",
"     </li>",
"     <li>",
"      Simarc-2 (ID);",
"     </li>",
"     <li>",
"      Tedicumar (ES);",
"     </li>",
"     <li>",
"      UniWarfin (IN);",
"     </li>",
"     <li>",
"      Varfine (PT);",
"     </li>",
"     <li>",
"      Waran (SE);",
"     </li>",
"     <li>",
"      Warfar (CO, KP);",
"     </li>",
"     <li>",
"      Warfarina (PE);",
"     </li>",
"     <li>",
"      Warfil 5 (DO);",
"     </li>",
"     <li>",
"      Warfin (PL);",
"     </li>",
"     <li>",
"      Warik (PH);",
"     </li>",
"     <li>",
"      Zydarin (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F234836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic synthesis of coagulation factors II, VII, IX, and X, as well as proteins C and S, requires the presence of vitamin K. These clotting factors are biologically activated by the addition of carboxyl groups to key glutamic acid residues within the proteins&rsquo; structure. In the process, &ldquo;active&rdquo; vitamin K is oxidatively converted to an &ldquo;inactive&rdquo; form, which is then subsequently reactivated by vitamin K epoxide reductase complex 1 (VKORC1). Warfarin competitively inhibits the subunit 1 of the multi-unit VKOR complex, thus depleting functional vitamin K reserves and hence reduces synthesis of active clotting factors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F234855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Anticoagulation: Oral: 24-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Full therapeutic effect: 5-7 days; INR may increase in 36-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 2-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid, complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.14 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily via CYP2C9; minor pathways include CYP2C8, 2C18, 2C19, 1A2, and 3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Genomic variants:",
"     </i>",
"     Approximately 37% reduced clearance of S-warfarin in patients heterozygous for 2C9 (*1/*2 or *1/*3), and ~70% reduced in patients homozygous for reduced function alleles (*2/*2, *2/*3, or *3/*3)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 20-60 hours; Mean: 40 hours; highly variable among individuals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: ~4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (92%, primarily as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ageno W, Gallus AS, Wittkowsky A, et al, &ldquo;Oral Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e44-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/22315269/pubmed\" id=\"22315269\" target=\"_blank\">",
"        22315269",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anand SS, Yusuf S, Pogue J, et al, &ldquo;Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non-Q-Wave Myocardial Infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study Results,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(11):1064-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/9736592/pubmed\" id=\"9736592\" target=\"_blank\">",
"        9736592",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arepally GM and Ortel TL, &ldquo;Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355 (8):809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/16928996/pubmed\" id=\"16928996\" target=\"_blank\">",
"        16928996",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baillargeon J, Holmes HM, Lin YL, et al, \"Concurrent Use of Warfarin and Antibiotics and the Risk of Bleeding in Older Adults,\"",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2012, 125(2):183-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/22269622/pubmed\" id=\"22269622\" target=\"_blank\">",
"        22269622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e691-736.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/22315276/pubmed\" id=\"22315276\" target=\"_blank\">",
"        22315276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carabello PJ, Heit JA, Atkinson EJ, et al, &ldquo;Long-Term Use of Oral Anticoagulants and the Risk of Fracture,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1999, 159(15):1750-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/10448778/pubmed\" id=\"10448778\" target=\"_blank\">",
"        10448778",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chimowitz MI, Lynn MJ, Howlett-Smith H, et al, \"Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(13):1305-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/15800226/pubmed\" id=\"15800226\" target=\"_blank\">",
"        15800226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dager WE and White RH, &ldquo;Pharmacotherapy of Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2003, 4(6):919-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/12783589/pubmed\" id=\"12783589\" target=\"_blank\">",
"        12783589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dager WE, King JF, Regalia RC, et al,  &ldquo;Reversal of Elevated International Normalized Ratios and Bleeding With Low-Dose Recombinant Activated Factor VII in Patients Receiving Warfarin,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2006, 26(8):1091-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/16863486/pubmed\" id=\"16863486\" target=\"_blank\">",
"        16863486",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Long-Term Oral Anticoagulant Treatment on Mortality and Cardiovascular Morbidity After Myocardial Infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1994, 343(8896):499-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/7906757/pubmed\" id=\"7906757\" target=\"_blank\">",
"        7906757",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furie KL, Goldstein LB, Albers GW, et al, &ldquo;Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals from the American Heart Association/American Stroke Association,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2012, 43(12):3442-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/22858728/pubmed\" id=\"22858728\" target=\"_blank\">",
"        22858728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furie KL, Kasner SE, Adams RJ, et al, &ldquo;Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2011,42(1):227-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/20966421/pubmed\" id=\"20966421\" target=\"_blank\">",
"        20966421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gage BF, Birman-Deych E, Radford MJ, et al, &ldquo;Risk of Osteoporotic Fracture in Elderly Patients Taking Warfarin. Results From the National Registry of Atrial Fibrillation 2,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(2):241-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/16432096/pubmed\" id=\"16432096\" target=\"_blank\">",
"        16432096",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldstein LB, Bushnell CD, Adams RJ, et al, \"Guidelines for the Primary Prevention of Stroke: A  Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,\"",
"      <i>",
"       Stroke",
"      </i>",
"      ,  2011, 42(2):517-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/21127304/pubmed\" id=\"21127304\" target=\"_blank\">",
"        21127304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grand&rsquo;Maison A, Charest AF, and Geerts WH, &ldquo;Anticoagulant Use in Patients With Chronic Renal Impairment,&rdquo;",
"      <i>",
"       Am J Cardiovasc Drugs",
"      </i>",
"      , 2005, 5(5):291-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/16156685/pubmed\" id=\"16156685\" target=\"_blank\">",
"        16156685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaff MR, McMurtry MS, Archer SL, et al, &ldquo;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(16):1788-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/21422387/pubmed\" id=\"21422387\" target=\"_blank\">",
"        21422387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jamal SA, Browner WS, Bauer DC, et al, &ldquo;Warfarin Use and Risk for Osteoporosis in Elderly Women. Study of Osteoporotic Fractures Research Group,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1998, 128(10):829-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/9599195/pubmed\" id=\"9599195\" target=\"_blank\">",
"        9599195",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Karsli ED, Erdogan &Ouml;, Esen E, et al, \"Comparison of the Effects of Warfarin and Heparin on Bleeding Caused by Dental Extraction: A Clinical Study,\"",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2011, 69(10):2500-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/21764203/pubmed\" id=\"21764203\" target=\"_blank\">",
"        21764203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kovacs MJ, Rodger M, Anderson DR, et al, &ldquo;Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together With Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism. A Randomized, Double-Blind, Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 138(9):714-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/12729425/pubmed\" id=\"12729425\" target=\"_blank\">",
"        12729425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(16):2250-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/19332472/pubmed\" id=\"19332472\" target=\"_blank\">",
"        19332472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMahan DA, Smith DM, Carey MA, et al, &ldquo;Risk of Major Hemorrhage for Outpatients Treated With Warfarin,&rdquo;",
"      <i>",
"       J Gen Intern Med",
"      </i>",
"      , 1998, 13(5):311-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/9613886/pubmed\" id=\"9613886\" target=\"_blank\">",
"        9613886",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chan A, Goldenberg NA, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e737-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/22315277/pubmed\" id=\"22315277\" target=\"_blank\">",
"        22315277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgenstern LB, Hemphill JC, Anderson C, et al, \"Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,\"",
"      <i>",
"       Stroke",
"      </i>",
"      , 2010, 41(9):2108-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/20651276/pubmed\" id=\"20651276\" target=\"_blank\">",
"        20651276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patriquin C and Crowther M, &ldquo;Treatment of Warfarin-associated Coagulopathy With Vitamin K,&rdquo;",
"      <i>",
"       Expert Rev Hematol",
"      </i>",
"      , 2011, 4(6):657-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Randomised Double-Blind Trial of Fixed Low-Dose Warfarin With Aspirin After Myocardial Infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1997, 350(9075):389-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/9259652/pubmed\" id=\"9259652\" target=\"_blank\">",
"        9259652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sacco RL, Adams R, Albers G, et al, &ldquo;Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology Affirms the Value of this Guideline,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2006, 37(2):577-617.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/16432246/pubmed\" id=\"16432246\" target=\"_blank\">",
"        16432246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singer DE, Albers GW, Dalen JE, et al, &ldquo;Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),&rdquo; Chest, 2008, 133(6 Suppl):546-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/18574273/pubmed\" id=\"18574273\" target=\"_blank\">",
"        18574273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith P, Arnesen H, and Holme I, &ldquo;The Effect of Warfarin on Mortality and Reinfarction After Myocardial Infarction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1990, 323(3):147-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/2194126/pubmed\" id=\"2194126\" target=\"_blank\">",
"        2194126",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smythe MA, Warkentin TE, Stephens JL, et al, &ldquo;Venous Limb Gangrene During Overlapping Therapy With Warfarin and a Direct Thrombin Inhibitor for Immune Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 2002, 71(1):50-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/12221676/pubmed\" id=\"12221676\" target=\"_blank\">",
"        12221676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stein PD, Alpert JS, Bussey HI, et al, &ldquo;Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves,&rdquo; Chest, 2001, 119(1 Suppl):220-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/11157651/pubmed\" id=\"11157651\" target=\"_blank\">",
"        11157651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suvarna R, Pirmohamed M, and Henderson L, &ldquo;Possible Interaction Between Warfarin and Cranberry Juice,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2003, 327(7429):1454.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/14684645/pubmed\" id=\"14684645\" target=\"_blank\">",
"        14684645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/41/28314/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10050 Version 55.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28314=[""].join("\n");
var outline_f27_41_28314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708848\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234876\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234877\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234916\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234880\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234898\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234881\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401678\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234882\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234849\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234833\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874933\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234853\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234923\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234852\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234913\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234925\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234914\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234856\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234837\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234911\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234842\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234872\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234845\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234859\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234887\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234860\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234861\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234858\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234847\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234850\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234862\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234836\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234855\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10050\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10050|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=related_link\">",
"      Warfarin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/4/21578?source=related_link\">",
"      Warfarin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_41_28315="Resistant bacteria in LTCFs";
var content_f27_41_28315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations of the Society for Hospital Epidemiology of America (SHEA) for controlling antibiotic resistant bacteria in long term care facilities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Residents who are colonized with antimicrobial resistant",
"pathogens should not be denied entry into long term care facilities",
"(LTCFs).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decolonization therapy should not be required for residents",
"colonized with antimicrobial resistant pathogens prior to their",
"admittance to a LTCF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LTCF residents colonized with antimicrobial resistant",
"pathogens should not be restricted from participation in social or",
"therapeutic group activities within the facility unless there is reason",
"to think that they are shedding large numbers of bacteria and have been",
"implicated in the development of infections in other residents.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LTCFs should obtain information on colonization or infection",
"with antimicrobial resistant pathogens of concern prior to receiving",
"new admissions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine surveillance for selected antimicrobial resistant",
"pathogens should be performed in LTCFs and should include regular",
"review of all microbiologic data obtained in association with patient",
"care.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A line list of residents with antimicrobial resistant",
"pathogens should be maintained, differentiating colonization from",
"infection. Infection rates for resistant pathogens should be calculated.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Nicolle, LE, Bentley, D, Garibaldi, R, et al, Infect Control Hosp&nbsp;Epidemiol 1996;17:119.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28315=[""].join("\n");
var outline_f27_41_28315=null;
var title_f27_41_28316="TOLAC recommendations of professional societies";
var content_f27_41_28316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TOLAC recommendations of professional societies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Society",
"       </td>",
"       <td class=\"subtitle1\">",
"        VBAC counseling",
"       </td>",
"       <td class=\"subtitle1\">",
"        Facilities and personnel",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The College",
"       </td>",
"       <td>",
"        VBAC should be offered to most women with one previous cesarean delivery with low transverse incision; consider those with two previous low transverse cesarean deliveries.",
"       </td>",
"       <td>",
"        Safest where staff can provide immediate emergency cesarean delivery, but patients should be allowed to accept increased risk when such resources are not available.",
"       </td>",
"       <td>",
"        Twins, macrosomia, postdatism, low vertical incision, and unknown type of uterine incision should not preclude.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RCOG",
"       </td>",
"       <td>",
"        Women with one prior low segment cesarean delivery should be able to discuss option of VBAC; final decision between woman and her obstetrician.",
"       </td>",
"       <td>",
"        Should be conducted in suitably staffed and equipped delivery suite with continuous intrapartum care and monitoring and available resources for immediate cesarean delivery and advanced neonatal resuscitation.",
"       </td>",
"       <td>",
"        Caution with twins and macrosomia (uncertainty due to underpowered studies).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SOGC",
"       </td>",
"       <td>",
"        VBAC should be offered to women with one previous cesarean delivery with low transverse incision.",
"       </td>",
"       <td>",
"        In hospital where a timely cesarean is available; an approximate timeframe of 30 min should be considered adequate for urgent laparotomy.",
"       </td>",
"       <td>",
"        Twins, macrosomia, and postdatism are not contraindications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AAFP",
"       </td>",
"       <td>",
"        VBAC should be offered to women with one previous cesarean delivery with low transverse incision.",
"       </td>",
"       <td>",
"        Should not be restricted only to those facilities with available surgical teams present throughout labor because there is no evidence that these additional resources result in improved outcome.",
"       </td>",
"       <td>",
"        Not addressed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AHRQ",
"       </td>",
"       <td>",
"        VBAC is a reasonable choice for the majority of women with prior cesarean delivery.",
"       </td>",
"       <td>",
"        Not addressed.",
"       </td>",
"       <td>",
"        Not addressed.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VBAC: vaginal birth after cesarean delivery; The College: American College of Obstetricians and Gynecologists; RCOG: Royal College of Obstetricians and Gynecologists; SOGC: Society of Obstetricians and Gynecologists of Canada; AAFP: American Academy of Family Physicians; AHRQ: Agency for Healthcare Research and Quality.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Scott JR. Vaginal birth after cesarean delivery: a common-sense approach. Obstet Gynecol 2011; 118:342. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28316=[""].join("\n");
var outline_f27_41_28316=null;
var title_f27_41_28317="Pravastatin heart transplant";
var content_f27_41_28317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66561&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Pravastatin improves survival in cardiac transplant recipients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 381px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study of 97 heart transplant recipients randomly assigned to pravastatin or placebo, survival at one year was significantly better with pravastatin (94 versus 78 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kobashigawa JA, Katznelson S, Laks H, et al. N Engl J Med 1995; 333:621.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28317=[""].join("\n");
var outline_f27_41_28317=null;
var title_f27_41_28318="Pediatric hyperkalemia rapid overview";
var content_f27_41_28318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F85978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F85978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric hyperkalemia management rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum potassium 5 to 7 mEq/L: Generally asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum potassium greater than 7 mEq/L: Muscle weakness, paralysis, and cardiac changes on electrocardiography and arrhythmias. Sudden arrest may occur.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pseudohyperkalemia, usually due to hemolysis of the blood specimen, is the most likely cause of an elevated serum or plasma potassium in children. It does not reflect true hyperkalemia and is not associated with cardiac conduction disturbances.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The two major mechanisms of true hyperkalemia and their major causes are:",
"        <ul>",
"         <li>",
"          Increased potassium release from cells most commonly due to rhabdomyolysis (eg, crush injury, prolonged seizure, hyperthermia, or exercise), tumor lysis syndrome, massive transfusion, and metabolic acidosis",
"         </li>",
"         <li>",
"          Reduced urinary potassium excretion most commonly due to severe hypovolemia, impaired renal function, or hypoaldosteronism (eg, adrenal insufficiency)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laboratory tests are based upon probable etiology. All patients with true hyperkalemia should have the following tests obtained:",
"        <ul>",
"         <li>",
"          Blood urea nitrogen (BUN)",
"         </li>",
"         <li>",
"          Creatinine",
"         </li>",
"         <li>",
"          Blood glucose",
"         </li>",
"         <li>",
"          Serum electrolytes",
"         </li>",
"         <li>",
"          Urine specific gravity, pH, and electrolytes",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        In cases where rhabdomyolysis is suspected, the following studies are also indicated:",
"        <ul>",
"         <li>",
"          Serum creatine kinase and lactic dehydrogenase",
"         </li>",
"         <li>",
"          Urine for myoglobin",
"         </li>",
"         <li>",
"          Blood gas",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        In cases where adrenal insufficiency is suspected, additional testing includes:",
"        <ul>",
"         <li>",
"          Serum cortisol and ACTH (prior to administration of exogenous corticosteroids)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Electrocardiogram (ECG) changes*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ECG findings commonly progress as follows:",
"        <ul>",
"         <li>",
"          Peaked T waves",
"         </li>",
"         <li>",
"          Prolonged PR and QRS intervals, and small P waves",
"         </li>",
"         <li>",
"          Loss of P wave, further prolongation of QRS interval (\"sine wave\" pattern), and conduction delay that can manifest as bundle branch or atrioventricular (AV) nodal block",
"         </li>",
"         <li>",
"          Ventricular fibrillation or asystole",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Confirm the patient is truly hyperkalemic",
"        </strong>",
"        (ie, exclude pseudohyperkalemia) by obtaining a venous or arterial blood sample that is not hemolyzed for rapid analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Obtain ECG and place patient on a cardiac monitor",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         The following specific therapies are listed according to their effectiveness and rapidity of action, the choice of intervention is dependent upon the severity of ECG changes and muscle weakness:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Stabilize cardiac membranes with calcium:",
"        </strong>",
"        <ul>",
"         <li>",
"          Give",
"          <strong>",
"           only",
"          </strong>",
"          for hyperkalemia with significant ECG findings (eg, widening of the QRS complex or loss of P waves, but",
"          <strong>",
"           not",
"          </strong>",
"          peaked T waves alone) or severe arrhythmias thought to be caused by hyperkalemia or in patients with a potassium level greater than 7.0 mEq/L.",
"         </li>",
"         <li>",
"          Give",
"          <strong>",
"           calcium gluconate 10 percent solution",
"          </strong>",
"          at a dose of 0.5 mL/kg (maximum dose 20 mL [2 grams]) per dose by intravenous slow infusion over five minutes. Time to onset of action is immediate. Suggested dose is equivalent to a dose of elemental calcium 5 mg/kg (0.15 mmol/kg), (maximum dose of 180 mg elemental calcium [4.5 mmol]).",
"         </li>",
"         <li>",
"          Calcium treatment may be repeated one to two times after 5 to 10 minutes if ECG changes persist.",
"         </li>",
"         <li>",
"          Calcium gluconate should be administered in a large vein or, preferably, central line as it is an irritant. Sodium bicarbonate should not be administered in the same line because of the potential for precipitation. Calcium gluconate can be given intraosseously (IO) using the same dose if intravenous access is not available.",
"         </li>",
"         <li>",
"          Since the effect of calcium is transient, patients with hyperkalemia also require concomitant or immediate treatments to shift potassium into cells and to remove potassium.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Shift potassium into cells:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Insulin and glucose:",
"         </strong>",
"         Onset of action is 10 to 20 minutes. Only give if significant ECG changes OR confirmed serum potassium &ge;7 mEq/L.",
"        </p>",
"        Give regular insulin (dose of 0.1 units per kg, maximum dose of 10 units) along with dextrose (glucose) dose of 0.5 g/kg over 30 minutes. The administration of dextrose is based upon the age of the patient as follows:",
"        <ul>",
"         <li>",
"          Children younger than five years of age: Give 10 percent dextrose (100 mg/mL) at a dose of 5 mL/kg",
"         </li>",
"         <li>",
"          Children five years of age and older: Give 25 percent dextrose (250 mg/mL) at a dose of 2 mL/kg",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         For patients with severe acute symptoms, ECG changes, arrhythmias, or impending arrest: larger doses of regular insulin (0.2 units/kg) and dextrose (1 g/kg, 10 mL/kg of 10 percent dextrose or 4 mL/kg of 25 percent dextrose) can be administered.",
"        </p>",
"        <p>",
"         Repeat dosing can be given after 30 minutes if needed. The major adverse effect is hypoglycemia, and serum glucose level should be monitored closely and additional dextrose administered as needed.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Beta-2 agonist:",
"         </strong>",
"         Onset of action is 20 to 30 minutes.",
"        </p>",
"        Give nebulized albuterol (salbutamol) with dosing based upon patient weight as follows:",
"        <ul>",
"         <li>",
"          Neonates: 0.4 mg in 2 mL of saline",
"         </li>",
"         <li>",
"          Infants and small children &lt;25 kg: 2.5 mg in 2 mL of saline",
"         </li>",
"         <li>",
"          Children between 25 to 50 kg: 5 mg in 2 mL of saline",
"         </li>",
"         <li>",
"          Older children and adolescents &gt;50 kg: 10 mg in 2 to 4 mL of saline (doses up to 20 mg have been used)",
"         </li>",
"        </ul>",
"        <p>",
"         &nbsp;",
"        </p>",
"        <p>",
"         Inhalation may be repeated after 20 minutes. Inhaled albuterol may also be administered by metered dose inhaler (MDI) as 4 to 8 puffs with spacer.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Sodium bicarbonate:",
"         </strong>",
"         Onset of action is 15 minutes. Provides minimal effect on shifting potassium intracellularly and should",
"         <strong>",
"          not",
"         </strong>",
"         be the only therapy used in the management of hyperkalemia, even in acidotic children.",
"        </p>",
"        <p>",
"         Give 1 mEq/kg (1 mmol/kg). Maximum single dose of 50 mEq (50 mmol) which can be provided as 1 mL/kg of 8.4 percent solution or, for children less than six months of age, 2 mL/kg of 4.2 percent solution administered over 10 to 15 minutes.",
"        </p>",
"        <p>",
"         A repeat dose may be given 10 to 15 minutes after last administration. Do not give in the same intravenous line as calcium because of a risk of precipitation.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Remove potassium; since the effect of above therapies is transient, treatments to remove potassium are also required",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Stop all potassium intake",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Loop diuretic:",
"        </strong>",
"        Provides only limited short-term effect. Give furosemide 1 mg/kg IV (maximum single dose of 40 mg); higher dose may be required with renal insufficiency; fluid losses must be replaced unless the patient is volume expanded. The onset of effect is one to two hours. May be repeated after six hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Cation exchange resin (sodium polystyrene sulfonate):",
"         </strong>",
"         Give sodium polystyrene sulfonate (without sorbitol) at a dose of 1 g/kg (maximum dose of 30 g) orally, through nasogastric tube, or as a retention enema. One g of resin will bind 1 mEq (mmol) of potassium. Onset is approximately one to two hours; may repeat dose after four to six hours based upon repeat serum potassium.",
"        </p>",
"        <p>",
"         Sodium polystyrene sulfonate should not be used in preterm neonates, term neonates with intestinal hypomotility and/or those at risk for necrotizing enterocolitis, postoperative patients, or those with bowel obstruction or ileus. Sorbitol can cause intestinal necrosis and should be avoided. A laxative that contains no magnesium or potassium (eg, lactulose) is an alternative to sorbitol use to prevent colonic impaction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Hemodialysis:",
"        </strong>",
"        In children unresponsive to diuretic or cation exchange resin therapy, or with severe renal dysfunction, dialysis may be necessary to remove excess potassium from the body. Hemodialysis is the preferred modality to reduce potassium levels as it is the quickest and most controlled renal replacement treatment.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Large interpatient variability exists in the relationship between the serum potassium and electrocardiogram (ECG) changes; at a given serum potassium, ECG changes are more common with acute elevations and less common with chronic elevations (eg, chronic kidney disease). Infants generally have a higher range of normal potassium levels, so ECG changes are usually observed at higher values.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28318=[""].join("\n");
var outline_f27_41_28318=null;
var title_f27_41_28319="Bronchogenic cyst CT";
var content_f27_41_28319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 201px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large subcarinal mass of low attenuation coefficient is clearly visible occupying the azygo-esophageal recess.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_41_28319=[""].join("\n");
var outline_f27_41_28319=null;
